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EARLY PERIPHERAL IMMUNOLOGICAL EVENTS DICTATE CHRONIC WASTING 
DISEASE 
Chronic wasting disease (CWD) is an emerging prion disease of captive and free-ranging 
cervid populations that, like scrapie, has been shown to involve the immune system, which most 
likely contributes to their relatively proficient horizontal and environmental transmission.  While 
CWD prions probably interact with the innate immune system immediately following peripheral 
exposure, little is known about this initial encounter.  In the first chapter of this dissertation we 
examined initial events in lymphotropic and intranodal prion trafficking by tracking highly 
enriched, fluorescent CWD prions from infection sites to draining lymph nodes.  We observed 
biphasic lymphotropic transport of prions from the initial entry site upon peripheral prion 
inoculation.  CWD prions rapidly reached draining lymph nodes in a cell autonomous manner 
within two hours of intraperitoneal administration.  Monocytes and dendritic cells (DCs) showed 
a strong dependence on Complement for optimal prion delivery to lymph nodes hours later in a 
second wave of prion trafficking.  B cells comprised the majority of prion-bearing cells in the 
mediastinal lymph node by six hours.  As most B cells are mainly located in the follicles, 
acquisition of prions by these cells most likely occurred through interaction with resident DCs, 
subcapsulary sinus macrophages, or directly from the follicular conduit system. These data 
highlight a novel mechanism of cell autonomous prion transport, and a vital role for B cells in 
intranodal prion trafficking. 
  Upon entry into the draining lymph nodes, prion accumulation and replication on 
follicular dendrtic cells (FDCs) is greatly facilitated by the complement system. Complete 
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elimination of CD21/35 significantly delays splenic prion accumulation and terminal prion 
disease in mice inoculated intraperitoneally with mouse-adapted scrapie prions.  In the second 
chapter of this thesis we show that mice overexpressing the cervid prion protein and susceptible 
to CWD (Tg(cerPrP)5037 mice) but lack CD21/35 expression completely resist clinical CWD 
upon peripheral infection.  Ablation of complement receptors CD21/35 greatly diminished 
splenic prion accumulation and replication throughout the course of disease, similar to CD21/35 
deficient murine PrP mice infected with mouse scrapie.  Mice with deficiencies in CD21/35 
showed a reduction in severity of neuropathology and deposition of misfolded, protease-resistant 
PrP associated with CWD.  Prion infection resulted in translocation of CD21/35 to lipid rafts in 
B cells, and FDC expression of CD21/35 mediated a strong germinal center response that may be 
conducive to prion amplification. 
Complement component C3 is a central protein in the complement system whose 
activation is essential for the elimination of infectious pathogens.  C3 is the most abundant 
complement protein, being found in the blood at physiological concentrations of 1 mg/ml.  
Among the complement proteins, C3 is perhaps the most adaptable and multifunctional protein 
identified to date, having evolved structural characteristics that allow it to associate with over 25 
different proteins.  Previous experiments suggest a vital role of C3 in scrapie prion pathogenesis.  
In the last chapter of my thesis we showed that lack of C3 expression by 5037 mice either 
transiently or genetically leads to delays in prion pathogenesis.  C3 impacts disease progression 
in the early stages of disease by slowing the kinetic rate of accumulation and/or replication of 
PrPRES. This slower kinetic increase in PrPRES correlates with an increase in survival time in mice 
deficient in C3.  This delay in disease is in sharp contrast to the complete rescue we saw in CWD 
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infected Tg 5037;CD21-/- mice.  This suggests a role for CD21/35 in peripheral prion 
pathogenesis independent of their endogenous ligands. 
Taken together we show that the innate immune system dictates the course of CWD.  We 
have discovered novel immune cells, trafficking pathways, and complement components 
important in CWD pathogenesis.  These data not only highlight the key role of the innate 
immune system in CWD, but also provide a strong foundation for future immunological studies 
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Prion disorders, also known as transmissible spongiform encephalopathies (TSEs), are a 
set of unique neurodegenerative disorders that affect a wide range of mammalian species 1.  
According to the widely accepted “protein only” hypothesis, prions are composed mainly, if not 
solely, of PrPSc, an abnormal isoform of the host glycoprotein, PrPC 2.  Transmission and 
propagation of PrPSc occur through a process of seeded polymerization, in which PrPC is 
recruited into PrPSc, adopting its abnormal conformation 3,4. While PrPC and PrPSc both appear 
essential in disease replication and transmission, the roles each play in cellular function and 
neurodegeneration remain unclear.     
Chronic wasting disease (CWD) is a prion disease that affects both captive and free 
ranging cervids 5-7.  CWD is unique among TSEs in that it seems to be the most contagious prion 
disease, transmitting in natural settings with high efficiency.  Recently, increased surveillance 
across the United States revealed incidents of CWD in states where hunting big game is 
extremely popular 6.  This finding raises legitimate concerns about the transmissibility of CWD 
to humans, as typified by the zoonotic transmission of bovine spongiform encephalopathy (BSE) 
8,9.  Although there is no direct evidence of CWD transmission to humans, the staggering rise in 
CWD cases in the United States underscores a need for a better understanding of this disease. 
As with other TSEs, CWD exhibits a strong correlation between inflammatory responses 
and neurological abnormalities.  Although these neurological inflammatory events are of grave 
importance, it may be that the initial events in a CWD infection dictate the outcome of disease 
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progression.  These inaugural events seem in most cases to involve the peripheral immune 
system 10,11.  Although numerous experiments provide great insight into the immunological 
events that precede neuroinvasion, many questions still remain on the nature of this response and 
the cells involved.  Within this context, we sought to characterize the early immunological events 
involved in the development of CWD.  
Gaining crucial insight into the immunological events in CWD may have far reaching 
implications in our understanding of other protein misfolding diseases.  For example, it is well 
known that non-prion protein misfolding disorders, such as Alzeimer’s disease and Parkinson’s 
disease, mirror certain morphological and pathophysiological features seen in prion disorders 12. 
With this in mind, it seems reasonable to think that prion diseases may represent a general model 
for amyloidogenic disorders in their ability to elicit an immune response, replicate, and transmit 
disease.  Therefore, advances in our knowledge of prion diseases may not only provide critical 
insight into other protein misfolding disorders, but may also provide critical therapeutic 
interventions and preventative measures necessary for control of these devastating diseases.  
PrPC structure  
As revealed by nuclear magnetic resonance (NMR) and gene sequencing, the amino acid 
sequence and atomic structure of mature PrPC is highly conserved between mammalian species 
13-15.  Mature PrPC is a glycosyl phosphatidyl inositol (GPI)-linked glycoprotein composed of a 
highly flexible NH2-proximal tail proceeded by a well-defined globular COOH-proximal domain 
(Figure 1).  Although the NH2-terminal region is disordered, it contains a highly conserved 
octapeptide-repeat region.  This region has been shown to bind divalent cations Cu2+, Zn2+, Ni2+, 
and Mn2+ 16-19 .  The COOH-globular domain consists of three alpha helices corresponding to 
residues 144-154, 173-194, and 200-228.  Interspersed within these alpha helices are two anti-
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parallel β-strands, which make up residues 128-131 and 161-164.  A disulfide bond, C179-C214, 
join helices 2 and 3, while the second β-strand and α-helix are linked by a large loop with 
intriguing structural properties 13-15,20.  Analysis by NMR shows this loop to be extremely 
flexible in most species, including humans, bovine, sheep, mouse, and hamsters, but it is almost 
completely inflexible in the prion protein of elk and deer 15,20-23. The importance of this rigid β2–
α2 loop of PrP may extend beyond structural–biological curiosity.  Some hypothesize that this 
rigid loop my influence other properties of PrP such as PrPSc conversion and transmission 24.  
Interestingly, Sigurdson et al. postulates that similarities in the local structure of β2–α2 loop 




Figure 1.1 Aguzzi A, Sigurdson C, Heikenwaelder M. Molecular mechanisms of prion 
pathogenesis. Annu. Rev. Pathol. 3, 11-40 (2008). 
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PrP physiological function 
Although advances towards the characterization of PrPC structure have been made, the 
physiological function of PrPC remains controversial 26.  To date, there is no evidence that a 
naturally occurring Prnp-null allele exists in any mammalian species.  This lack of Prnp-null 
allele, coupled with the broad and diverse expression of PrPC in the CNS and many of the 
peripheral organs implies a highly conserved and broad physiological function 27.  Several 
functions have been ascribed to PrPC, including functions in neuronal survival, cellular signaling, 
immune cell activation, and as a pattern recognition receptor (PRR) for misfolded proteins 28-36.  
Insight into these physiological functions will have profound influence on the way scientists 
approach prion research.          
Apoptosis 
Neuroprotection against apoptosis may be the most attributed function of PrPC.  Cultured Prnp-/- 
neurons were suggested to be more prone to develop apoptosis during serum-deprivation than 
were cells expressing PrPC 28. Albeit an interesting observation, some researchers attributed this 
effect to dopple (Dpl) overexpression rather than PrP ablation 37.  Doppel, a protein encoded by 
the gene Prnd, shows similarities to PrPC in amino acid sequence, primary structure, and 
subcellular localization 38. Although dopple appears to show many biochemical similarities PrPC, 
it’s overexpression in the brain has been shown to be deleterious in certain PrP deficient mice39-
41.  Other studies suggest that PrPC offers a cytoprotective function to cells against harmful 
agents.  This hypothesis is supported by the finding that PrPC diminishes the rate of apoptosis 
caused by certain apoptotic stimuli such as Bax overexpression or TNF-α 42,43.   
It has been shown that artificially generating cytosolic PrP in neurons induces cell death 
44.  However, several other studies argue against this neurotoxicity and showed a more 
	  5	  
cytoprotective role of cyPrP. Data from these studies suggested that cyPrP might function as an 
anti-apoptotic protein against Bax-mediated apoptosis by inhibiting the Bax proapoptotic 
conformational changes that takes place initially in Bax activation 45,46.  PrPC also exerts its 
cytoprotective function against TNF-α in a human MCF-7 breast cancer cell line 43.  In this 
experiment it was demonstrated that PrPC overexpression transformed TNF-sensitive MCF-7 
cells into TNF-resistant cells.  It was speculated that the mechanism of transformation involved 
alteration of cytochrome c release from mitochondria and nuclear condensation. 
Role in cell signaling 
Attachment to the plasma membrane by a GPI anchor and localization in lipid rafts has 
made PrPC an ideal candidate for signal transduction.  PrPC has shown an ability to regulate 
many signaling components and pathways involved in neuronal survival; therefore, PrPC has 
been suggested to function as a trophic receptor 30,47-49.  Signal transduction pathways triggered 
by PrPC, through antibody crosslinking or PrP binding peptides, has been partially characterized 
and is mediated by tyrosine kinase p59fyn and cAMP/PKA-dependent pathways 30,49.  Some 
groups have suggested that interaction of PrPC with membrane proteins can also transduce 
neuroprotective signals. Stress-induced protein I (STI1) co-immunoprecipitated with PrPC, and 
interaction of PrPC with this molecule induced neuroprotective signals through camp/protein 
kinase A and Erk signaling pathways 47.  This interplay between PrP and STI1 produced distinct 
signaling pathways, promoting neuroprotection and neuritogenesis by activation of PKA and 
MAPK pathways respectively 48.  
Role in the immune system 
Several studies have suggested that PrPC may exert its physiological function in the early 
stages of immune cell development.  PrPC has been detected on CD34+ hematopoietic stem cells 
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(HSCs) 50.  This PrPC expression seems to be transient, as differentiation into CD15+ 
granulocytes leads to PrPC down regulation.  Similarly, CD43+Gr-1 granulocyte precursors 
transiently express PrPC before differentiating into neutrophils 51.  Although the role of this 
transient expression of PrPC remains unknown, it seems reasonable to suggest that it may play a 
role in development of certain myeloid lineages. Using affinity purification techniques and bone 
marrow transplantation experiments, PrPC expression by HSCs has recently been shown to be 
important in self-renewal 52. Although the molecular mechanism of this self-renewal is not 
known, the authors suggest that PrPC might be a coreceptor for a hormone that affects HSC 
activity.   
PrPC’s physiological role may extend beyond immune cell development.  PrPC can be 
detected on T and B lymphocytes, plateletes, monocytes, DCs, FDCs, and NK cells 32,35,50,53-58. 
The role of PrPC expression by these immune cells has not been fully elucidated; however, 
several studies suggest that PrPC may function in immune cell activation.  PrPC expression by T 
lymphocytes was upregulated within hours following mitogenic activation with concanavalin A 
(ConA), phytohaemagglutinin (PHA), or anti-CD3 antibodies 32-35.  As mentioned above, PrP 
may function as a signaling molecule; therefore, this upregulation of PrP by these immune cells 
may lead to interactions with specific ligands that results in signal transduction.  Indeed, 
antibody induced PrP cross-linking on T lymphocytes led to phosphorylation of signaling 
proteins ERK1/2 and Src family kinases 59-61.  Similar results could be seen in a 
monocyte/macrophage cell line treated with PrPC fusion proteins 62.  Although these experiments 
identify a plausible role of PrPC in immune cell activation and signaling, it has yet to be seen 
whether these events have any real affect on prion pathogenesis. 
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PrPC’s role in Alzheimer’s disease 
Recently several studies have implicated PrPC as a receptor for other abnormally folded 
proteins 36. In Alzheimer’s disease (AD), accumulation of amyloid-β (Aβ) is thought to be 
responsible for dementia and neurodegeneration.  Tiny, soluble aggregates of Aβ hinder memory 
by disturbing memory-related functions of synaptic junctions between neurons 63,64.  It has been 
suggested that PrP mediates these pathogenic effects by binding to Aβ.  Indeed, treatment of 
normal hippocampal slices with Aβ inhibited long-term potentiation (LTP) compared to 
hippocampal slices lacking PrPC, and this effect was mediated by Aβ binding to amino acids 95-
110 on PrPC 36.  Recently these same authors crossed familial AD transgenes into PrP deficient 
mice to address the need of PrP for AD-related pathogenesis in vivo 65.  AD transgenic mice 
lacking PrPC, but containing Aβ!plaques derived from AD transgenes, showed no noticeable 
impairment of spatial learning and memory.  These data indicate the requirement for PrPC in Aβ 
induced memory impairment. 
Although binding of PrPC to Aβ oligomers is thought to trigger Alzheimer’s disease 
pathophysiology, the molecular mechanisms underlining this toxicity remains unknown. N-
methyl-D-aspartate receptors (NMDAR) are a key ionotropic glutamate/glycine receptor in the 
CNS that plays a critical role in development, memory, and learning 66,67.  Alterations in this 
receptor have been shown to contribute to AD pathogenesis 64,68,69.  Some scientists hypothesize 
that Aβ-PrPC complexes modify NMDARs through a phosphorylation event mediated by Fyn 
signaling. Indeed, Aβ binding to PrPC activated a Fyn signaling pathway that led to NR2B 
phosphorylation, altered NMDAR localization, and loss of dendritic spines 70.   
Other scientists provide evidence that Aβ neurotoxicity might depend on interactions 
between copper ions, PrPC, and NMDARs 71.  Here it is suggested that under normal 
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physiological conditions, PrPC forms a complex with NMDAR in a copper-dependent manner to 
reduce glycine affinity for this receptor.  This desensitization of NMDARs to glycine by PrPC 
protects neurons from calcium overload and neuronal toxicity. However, under certain 
pathological states of excessive Aβ production, Aβ functions as copper chelator, precluding 
copper ions from binding to PrPC.  This lack of binding of copper ions to PrPC in turn alters the 
ability of PrPC to regulate NMDAR desensitization and/or causes separation of the two proteins. 
Ultimately Aβ sequestration of copper ions leads to an increase in glycine affinity, resulting in 
prolonged steady-state current and pathological calcium influx. 
These findings have come with great excitement and skepticism.  Although it is tempting 
to extrapolate these findings towards real AD, one should do so with extreme caution as several 
findings conflict with the results mentioned above.  Indeed, Balducci et al. has shown that 
synthetic Aβ oligomers impedes long-term memory independently of cellular PrPC 72. Using a 
second, independent AD transgenic mouse model, Calella et al. showed that removal or 
overexpression of PrPC has no effects on the impairment of hippocampal synaptic plasticity 73. 
Ever since the identification of the Prnp gene in 1986 and the subsequent development of 
Prnp knockout mice in 1992, research into the physiological function of PrPC has intensified 74,75.  
Despite being a central player in the development of prion disease, PrPC has failed to show any 
definitive molecular function.  As mentioned above, several functions can be attributed to PrPC; 
however, further understanding into these physiological functions is needed to establish a 
peripheral therapeutic strategy. 
 Development of the protein only hypothesis 
Tikvah Alper and colleagues first described the agent that causes TSEs through 
experiments that elegantly showed that PrPSc infectivity is resistant to inactivation by UV and 
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ionizing irradiation 76,77.  These findings led to a plethora of hypotheses on the chemical make up 
PrPSc, including the prophetic notion by John Griffith in 1967 that PrPSc may be composed of 
self-replicating protein 78.  Later it was shown that a reduction in infectivity could be achieved if 
purified fractions of scrapie, derived from hamster brain, were treated with procedures that alter 
or denature protein structure 79-82.  These findings, along with the inability to show a dependence 
on an infectious scrapie-specific nucleic acid led Stanley Prusiner to proclaim the infectious 
agent a prion, which is presently defined as a small protienacious infectious particle that resists 
treatments that modify nucleic acids 2. 
While a wealth of scientific evidence gathered over the past decade provides substantial 
support for the prion hypothesis, observed in vitro refolding of synthetic or bacterially derived 
PrP into an infectious conformation would be the final proof of the protein only hypothesis.  
Developments in the use of transgenic mice, synthetic and recombinant PrP (recPrP), and protein 
misfolding cyclic amplification (PMCA) have provided significant advancement toward 
achieving this goal.   
Initial attempts to create prions in the laboratory laid the foundation for recent advances 
in the validation of the protein only hypothesis.  The use of Tg mice greatly facilitates this 
progress by showing a tight genetic linkage of inherited prion diseases to the Prnp gene.  
Nowhere is this genetic linkage more apparent than in Tg(GSSPrP)174 mice.  These Tg mice 
express PrP with a Pro100Leu mutation, which corresponds to the mutation that causes 
Gerstmann-Straussler Scheinker syndrome (GSS) in humans.  High-level expression of this 
transgene results in neurodegeneration, with disease onset times that correlate with the level of 
expression 83.    
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Similar to Tg(GSSPrP)174 mice, Tg196 mice also express the PrP(Pro101Leu) transgene.  
However, Tg196 mice express much lower levels of this transgene and were used as a model to 
help produce evidence that prions can be artificially generated in the absence of an infectious 
seed.  Disease acceleration or initiation in these mice can be achieved through the inoculation of 
a chemically synthesized 55-mer peptide that was folded into a beta-rich conformation 
containing the Pro101Leu mutation 84.  Similar results are shown in Tg9949 mice, which 
overexpress N terminally truncated mouse PrP (PrP(89-231)).  When amyloid fibrils consisting 
of recMoPrP(89-230) were inoculated into these mice, a progressive neurological dysfunction 
was observed 85.  These data show that a chemically synthesized peptide refolded into the right 
conformation can act as an infectious agent that causes TSEs.  
Although the use of Tg mice, synthetic PrP, and recPrP represents a major step forward, 
some argue that essential issues emerge in the interpretation of these experiments 86.  First, 
prions created de novo in Tg(GSSPrP)174 mice only infect mice expressing the identical 
mutation at lower levels (some of which develop spontaneous disease later in life).  Second, 
primary passage of infectivity to Tg9949 mice requires these mice to over express PrPC by 16 
fold. Another interpretation of these results is that these Tg mice are predisposed to develop 
spontaneous prion disease, and that onset of disease in these mice represents a disease 
acceleration process, due to the inoculation of further PrP 86.  Therefore, the term 
“transmissibility” may be unsuitable for this disease acceleration process 87.   
This begs the question of whether these experiments actually produce prions.  Some 
contend that these scientists simply created an agent that triggered prion production in a host 
that, due to the high levels of PrPC expression, is on the verge of developing spontaneous disease 
86. Although a valid point, recent data demonstrates that brain homogenates derived from 
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uninoculated aged Tg9949 mice show no evidence of prions by biochemical analysis, 
histological analysis, or by serial transmission of their brain homogenates.  This indicates that 
prions were indeed generated in a cell free system and not just in the host 88.   
Recently, a more ideal mouse model has been generated that gives the strongest case yet 
that PrP misfolding induced by mutations and associated with genetic prion diseases is sufficient 
to create prions in vivo.  Jackson et al. created knock-in mice to express a PrP mutation, which 
correlates with a well-defined human prion disease, fatal familial insomnia (FFI) 89.  These mice 
spontaneously develop prion disease different from that of other mouse prion models and very 
similar to FFI in humans.  Although similar results were found in Tg(GSSPrP)174 mice, the 
knock-in FFI mice offered several key advantages over Tg(GSSPrP)174 mice.  First, with a 
knock-in model FFI mutations are introduced into the Prnp locus. This is crucial because it 
assures that the allelic modifications will continue to be governed by all of the regulatory 
elements that typically control the expression pattern of PrP.  Second, an additional substitution 
was introduced in these mice to create a strong transmission barrier against prions that already 
exist.  This additional mutation was important because it made these mice highly resistant to 
infection with pre-existing prions, which enabled the authors to conclude that infectivity in these 
mice did not arise from a contaminating agent 89.     
In addition to describing infectivity, the protein only hypothesis also needs to explain the 
phenomenon of prion strains.  Through altering pH, temperature, the length of recPrP constructs, 
and using varying concentrations of urea, Colby et al. made it possible to design and construct 
various prion strains 90.  When these recPrP amyloids were inoculated into mice that overexpress 
full-length PrPC, the incubation periods and the resulting prion strains relied on the 
conformational stability of the recPrP amyloid from which they were derived from. This 
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correlation between disease phenotype and amyloid conformational stability strongly indicates 
that synthetic prions originated from recombinant amyloid preparations, and not from host or 
contamination.  These results led some to believe that if prions had arisen spontaneously in these 
mice, then the autonomous properties of these strains would be enough to distinguish them from 
the amyloid properties 91.  As powerful as these results may be, the inability to infect wild-type 
mice on primary passage left some to doubt whether these artificially generated peptides are 
indeed prions.  Others argue that the inability to infect wild-type animals is not a question of 
whether these peptides are prions, but rather a consequence of low titers of infectivity or the lack 
of nonproteinaceous phospholipids and RNA 86,92. 
The use of PMCA resolves the issues of low infectious titers and lack of cofactors. 
PMCA is able to create new infectious PrPSc molecules by combining PrPSc with PrPc and short 
bursts of ultrasound 93,94.  Using this technique, Soto and co-workers demonstrated that it is 
possible, through serial dilutions, to create new PrPSc in the absence of the original PrPSc used to 
seed the experiment 95.  This experiment not only supports the protein only hypothesis, but also 
shows that prions can be propagated in vitro indefinitely.  As powerful as these results are, it is 
the spontaneous generation of infectivity by Supattapone and co-workers that led many to 
believe that PMCA could be used as a tool to generate prions de novo 96.  However, no one 
experiment supports the protein only hypothesis more than the one performed by Wang et al. 97.  
This study elegantly demonstrates that highly infectious prions capable of infecting wild type 
mice could be generated from recPrP using PMCA in the presence of lipids and RNA.  This 
experiment also implies that cofactors likely aid in the production of prions with relatively high 
specific infectivity.  Future research will need to address whether these cofactors are vital parts 
of an infectious protein complex, or just simply catalyze the formation of prions from PrPC.   
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Prions and Their Role in Neurodegeneration 
One question that has puzzled researchers over the past two decades is “how do prions 
cause neurodegeneration?”  Despite substantial knowledge about the characteristics of prions, 
this question remains shrouded in mystery.  Several models have been put forth that may explain 
the neurodegeneration seen at terminal disease.  These models include direct toxic activity by 
PrPSc, alteration in PrPC signaling, PrPC mislocalization, and the creation of a PrP-derived 
oligomeric species.  With the ability to transmit infection, arise sporadically, or be inherited as an 
autosomal dominant condition, prions may exert their neurotoxicity through a multitude of 
mechanisms depending on how one acquires the disease.  Whatever the case, understanding the 
mechanism by which prions cause neurodegernation is vital in our understanding of prion 
diseases. 
Direct Toxicity of PrPSc  
The development of PrPC deficient mice greatly facilitated our knowledge of prion-mediated 
toxicity.  Early models proposed that it was a loss of function that facilitated the process of 
neurodegeneration; however, mice deficient in PrPC remain relatively healthy and it was 
speculated that a related or different protein adopts the missing prion protein within the cell, or 
that the function is redundant 98. This finding rules out neuronal toxicity due to PrPC loss of 
function.  A more accepted idea is that PrPSc is directly neurotoxic. This idea is logically 
supported by the observation that other more common neurodegenerative disorders, such as 
Alzheimer’s disease and Parkinson’s disease, also feature cerebral accumulation of misfolded 
protein aggregates 99-101.  Although several lines of in vitro data show PrPSc to be directly 
neurotoxic 102,103, observations in vivo show this model to be too simplistic.  There seems to be 
an inconsistency between the amount of PrPSc amyloids and the magnitude of brain damage and 
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disease 83,104-106.  Furthermore, PrPC deficient mice inoculated with scrapie show no signs of 
disease 74. This finding is of particular interest because it implies that induction of neurotoxicity 
by PrPSc may depend on a PrPC process.  Support of this hypothesis was shown by an experiment 
in which neural tissue graphs overexpressing PrPC were implanted into the brains of mice 
deficient in PrPC 107.  Inoculation of these mice with scrapie prions resulted in a lack of clinical 
signs, despite histopathological changes in the grafted tissue, which were similar to scrapie 
inoculated wildtype mice. Interestingly pathology never spread into the recipient brain, despite 
the appearance of PrPSc in both graft and host tissue.  This experiment clearly demonstrates the 
need for PrPC in neurotoxicity, as the presence of a continuous source of PrPSc is insufficient to 
cause neuropathological changes in PrPC deficient mice 107.  Similarly, suppressing the 
expression of neuronal PrPC during an established prion infection will avert neuronal loss and 
prevent signs that are associated with disease 108,109.  This prevention of prion disease occurs 
even though the extraneuronal PrPSc accumulates to levels seen in terminally infected animals 108.  
These findings show that it is the expression of PrPC, not the extracellular deposition of PrPSc, 
that dictates the development of disease.   
Aberrant PrPC Signaling  
Some hypothesize that it is not only the expression of PrPC that is important in neurotoxicity, but 
also the localization of PrPC within the plasma membrane. Transgenic mice expressing PrP 
lacking the GPI membrane anchor do not develop clinical signs when inoculated with scrapie 
prions 110.  This study is of particular interest because it implies that the PrPC GPI anchor plays a 
critical role in the pathogenesis of prion diseases.  With GPI-anchored molecules playing an 
important role in signal transduction, it has been hypothesized that transgenic mice deficient in 
GPI anchored PrP molecules lack the ability to send apoptotic signals when binding to PrPSc 110.  
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Indeed, antibody induced cross-linking of PrPC leads to neuronal cell death 111.  Although this 
antibody induced neurotoxicity represents a plausible model in which PrPSc binding to PrPC 
causes neurodegeneration, another laboratory failed to show similar results 112.  However, due to 
the structure and location of PrPC, it seems reasonable that apoptotic signaling by PrPC plays a 
critical role in prion pathogenesis.    
Altered PrPC Trafficking and Abnormal Topology  
Another suggested mechanism by which PrP can mediate neurotoxicity is through aberrant 
trafficking of PrP from the ER to the cytoplasm.  Here it is the normal cellular process of protein 
synthesis and degradation that may contribute to prion induced neurotoxicity.  Protein synthesis, 
under normal circumstances, can occur through a co-translational process by which proteins are 
translocated into the ER lumen during biosynthesis 113,114.  While in the lumen, chaperones assist 
in folding of the protein.  However in the event of misfolding, proteins are transported out of the 
ER lumen by a retrograde process marking the beginning of ER-associated degradation (ERAD) 
115.  This process culminates in the polyubiquitination and degradation of the misfolded protein 
by the proteosome.  It is this quality control mechanism within the ER that ensures fidelity of 
protein synthesis. Although this process is essential in maintaining PrPC homeostasis, it has been 
shown that ERAD mediated transport of PrP peptides into the cytoplasm and PrP accumulation 
through inhibition of the proteasome leads to PrPSc formation and neurotoxicity 44,116.  Thus, this 
mechanism of protein quality control by the ER may have a negative effect on the cell as it leads 
to the toxic accumulation and aggregation of PrP in the cytoplasm. 
Although ERAD may play an important role in (cyPrP)-induced neurotoxicity, other 
cellular mechanisms may contribute to the generation of cyPrP during neurodegernation.  Indeed, 
Rane et al. describes a possible mechanism by which nascent PrP peptides bypass translocation 
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into the ER lumen leading to their toxic accumulation in the cytoplasm 117.  In this model it is ER 
stress, due to PrPSc accumulation, that activates a “preemptive” quality control system (pQC). 
This system aborts PrP translocation into the ER lumen, allowing its degradation in the 
cytoplasm by the proteasome.  It is this rerouting into the cytoplasm through translocation 
attenuation that reduces PrP entry into and misfolding within the ER lumen.  This pathway of 
PrP rerouting represents a defense mechanism to inhibit nascent peptide entry into the ER lumen 
during a time when the ER’s normal function is in jeopardy.  However, during a TSE infection, 
chronic ER stress may cause a constant rerouting of PrP into the cytoplasm.  Consequently this 
influx of PrP may overwhelm the proteasome thereby causing neuronal cell death 118.   
In addition to aberrant trafficking, different topological forms of PrPC are suggested to be 
involved in the development of prion disease.  Although the majority of PrPC is found at the 
plasma membrane attached by its GPI anchor, a minor population of PrP can also be found 
within the ER membrane.  This population located within the ER comprises two transmembrane 
topologies, CtmPrP and NtmPrP, which have either their COOH or NH2 terminus in the ER lumen, 
respectively 119, 120.  It is suggested that inefficiencies of translocation during PrP biosynthesis is 
responsible for the generation of these topological forms 120-122.  Interestingly, by using 
transgenic mice that express PrP mutations that alter the relative ratios of these topological 
isoforms, it was shown that CtmPrP produce neurodegenerative changes in mice with features 
similar to that of a prion disease 123,124.  This finding may extend beyond the laboratory, as it is 
known that a specific mutation found in GSS causes an increase formation of CtmPrP 123.  Thus 
the ability to form CtmPrP and NtmPrP intermediates could lead to neurotoxicity and the 
formation of prion disease.   
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Although the above models explain various phenomena observed in prion diseases, some 
argue that aberrant signaling, altered trafficking, and abnormal topology of PrPC is challenged by 
the observation of subclinical infections 86. Subclincal infections occur when prions from one 
species are inoculated into a second species.  These carrier states are characterized by slow prion 
propagation, which eventually leads to titers of PrPSc seen in end stage clinical disease.  It is 
these carrier states that have led some to hypothesize that it is the creation of a toxic PrP-derived 
oligomeric species during replication that is responsible for neurodegeneration 86.  This idea of 
small toxic oligomers is gaining great attention, as a growing number of scientists believe that it 
is these small aggregates that are the cause of other protein misfolding disorders 125.  
Linking Prion Propagation Kinetics to Neurotoxicity  
Some researchers suggest that a model of prion toxicity through the generation of toxic 
PrP oligomers, can account for these subclinical infections.  This model of prion 
neurodegeneration links prion propagation kinetics to neurotoxicity 86. It is hypothesized that 
during prion replication an intermediate form of the prion (PrPL) is created. 
This model developed by John Collinge can be written as: 
                                                                 K1                K2 
PrPSc+PrPC→PrPSc:PrPC→PrPSc:PrPL→ PrPSc:PrPSc→PrPSc+PrPSc 
Here, PrPL represents the toxic species, and the relative concentrations of PrPL and PrPSc 
are controlled by the ratio of the initial rate of conversion (K1) to the rate of maturation (K2) 86. 
This formula for prion neurodegeneration adequately explains subclinical infections, where the 
initial rate of conversation (K1) would be relatively slow compared to the rate of the rate of 
maturation (K2).  Consequently, this would result in low levels of PrPL, but relatively high levels 
of PrPSc 84.  Indeed, WT mice inoculated with hamster prions develop very high levels of PrPSc in 
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their brains, yet these mice live a relatively normal life 126.  This model also explains why prion 
infected Prnp+/- mice (50% of wild-type PrPC expression) succumb later to disease than Prnp+/+ 
mice.   The decreased expression of PrPC in Prnp+/- mice results in a slower rate of infectivity 
titer, which may result in a slower rate of accumulation of PrPL.  On the other hand, Tga20 mice, 
which express 10 fold more PrPC than WT mice, have a short incubation time.  This is due to the 
higher (K1) compared to (K2).  Consequently, this leads to rapid build up of PrPL and a short 
incubation period.  In these mice it is the high level of PrPC expression that allows for more 
PrPSc:PrPC complexes.  The increase in these encounters allow for a high level of PrPSc:PrPL and 
therefore a short life span.  Thus, the ability of prions to infect and cause disease in a host is 
determined by the delicate balance between (K1) and (K2) 86.     
Another alternative, but related model, postulated by John Collinge is that PrPL is not 
produced as an intermediate along the pathway to mature PrPSc 86.  In this scenario, mature PrPSc 
acts as a surface template for the convertion of PrPC to PrPL.  So essentially in this model PrPL is 
a toxic templated side product.  The difference between this model and the one mentioned above 
is that PrPL is not generated as an intermediate, but a side product generated by PrPSc.  This 
model of generating PrPL may explain why in vivo prion propagation and toxicity occur in two 
distinct phases 127.  In phase one nontoxic prions (PrPSc) replicate until they reach a similar 
plateau regardless of PrPC expression levels.  In phase two, where there is no increase in 
infectivity (PrPSc), the rate of formation of PrPL is dependent on the expression of PrPC.  
Although the above model describes a situation where production of PrPL is directly 
proportional to PrPC concentration, many argue another interpretation of this model can be 
extrapolated 128.  It is hypothesized that there is no need to postulate PrPL to account for the well-
accepted fact that PrPC expression determines the speed of prion disease.  With PrPL being 
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undefined, it is thought that PrPL may be identical to PrPSc and that PrPC controls neurotoxic 
signals arising from PrPSc.  This idea of toxic signaling is interesting because it postulates that 
lower PrPC expression leads to a decrease in sensitivity of neurons to toxicity.  This concept of 
toxic signaling threshold may explain why Prnp+/- mice (with 50% of the WT PrPC expression) 
shows delays in incubation period when compared to WT mice.  It is also thought that it may 
explain the findings by Mallucci et al., in which depletion of neuronal PrP during a established 
brain infection rescues mice from developing clinical disease 108, 128.  Although, this represents a 
valid model it still may not account for subclinical infections.  It is logical to suggest that prions, 
with their ability to arise through many etiologies, may exploit many of these mechanisms.         
Chronic Wasting Disease 
CWD was originally recognized as a syndrome in captive mule deer in the late 1960s at a 
wildlife research facility in Fort Collins, Colorado. Initially, it was believed that the syndrome 
was the result of nutritional deficiencies, intoxication, or stress associated with captivity 129. It 
was not until 1978 that E.S. Williams and S. Young observed clinical features and 
histopathological changes that were strikingly similar to other prion diseases.  It was these 
similarities that led E.S. Williams and S. Young to correctly identified CWD as a spongiform 
encephalopathy 5. Today CWD is recognized as a highly contagious prion disease of unknown 
origin affecting both wild and farmed raised deer, moose, and elk 5-7. 
Although the majority of natural sources of prion diseases are well established, the origin 
of CWD remains unknown.  It has been hypothesized that CWD is a spontaneous disease of 
cervids however, this notion is difficult to confirm.  The ability of other prion diseases to cross 
species barriers has led to the belief that CWD emerged by transmission of prions from another 
species.  Reports of sheep scrapie in the US, along with the ability of sheep, deer and elk to share 
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pastures, has led to the idea that trans-species transmission occurs between these animals 24.  
Support of this notion comes from studies showing transmission of scrapie prions to both elk and 
cervidized mice 130, 131.  Interestingly, polymorphisms at codon 132 of elk have been shown to 
dictate the susceptibility of cervids to scrapie 131.  
Once thought of as a rare TSE disease located exclusively in the central US, CWD has 
since become the most contagious and least understood of the prion diseases. Recent surveillance 
shows that the geographical distribution of CWD has expanded beyond Colorado and Wyoming, 
effecting 17 states and two Canadian provinces (Alberta and Saskatchewan) 24,132. 
Noncontiguous clusters characterize the geographical distribution of CWD with reported cases 
seen as far West as Utah and extending as far East to New York and West Virginia.  Recently, 
imports of deer from Canada have expanded the distribution of CWD to include countries 
outside North America, such as South Korea 133. With a seeming inability to control or contain 
CWD, it appears likely that this prion disease will continue to expand its geographical 
distribution throughout North America and possibly other countries. 
With the prevalence rates of CWD in wild and captive herds reaching as high as 50% and 
>90% respectively, intensive research has been put forth to determine the mode of transmission 
24, 134.  Infectious prions have been found in blood, saliva, feces, and urine from cervids affected 
with CWD 135-138.  These bodily fluids, along with decomposing carcasses, represent possible 
contaminants by which CWD could be transmitted in a natural environment.  There is also 
considerable evidence that prions can exist in the environment for extended periods of time, and 
this persistence in the environment represents a possible reservoir for CWD transmission 139-141. 
It is well established that prions are inherently stable, showing an ability to withstand UV, heat, 
and proteases 2,76,77.  This perceived stability has led many to hypothesize that prions are capable 
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of withstanding natural stresses such as UV, freeze/thaw cycles, and extracellular enzymes from 
fungi and bacteria 24.  Prions have also been shown to adhere to metals within soil and remain 
infectious for many years 139,141-143.  This remarkable persistence of prions in the environment 
may result in efficient transmission to naïve cervids that forage or drink from the same water 
sources as CWD infected animals. 
The clinical signs of CWD are similar between experimentally inoculated animals and 
wild cervids that are naturally exposed to the disease.  Most descriptions of clinical signs come 
from experimentally inoculated animals and are characterized by a long incubation period 
followed by a rapid clinical course.  Terminally sick animals present with progressive weight 
loss, polyuria, odontoprisis, and sialorrhea 134.  In captive animals sudden death is rare, and 
clinical disease can range from months to even a year in some cases 144. In wild populations, 
behavioral changes including depression and isolation from the herd have been observed.  
Extreme environmental conditions, predation, and an inability to forage or find water may 
decrease this period of clinical disease in wild cervids 24. 
CWD presents as a neurological disorder with clinical signs that include ataxia and head 
tremors 134.  The histopathological features observed in CWD in many ways mirror what are seen 
in other prion diseases 145,146.  Histolopathological analyses show lesions in the grey matter that 
are bilaterally symmetrical and anatomically uniform among cervids 24.  Severe vacuolization of 
neuronal perikarya and neuronal processes may be accompanied by deposition of PrPCWD 
plaques, astrocytic hyperplasia and hypertrophy 147,148.  Post-mortem analysis may also show 
PrPCWD deposition in extraneuronal sites such as secondary lymphoid organs (SLOs) 146,149. 
Due to the dissemination, persistence, and migratory capacity of wild cervids, control of 
CWD is extremely difficult.  Although no increase in cases of CJD have been reported in places 
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where CWD is endemic, the possibility of transmission remains feasible 24. Therefore, wildlife 
disease management and prion researchers must design diagnostic techniques and possible 
strategies to control and contain CWD.  Emphasis in control and containment may be needed 
most, as CWD seems to be expanding its geographical distribution. 
Peripheral Prion Immunology 
In a laboratory setting the most effective way to induce a prion disease is by delivering 
prions directly to the brain by intracerebral inoculation.  This route of infection may be of 
particular significance when studying neuroimmunological events in prion disease.  However, 
this artificial route of infection does not correspond to what is normally seen in nature, and when 
studying the early events in prion disease, it is essential to explore other more natural routes of 
infection 119.  Typically, infection through various different peripheral routes is the standard 
when studying incunabular events in prion mediated immune cell responses.  The majority of 
prions that cause human TSEs are acquired through oral challenge 150-153.  Prions can also infect 
the host through the blood, peritoneal cavity, skin, and eye 154-157.  Of these routes of infection, 
oral, intraperitoneal, intravenous, and skin scarification have all been shown to involve cells of 
the lymphoreticular system (LRS) 10, 164, 191,164.  
Although TSEs are thought of as neurological diseases, it is the early immunological 
events that dictate the course of prion pathogenesis.  Early transmission experiments showed that 
SLOs contain prions and led to the hypothesis that prions exploit lymphoid tissues for self-
propagation before entry into the CNS 158-160.  Since these early findings, substantial evidence 
showed that B lymphocytes, follicular dendritic cells (FDCs), complement proteins and 
complement receptors are the main immune components involved in peripheral prion replication 
161-163.  While the involvement of these components in prion replication remains crucial in 
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pathogenesis, recent data suggests that cells of the innate immune system also play an important 
role in dictating the outcome of infection. Temporarily depleting certain antigen presenting cells 
(APCs) or disrupting their pattern recognition receptors (PRRs) significantly alters prion 
pathogenesis 164,165.  Today it is well recognized that the immune system plays an instrumental 
role in prion pathogenesis; therefore, the identification of the cells and molecules involved in 
prion pathogenesis might pinpoint potential targets for therapeutic interventions.     
Prion uptake and trafficking: phagocytes take center stage 
Oral exposure 
Many TSEs, including Kuru, variant Creutzfeldt–Jakob disease (vCJD), BSE, scrapie, and CWD, 
are acquired through an oral route of infection 141,150,151,153,166.   After oral exposure prions 
accumulate in the distal ileum, and within several weeks can be found to accumulate and traffic 
in a defined temporal sequence throughout peripheral nerves.119,167.  This process of 
neuroinvasion relies on prion replication by follicular dendritic cells (FDCs) located in gut-
associated lymphoid tissue (GALT) 168-170.  Several immune cell interactions with prions precede 
this replication phase and are vital for establishing a disease.  Recently, several groups have 
identified a variety immune cell types that are important in uptake and transport of these prions 
during an oral infection. 
After ingestion of prion-contaminated food, it is critical for prions to cross the intestinal 
epithelium before replication on FDCs within Peyer’s patches (PP).  One way by which this is 
accomplished is through the follicle-associated epithelium (FAE), which is a unique cell layer 
comprised of enterocytes and specialized endocytic epithelial cells called Microfold cells (M 
cells) 171.  The FAE is located above the PP and establishes an interface between the GALT and 
the intestinal luminal.  PPs are devoid of afferent lymphatics, so antigens must travel from the 
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gut into PP through M cells.  This cell type plays a crucial role in microbial survalance because 
is allows the host to sample the intestinal lumen and induce the proper immune response 172,173.  
However, many pathogens have evolved to take advantage of this trans-epithelial transport to 
gain access into the mucosal tissues; therefore, it has been suggested that M cells play a crucial 
role in prion transcytosis after oral infection 174-176.  Studies show that orally administered prions 
incorporate into M Cells, and depleting these cells by RANKL neutralization at the time of oral 
exposure leads to ablation of disease 177-180. 
Several other studies show that enterocytes transport prions independent of M-cells, and 
this trancytosis may depend on a receptor-mediated pathway 181,182.  Ferritin was found to form a 
complex with PrPSc upon transcytosis across Caco-2 epithelial cells. Ferritin is an intracellular 
protein that stores iron and is abundantly present in meat dishes 183.  It has been suggested that 
this PrPSc-ferritin complex facilitates prion transport through a receptor-mediated pathway across 
the intestinal epithelium 182.  
After transcytosis by M cells and epithelial cells, antigen acquisition by dendritic cells 
and macrophages is thought to occur 184-186.  These cells are positioned in the sub-epithelial dome 
of PPs, where they sample antigens from the FAE.  Several experiments indicate that DCs and 
macrophages take up prions after oral infection and transport them to sites of replication within 
germinal centers of lymphoid tissues 164,179,187,188.  In some cases, this prion uptake and transport 
was independent of PrPC expression 179.  Although a model of prion capture and transport from 
the gut lumen to germinal centers of lymphoid tissues is well established, the mechanisms of 
how prions infect the peripheral enteric nervous system remains unknown. 
Phagocyte-prion interaction through other peripheral sites of infection 
In addition to oral exposure, other routes of peripheral infection have been explored.  
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Skin scarification has long been known to be highly efficient at causing prion disease 189,190.  It is 
conceivable that DCs in the skin play an important role in the early phase of disease.  Indeed, 
skin-derived dendritic cells capture and degrade prions following in vitro exposure 191.  
However, in vivo evidence of skin-derived DCs acquiring, degrading, or even trafficking prions 
remains unknown.  The notion that these cells take up and traffic prions to resident draining 
lymph nodes and the CNS is supported by a number of experiments 164,188,192,193.  One particular 
experiment shows that prion infected splenic DCs can propagate infection from the periphery to 
the CNS in the absence of any additional lymphoid elements 193.  This result is intriguing, as 
peripheral prion replication seem to be dispensable in this process.    
Prion diseases can also be initiated through the intraperitoneal route of infection 155.  Just 
as in oral infection and skin scarification, immune cells seem to dictate the early stages of 
disease.  Temporarily depleting CD11c+ dendritic cells after intraperitoneal infection results in 
delays in lymphoinvasion 192.  It is worth noting, however, that transient depletion of CD11c+ 
cells in CD11c-DTR transgenic mice, initially thought to specifically deplete DCs, has also been 
shown to reduce macrophage subsets in the lymph node and spleen 194,195.  This involvement of 
DCs and macrophages, along with the observation that peritoneal macrophages associate with 
and degrade prions, indicates a critical role of these cells in the intraperitoneal route of infection 
196.  While these experiments hint at a possible role of the LRS after i.p. infection, little is known 
about the initial confrontation between prions and these innate immune cells. 
Prion mediated activation of phagocytes  
Prion protein Fragment PrP 106-126 
Examination of human prion diseases has shown the existence of amyloid fibril deposits made up 
of insoluble cleavage products from PrPSc 197. These amyloid fragments, which can reach high 
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concentrations in the brain of infected individuals, have been shown to consist of N-terminally 
truncated forms of PrP that contain amino acids 106-126 198. PrP106-126, which has been shown to 
be toxic to cultured neuronal cells expressing PrPC, demonstrates high tendencies to form 
amyloid like fibrils morphologically similar to PrPSc. It also contains high β-sheet content, is 
partially resistant to proteases, and is capable of activating glial cells 103,199-202. Due to these 
biochemical properties, PrP106-126 is a suitable tool to model the molecular immunological 
features of prion disease.  
Prion mediated proinflammatory response 
As with other pathogens, prions show an ability to elicit an inflammatory response. In 
prion infected mice, several inflammatory transcription factors and mRNA transcripts have been 
characterized 203-207.  Treatment in vitro with PrP106-126 results in activation of microglial cells, 
monocyte-derived dendritic cells and macrophages 208-210.  This activation by PrP106-126 and 
prions involves transcription factors p38 mitogen-activated protein kinase (MAPK) and nuclear 
factor-κB (NFκB), which resulted in secretion of pro-inflammatory cytokines IL-6, TNF-α, and 
IL-1β 209,211-213.  These data demonstrate that although there is no humoral response to prions, 
activation of the innate immune system, possibly through PRRs, may play a critical role in the 
early events of infection.  Indeed, activation of toll-like receptor 4 (TLR-4) has shown to 
suppress prion disease after both ip and ic inoculations 165.  Interestingly, this suppression by 
TLR-4 was shown to be independent of MyD88, as infection of MyD88 deficient and wild-type 
mice exhibited similar incubation periods, infection kinetics, neuropathologies 214.         
Although immune cell uptake, activation, and trafficking remain an important aspect of 
prion diseases, several scientific groups have tried to elucidate the molecular and cellular 
mechanisms involved in peripheral prion propagation.  Interestingly, unlike many other 
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pathogens, prion trafficking to lymphoid tissues leads to enhanced susceptibility to disease.  
Over the last 20 years great strides in our knowledge of peripheral prion replication has led to a 
better understanding of how these TSEs infect and cause disease in the host.            
Lymphoid tissues; Sites of prion replication 
Although prion diseases are classified as a neurodegenerative disorder, it is well known 
that infectious prions colonize secondary lymphoid organs in infected hosts.  This colonization of 
lymphoid tissue results in lack of pathology despite replication of prionsto high titers 215.  This is 
in contrast to what is seen in the CNS, where prion replication leads to severe spongiosis, 
astrosytosis, and neuronal cell death 1.  
It is generally well accepted that during a prion infection lymphoid tissues play a vital 
role in pathogenesis.  Following intracerebral (ic), ip or oral exposure, prions can be detected in 
the spleen, lymph nodes, PP, and tonsils 10,74,158,170,216,217.  Prions can be identified in these 
lymphoid tissues in a matter of hours or days, whereas detection in the brain can only be 
observed after several months post inoculation 10.  Mice that have their spleen surgically 
removed prior to, or shortly after, peripheral inoculation of prions show delays in prion 
pathogenesis 158,215, 218. Similar results are seen in asplenic mice.  This is in stark contrast to what 
is observed in mice deficient in a thymus 219.  Inoculation of these mice with prions results in no 
alteration of disease.  This indicates that T lymphocytes have little to no role in prion 
pathogenesis.  Studies of splenectomy at various times after ip inoculation show that 
pathogenesis becomes independent of the spleen once prions have initiated replication in the 
spinal cord 220.  However, this requirement for the spleen in prion pathogenesis is not absolute, as 
inoculation of the Fukuoka-1 strain of Creutzfeldt-Jakob disease agent or scrapie (263K) into 
asplenic mice or hamsters, respectively, has no effect on disease progression 221,222.  Natural 
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cases of BSE and atypical scrapie also show no PrPSc in their lymph nodes, further exemplifying 
that prion replication by the LRS may be strain dependent 223,224.  These data suggest that prion 
strains can be categorized as either lymphotropic or neurotrophic depending on the requirement 
of the LRS. 
After it was suggested that lymphoid tissues contain infectious prions, cell isolation 
experiments were performed in an attempt to find the prion distribution among the LRS.  Cells 
separated in density gradients of isotonic albumin showed that immune cells associated with 
relatively high infectivity had a density gradient characteristic of lymphoblasts, myeoblasts, and 
macrophages 225.  Although these initial studies implicated these cell populations in prion uptake, 
prion replication by these cells could not be demonstrated.  In an effort to characterize the cell 
compartment important in prion replication (or accumulation), spleen fractions were isolated 
from mice infected with scrapie.  It was shown that stromal compartments of the spleen 
contained 10 times greater infectivity than the pulp.  There was a strong correlation between the 
total titers in the stroma and the weight of both whole spleen and stroma fractions 226.  This 
observation led to the hypothesis that replication takes place on the metabolically and 
structurally stable cells of the stroma.  It was also suggested that these cells involved in prion 
replication were not mitotically active.  Whole body irradiation, which selectively targets 
mitotically active cells, failed to alter the disease progression in mice infected with scrapie 227.  
Taken together, these data show that replicate or accumulate of prions occurs largely on 
radioresistant, post-mitotic cells located in the stromal compartments of lymphoid tissues.  
Peripheral Immune Cells involved in prion replication 
The role of B lymphocytes in prion replication 
With the discovery that lymphoid tissues transmit infectivity to naïve animals, it was 
	  29	  
becoming increasingly apparent that immune cells participate in peripheral prion pathogenesis.  
With the use of immunocompromised mice and bone marrow reconstitution experiments, cells of 
hematopoietic origin were soon shown to be involved in prion replication.  Although their 
involvement was evident, it became clearer that only a subset of these immune cells contributed 
to prion replication in lymphoid tissues.             
Characterizing immune cells important in prion replication using a panel of immune-
deficient mice provided crucial information about prion pathogenesis.  When mice deficient in 
CD4, CD8, β2 microglobulin, poriforin, and therefore T lymphocytes, were exposed to prions, 
they developed disease and latency periods similar to WT control mice.  However, ip inoculation 
of µMT and Rag-deficient mice, both of which are devoid of B lymphocytes, showed no disease 
or infectivity in the spleen 161.  These data indicated that defects in B lymphocytes, but not T 
lymphocytes, had a profound impact on prion disease progression.  However, the question of 
whether these B lymphocytes directly participated in prion replication or played a more indirect 
role still was not known.  It was not until scientists employed the use of adoptive transfer 
experiments and transgenic mice that information on the role of B lymphocytes in prion 
replication become clear. 
To assess the requirement of PrPC expression by B lymphocytes in prion replication and 
neuroinvasion, fetal liver cells (FLCs) derived form either PrPC expressing or PrPC deficient 
mice were used to repopulate SCID and Rag deficient mice 228.  FLCs from both PrPC expressing 
and PrPC deficient mice had the same ability in restoring peripheral replication and 
neuroinvasion after ip inoculation of prions.  Furthermore, repopulating these 
immunocompromised mice with FLCs from T lymphocyte deficient mice, but not from B 
lymphocyte deficient mice, successfully restored disease.  This indicated that while B 
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lymphocytes are important in prion replication and neuroinvasion, the expression of PrPC by 
these cells were not.  Although PrPC expression was dispensable in these processes, splenic B 
lymphocytes could be observed associating with prions 229.  This raised the question of whether 
B lymphocytes had the capacity to replicate prions or just acquire them from other cells.  Using 
Tg mice, which express PrP exclusively on B lymphocytes, it was shown that these cells failed to 
replicate prions in the spleen after ip inoculation 230.  These data indicated that B lymphocytes 
themselves are unlikely involved in replication, and further supported the observation that cells 
of the stromal compartment are the main cell type involved in prion replication.  In light of these 
findings it was soon hypothesized that B lymphocytes play a critical role in prion pathogenesis 
by supporting or maintaining cells important in prion replication. 
 The role of FDCs in prion replication 
Follicular dendritic cells (FDCs) are the main cell type responsible for prion replication, 
and the capacity of FDCs to replicate prions is dependent on B lymphocytes 231-237.  These cells 
express high levels of PrPC and are found in the follicles of lymphoid tissues.  FDCs under 
normal physiological conditions are responsible for the maintenance of the lymphoid 
microarchitecture 238,239.  However, after exposure to pathogens these cells are involved in 
antigen trapping of immune complexes by Fcγ receptors.  FDCs also bind opsonized antigens 
through complement receptors CD21/35 240-242.  These specific characteristics of FDCs establish 
these cells as important contributors to prion replication and neuroinvasion.  
Not only do FDCs accumulate PrPSc following inoculation of mice with prions, but many 
studies suggest that replication of prions in the spleen requires PrPC-expressing FDCs 234,236.  
FDC development and maintenance was shown to be dependent on tumor necrosis factor (TNF) 
and lymphotoxins (LTs) α and β, which are proinflammatory cytokines mainly produced by B 
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lymphocytes 237.  Treatment of mice with soluble lymphotoxin-β receptor, which depletes LT, 
resulted in a lack of mature FDCs and significantly impaired peripheral prion pathogenesis 236. 
This indicated that mice deficient in LT signaling show a significant resistance to peripheral 
prion exposure.  These data not only highlight the role of B lymphocytes in peripheral prion 
pathogenesis, but give substantiating evidence for a direct role of FDCs in prion replication. 
Although FDCs play a critical role in peripheral prion replication, it has been suggested 
that other cells may also participate in prion replication.  TNFR-/- and TNFα-/- mice inoculated ip 
with prions showed similar attack rates to WT mice 243.  Despite the absence of FDCs or 
germinal centers in these mice prion infectivity could be detected in the lymph nodes; however, 
no infectivity could be detected in the spleens.  This illustrates that prion infectivity could be 
restricted to certain lymphoid tissues, and prion replication by FDCs are expendable in this 
process 243.   
Recently, ectopic prion replication in granulomas was shown in mice inoculated with 
prions 244.  Reciprocal bone-marrow grafting experiments indicated that cells of stromal origin 
were the source of PrPC and prion replication.  Interestingly, granulomas from these prion-
inoculated mice lacked FDCs, but expressed almost equal amounts of LTβR mRNA as Prnp+/+ 
mouse spleens.  Treatment of these mice with a LTβR-immunoglobulin fusion protein (LTBR-
Fc) suppressed prion replication in these granulomas.  However, LTβR-Fc treatment did not alter 
PrPC expression, formation, maintenance, and morphology of these inflammatory stromal cells.  
These data showed that stromal cells distinct from FDCs could attain prion-replication capability 
in vivo in a LTβR-signaling-dependent manner 244.  
The Complement system; its role in FDC mediated prion uptake and replication 
The complement system, composed of nearly 30 soluble and cellular membrane proteins, 
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is a group of heat-labile proteins found in normal plasma that provides an innate immune defense  
mechanism against invading pathogens 245,246.  All pathogens express a unique set of pathogen-
associated molecular patterns (PAMPS) that are involved in the activation of the complement 
cascade 247,248. 
Once activated, complement proteins can interact with one another to aid in the 
opsonization of pathogens, lyse infected cells, and promote a series of inflammatory responses.  
Not only does the complement system eliminate infectious microorganisms, but it also provides a 
bridge between the innate and adaptive immune systems 249,250.  One immune cell that facilitates 
this complement mediated bridge between the innate and adaptive immune system is the FDC.   
The main function of FDCs during an immune response is to trap and retain antigens 
derived from pathogens.  These antigens, in the form of antigen:antibody:complement 
complexes, are retained on the cell surface for extended amounts of time through Fc and 
complement receptors 241,251-253.  These immune complexes are presented to B lymphocytes 
initiating a humoral response, and hence, eliminating the pathogen 253.  Thus complement 
activation leads to bound immune complexes and initiation of an antibody response. However, 
many pathogens have countered this complement-mediated assault by developing unique 
strategies to disrupt complement regulatory components to prevent being eliminated.  Other 
pathogens have persisted and replicated in the host by taking advantage of complement 
interactions, which facilitated their attachment to host cells. 163, 254-256.  
The contribution of the complement system during a prion infection has been studied for 
several years.  Mice lacking complement components C1q, factor B, C2, C4, and C3 have been 
used to show the role of the complement system in retention of PrPSc in lymphoid tissues after 
peripheral exposure to prions.  These experiments demonstrate that depletion of these 
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complement components leads to a decrease in PrPSc accumulation and an increase in survival 
time 11.  Interestingly, depletion of C1q has a greater impact on prion disease progression than an 
absence in the other downstream complement components. This implies that C1q might directly 
bind and mediate uptake of prions after peripheral exposure.  Indeed, C1q has bound PrPC in 
vitro in a conformation- and density-dependent manner, and these C1q-PrP complexes have been 
shown to activate the complement classical pathway 257-260.  These data indicate that complement 
activation and opsonization is the main mechanism by which FDCs accumulate and retain prions 
in lymphoid tissues. 
With the knowledge that FDCs associate with complement opsonized antigens through 
the complement receptor CD21/35, many scientists speculate whether there is a role of this 
complement receptor in prion disease pathogenesis.  Through reciprocal adoptive bone marrow 
transfer experiments between WT and CD21/35-/- mice, it was shown that FDCs deficient in 
CD21/35 exhibit an incomplete attack rate or a delay in incubation time when exposed 
peripherally to prions 163.  Interestingly, elimination of CD21/35 impacted prion trapping and 
disease more profoundly than ablating their ligand sources, C3 and C4.  This implies a role for 
CD21/35 in peripheral prion pathogenesis independent of their endogenous ligands.  
Ectopic prion replication 
Although the contribution of immune cells and proinflammatory cytokines during prion 
replication are well established, several studies have suggested that prion replication may extend 
beyond lymphoid tissues, expanding the tissue tropism of prions 261,262.  CJD patients suffering 
from inclusion body myositis, an inflammatory disease of muscle, accumulate PrPSc 263.  This 
ectopic prion replication in nonlymphoid organs is suggested to involve similar immune cells 
and proinflammatory cytokines as lymphoid tissues.  Indeed, inoculation of prions into mice 
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suffering from nephritis, hepatitis, or pancreatitis showed PrPSc accumulation and a strong 
upregulation of LT and FDCs in these inflamed organs 262.  These data suggest that prion 
distribution throughout the host could be dictated by inflammation or exacerbated by concurrent 
infections. 
Farmed raised animals are commonly exposed to inflammatory pathogens.  This 
opportunistic interaction has led to the hypothesis that ectopic prion replication may be a 
common occurrence in livestock.  Indeed, Sarda sheep with natural scrapie infections and 
coexisting mastitis accumulated PrPSc in their mammary glands 261.  Interestingly, some of these 
chronic inflammatory disorders affect organs that are important in secretion of bodily fluids.  
Milk from lentiviral-induced mastitis or urine from mice suffering from nephritis infected naïve 
suckling lambs and mice respectively 264,265.  Taken together these data implicate inflammatory 
processes in the tissue distribution and horizontal transmission of prion diseases.   
Conclusion 
Advances in the development of techniques and tools have enabled prion biologists to 
answer some long-standing questions in prion biology; however, several questions still remain.  
The exact physiological function of PrPC remains to be clarified.  Answering this vital question 
could potentially help prion biologist understand the exact molecular mechanism of prion-
induced toxicity. Although significant progress has been made in prion immunology, several 
long standing-questions remain unanswered.  The initial immunological events that occur upon 
infection remain to be characterized.   
Although several experiments implicate immune cells in prion trafficking, no real direct 
evidence has been put forth to show this to be the case.  In addition, several studies have shown 
immune cells to play a vital role in prion replication; however, the role of complement proteins 
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and their receptors in CWD remains shrouded in mystery. Elucidation of these immunological 
events could better help researchers understand the process of peripheral prion pathogenesis.  
Furthermore, the characterization of immune cells involved in prion capture, trafficking, and 
replication would have dramatic implications in prion immunotherapeutics.           
Introduction to work in this Dissertation Research 
The main objective of the current research is to gain a greater understanding of the 
immunological events involved in a CWD prion infection.  The overall hypothesis for the 
thesis is that early immunological events in CWD prion infection dictate the course of 
disease.  Utilizing fluorescently labeled prion rods and transgenic mice deficient in certain 
complement components we addressed the following questions: 
Question 1: What are the immune cells that associate with prions in the earliest stages of a 
CWD prion infection? 
While prions most likely interact with the innate immune system shortly following 
infection, little is known about this initial encounter. Here we investigated incunabular events in 
lymphotropic and intranodal prion trafficking by following highly enriched, fluorescent prions 
from infection sites to draining lymph nodes.  As we have shown in an earlier study, prions can 
be detected in the draining lymph nodes within hours of intraperitoneal inoculation.  However, 
through adoptive transfer experiments we demonstrate here that prions arrive in draining lymph 
nodes cell autonomously within two hours of intraperitoneal infection.  We show that DCs and 
monocytes require C1q and/or C3 for optimal prion capture, whereas macrophages 
predominantly and efficiently captured prions independent of these complement components.  
We show an incredible proportion of prion bearing B cells in MedLNs at early time points, and 
suggest that these cells are most likely receiving prions from other immune cells, most likely 
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SCS macrophages and resident DCs within the lymph nodes.  Based on these data, we introduce 
an updated, more detailed model of lymphotropic and intranodal prion trafficking by immune 
cells. 
Question 2: What is the role of complement receptor CD21/35 in a CWD prion infection?  
The Complement System has been shown to play an integral part in peripheral prion 
pathogenesis. Mice lacking Complement receptors CD21/35 showed delays in prion 
pathogenesis when exposed peripherally to mouse-adapted scrapie prions. Chronic wasting 
diseae (CWD) is a highly contagious prion disease of captive and free-ranging cervid 
populations, and similar to scrapie has been suggested to involve the peripheral immune system. 
Here we show that mice overexpressing the cervid prion protein and susceptible to CWD 
(Tg(cerPrP)5037 mice) but lack CD21/35 expression completely resist clinical CWD upon 
peripheral infection.  This resistance to CWD by Tg 5037;CD21-/- strongly correlates with little 
or no pathology in the brain.  Semi-quantitative analysis of these mice suggests an impairment of 
splenic prion accumulation and replication throughout disease.  We show that CD21/35 
translocates to lipid rafts during a prion infection and is accompanied by a strong germinal center 
response.  We postulate that this germinal center response provides an ideal environment for 
prion accumulation and replication.  Lastly, we propose that CD21/35 may exhibit a 
conformational bias towards certain prion quasi-species present in prion strains.  This may lead 
to selection of certain prion quasi-species that exhibit differential zoonotic potential compared to 
the parental strains.  
Question 3: What is the role of complement component C3 in CWD prion infection? 
Commonly described as linear in nature, the complement system actually functions as a 
hub-like network with C3 being one of the main components 245.  C3 is the most abundant 
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complement protein, being found in the blood at physiological concentrations of 1 mg/ml.  
Previous experiments suggest a vital role of C3 in scrapie prion pathogenesis.  Here we show 
that lack of C3 expression by 5037 mice either transiently or genetically leads to delays in prion 
pathogenesis.  Using semiquantitative PMCA we show that C3 impacts disease progression in 
the early stages of disease by slowing the kinetic rate of accumulation and/or replication of 
PrPRES. This slower kinetic increase in PrPRES correlates with an increase in survival time in mice 
deficient in C3.  This delay in disease is in sharp contrast to the complete rescue we saw in CWD 
infected Tg 5037;CD21-/- mice.  This suggests a role for CD21/35 in peripheral prion 
pathogenesis independent of their endogenous ligands. 
	  38	  
REFERENCES 
1. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. 
Annu. Rev. Neurosci. 24, 519–550 (2001). 
2. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136–
144 (1982). 
3. Carleton Gajdusek, D. Transmissible and non-transmissible amyloidoses: autocatalytic 
post-translational conversion of host precursor proteins to β-pleated sheet 
configurations. J. Neuroimmunol. 20, 95–110 (1988). 
4. Jarrett, J. T. & Lansbury, P. T., Jr. Seeding ‘one-dimensional crystallization’ of amyloid: 
A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055–1058 
(1993). 
5. Williams, E. S. & Young, S. Chronic wasting disease of captive mule deer: a spongiform 
encephalopathy. J. Wildl. Dis. 16, 89–98 (1980). 
6. Baeten, L. A., Powers, B. E., Jewell, J. E., Spraker, T. R. & Miller, M. W. A natural case 
of chronic wasting disease in a free-ranging moose (Alces alces shirasi). J. Wildl. Dis. 
43, 309–314 (2007). 
7. Williams, E. S. & Young, S. Spongiform encephalopathy of Rocky Mountain elk. J. 
Wildl. Dis. 18, 465–471 (1982). 
8. Hill, A. F. et al. The same prion strain causes vCJD and BSE. Nature 389, 448–450 
(1997). 
9. Scott, M. R. et al. Compelling transgenetic evidence for transmission of bovine 
spongiform encephalopathy prions to humans. Proc. Natl. Acad. Sci. U.S.A. 96, 15137–
15142 (1999). 
10. Michel, B. et al. Incunabular immunological events in prion trafficking. Sci. Rep. 2, 440 
(2012). 
11. Klein, M. A. et al. Complement facilitates early prion pathogenesis. Nat. Med. 7, 488–
492 (2001). 
12. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. 
Rev. Neurosci. 4, 49–60 (2003). 
13. Riek, R., Hornemann, S., Wider, G., Glockshuber, R. & Wuthrich, K. NMR 
characterization of the full-length recombinant murine prion protein, mPrP(23–231). 
FEBS Lett. 413, 282–288 (1997). 
14. Riek, R. et al. NMR structure of the mouse prion protein domain PrP(121-231). Nature 
382, 180–182 (1996). 
15. Zahn, R. et al. NMR solution structure of the human prion protein. Proc. Natl. Acad. Sci. 
U.S.A. 97, 145–150 (2000). 
16. Hornshaw, M. P., McDermott, J. R., Candy, J. M. & Lakey, J. H. Copper Binding to the 
N-Terminal Tandem Repeat Region of Mammalian and Avian Prion Protein: Structural 
Studies Using Synthetic Peptides. Biochem. Biophys. Res. Commun. 214, 993–999 
(1995). 
17. Garnett, A. P. & Viles, J. H. Copper binding to the octarepeats of the prion protein. 
Affinity, specificity, folding, and cooperativity: insights from circular dichroism. J. Biol. 




18. Hornshaw, M. P., McDermott, J. R. & Candy, J. M. Copper Binding to the N-Terminal 
Tandem Repeat Regions of Mammalian and Avian Prion Protein. Biochem. Biophys. 
Res. Commun.207, 621–629 (1995). 
19. Jackson, G. S. et al. Location and properties of metal-binding sites on the human prion 
protein. Proc. Natl. Acad. Sci. U.S.A. 98, 8531–8535 (2001). 
20. Gossert, A. D., Bonjour, S., Lysek, D. A., Fiorito, F. & Wuthrich, K. Prion protein NMR 
structures of elk and of mouse/elk hybrids. Proc. Natl. Acad. Sci. U.S.A. 102, 646–650 
(2005). 
21. López García, F., Zahn, R., Riek, R. & Wuthrich, K. NMR structure of the bovine prion 
protein. Proc. Natl. Acad. Sci. U.S.A. 97, 8334–8339 (2000). 
22. Lysek, D. A. et al. Prion protein NMR structures of cats, dogs, pigs, and sheep. Proc. 
Natl. Acad. Sci. U.S.A. 102, 640–645 (2005). 
23. Liu, H. et al. Solution structure of Syrian hamster prion protein rPrP(90-231). 
Biochemistry 38, 5362–5377 (1999). 
24. Gilch, S. et al. Top. Curr. Chem. 305, 51–77 (Springer Berlin Heidelberg: Berlin, 
Heidelberg, 2011). 
25. Christina J Sigurdson et al. molecular switch controls interspecies prion disease 
transmission in mice. J. Clin Invest. 120, 2590 (2010). 
26. Nicolas, O., Gavin, R. & del Rio, J. A. New insights into cellular prion protein (PrPc) 
functions: The ‘ying and yang’ of a relevant protein. Brain Res. Rev. 61, 170–184 
(2009). 
27. Aguzzi, A. & Polymenidou, M. Mammalian prion biology: one century of evolving 
concepts. Cell 116, 313–327 (2004). 
28. Kuwahara, C. et al. Prions prevent neuronal cell-line death. Nature 400, 225–226 
(1999). 
29. Chiarini, L. B. Cellular prion protein transduces neuroprotective signals. EMBO J. 21, 
3317–3326 (2002). 
30. Mouillet-Richard, S. Signal Transduction Through Prion Protein. Science 289, 1925–
1928 (2000). 
31. Graner, E. et al. Cellular prion protein binds laminin and mediates neuritogenesis. Mol. 
Brain Res. 76, 85–92 (2000). 
32. Li, R. L. et al. The expression and potential function of cellular prion protein in human 
lymphocytes. Cell Immunol. 207, 49–58 (2001). 
33. Mabbott, N. A., Brown, K. L., Manson, J. & Bruce, M. E. T-lymphocyte activation and 
the cellular form of the prion protein. Immunology 92, 161–165 (1997). 
34. Kubosaki, A. et al. Expression of normal cellular prion protein (PrPc) on T lymphocytes 
and the effect of copper ion: analysis by wild-type and prion protein gene-deficient mice. 
Biochem. Biophys. Res. Commun. 307, 810–813 (2003). 
35. Cashman, N. R. et al. Cellular isoform of the scrapie agent protein participates in 
lymphocyte activation. Cell 61, 185–192 (1990). 
36. Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular 
prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 
457, 1128–1132 (2009). 
37. Aguzzi, A., Baumann, F. & Bremer, J. The prion's elusive reason for being. Annu. Rev. 
Neurosci. 31, 439–477 (2008). 
	  40	  
38. Behrens, A. & Aguzzi, A. Small is not beautiful: antagonizing functions for the prion 
protein PrPC and its homologue Dpl. Trends Neurosci. 25, 150–154 (2002). 
39. Weissmann, C. & Aguzzi, A. Perspectives: neurobiology. PrP's double causes trouble. 
Science 286, 914–915 (1999). 
40. Moore, R. C. et al. Ataxia in prion protein (PrP)-deficient mice is associated with 
upregulation of the novel PrP-like protein doppel. J. Mol. Biol. 292, 797–817 (1999). 
41. Sakaguchi, S. et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a 
disrupted PrP gene. Nature 380, 528–531 (1996). 
42. Bounhar, Y. Prion Protein Protects Human Neurons against Bax-mediated Apoptosis. J. 
Biol. Chem. 276, 39145–39149 (2001). 
43. Diarra-Mehrpour, M. Prion Protein Prevents Human Breast Carcinoma Cell Line from 
Tumor Necrosis Factor-Induced Cell Death. Cancer Res. 64, 719–727 (2004). 
44. Ma, J. & Lindquist, S. Conversion of PrP to a self-perpetuating PrPSc-like conformation 
in the cytosol. Science 298, 1785–1788 (2002). 
45. Roucou, X., Guo, Q., Zhang, Y., Goodyer, C. G. & LeBlanc, A. C. Cytosolic prion 
protein is not toxic and protects against Bax-mediated cell death in human primary 
neurons. J. Biol. Chem. 278, 40877–40881 (2003). 
46. Roucou, X. et al. Cellular prion protein inhibits proapoptotic Bax conformational change 
in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ. 12, 783–795 
(2005). 
47. Zanata, S. M. et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion 
that triggers neuroprotection. EMBO J. 21, 3307–3316 (2002). 
48. Lopes, M. H. et al. Interaction of cellular prion and stress-inducible protein 1 promotes 
neuritogenesis and neuroprotection by distinct signaling pathways. J. Neurosci. 25, 
11330–11339 (2005). 
49. Chen, S., Mangé, A., Dong, L., Lehmann, S. & Schachner, M. Prion protein as trans-
interacting partner for neurons is involved in neurite outgrowth and neuronal survival. 
Mol. Cell. Neurosci. 22, 227–233 (2003). 
50. Dodelet, V. C. & Cashman, N. R. Prion protein expression in human leukocyte 
differentiation. Blood 91, 1556–1561 (1998). 
51. Lin, T. et al. Normal cellular prior protein is preferentially expressed on subpopulations 
of murine hemopoietic cells. J. Immunol. 166, 3733–3742 (2001). 
52. Zhang, C. C., Steele, A. D., Lindquist, S. & Lodish, H. F. Prion protein is expressed on 
long-term repopulating hematopoietic stem cells and is important for their self-renewal. 
Proc. Natl. Acad. Sci. U.S.A. 103, 2184–2189 (2006). 
53. Burthem, J., Urban, B., Pain, A. & Roberts, D. J. The normal cellular prion protein is 
strongly expressed by myeloid dendritic cells. Blood 98, 3733–3738 (2001). 
54. Politopoulou, G., Seebach, J. D., Schmugge, M., Schwarz, H. P. & Aguzzi, A. Age-
related expression of the cellular prion protein in human peripheral blood leukocytes. 
Haematologica 85, 580–587 (2000). 
55. Barclay, G. R., Hope, J., Birkett, C. R. & Turner, M. L. Distribution of cell-associated 
prion protein in normal adult blood determined by flow cytometry. Br. J. Haematol. 107, 
804–814 (1999). 
56. Antoine, N. et al. Differential expression of cellular prion protein on human blood and 
tonsil lymphocytes. Haematologica 85, 475–480 (2000). 
	  41	  
57. Holada, K. & Vostal, J. G. Different levels of prion protein (PrPc) expression on 
hamster, mouse and human blood cells. Br. J. Haematol. 110, 472–480 (2000). 
58. Thielen, C. et al. Human FDC express PrPc in vivo and in vitro. Dev. Immunol. 8, 259–
266 (2001). 
59. Hugel, B. et al. Modulation of signal transduction through the cellular prion protein is 
linked to its incorporation in lipid rafts. Cell. Mol. Life Sci. 61, 2998–3007 (2004). 
60. Stuermer, C. A. O. et al. PrPc capping in T cells promotes its association with the lipid 
raft proteins reggie-1 and reggie-2 and leads to signal transduction. The FASEB J. 18, 
1731–1733 (2004). 
61. Schneider, B. et al. NADPH oxidase and extracellular regulated kinases 1/2 are targets 
of prion protein signaling in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. 
U.S.A. 100, 13326–13331 (2003). 
62. Krebs, B. et al. Prion protein induced signaling cascades in monocytes. Biochem. 
Biophys. Res. Commun. 340, 13–22 (2006). 
63. Lesné, S. et al. A specific amyloid-beta protein assembly in the brain impairs memory. 
Nature 440, 352–357 (2006). 
64. Shankar, G. M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce 
reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent 
signaling pathway. J. Neurosci. 27, 2866–2875 (2007). 
65. Gimbel, D. A. et al. Memory Impairment in Transgenic Alzheimer Mice Requires 
Cellular Prion Protein. Journal of Neuroscience 30, 6367–6374 (2010). 
66. MacDonald, J. F., Jackson, M. F. & Beazely, M. A. Hippocampal Long-Term Synaptic 
Plasticity and Signal Amplification of NMDA Receptors. Crit. Rev. Neurobiol. 18, 71–
84 (2006). 
67. Yashiro, K. & Philpot, B. D. Regulation of NMDA receptor subunit expression and its 
implications for LTD, LTP, and metaplasticity. Neuropharmacology 55, 1081–1094 
(2008). 
68. Lacor, P. N. et al. Abeta oligomer-induced aberrations in synapse composition, shape, 
and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. 
Neurosci. 27, 796–807 (2007). 
69. Snyder, E. M. et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat. 
Neurosci. 8, 1051–1058 (2005). 
70. Um, J. W. et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein 
activates Fyn to impair neurons. Nat. Neurosci. 15, 1227–1235 (2012). 
71. You, H. et al. Aβ neurotoxicity depends on interactions between copper ions, prion 
protein, and N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U.S.A. 109, 1737–
1742 (2012). 
72. Balducci, C. et al. Synthetic amyloid-beta oligomers impair long-term memory 
independently of cellular prion protein. Proc. Natl. Acad. Sci. U.S.A. 107, 2295–2300 
(2010). 
73. Calella, A. M. et al. Prion protein and Aβ-related synaptic toxicity impairment. EMBO 
Mol. Med. 2, 306–314 (2010). 
74. Büeler, H. et al. Mice devoid of PrP are resistant to scrapie. Cell 73, 1339–1347 (1993). 
75. Basler, K. et al. Scrapie and cellular PrP isoforms are encoded by the same 
chromosomal gene. Cell 46, 417–428 (1986). 
	  42	  
76. Alper, T., Cramp, W. A., Haig, D. A. & Clarke, M. C. Does the Agent of Scrapie 
Replicate without Nucleic Acid ? Nature 214, 764–766 (1967). 
77. Alper, T., Haig, D. A. & Clarke, M. C. The exceptionally small size of the scrapie agent. 
Biochem. Biophys. Res. Commun. 22, 278–284 (1966). 
78. Griffith, J. S. Nature of the Scrapie Agent: Self-replication and Scrapie. Nature 215, 
1043–1044 (1967). 
79. Prusiner, S. B., Cochran, S. P. & Downey, D. E. Determination of scrapie agent titer 
from incubation period measurements in hamsters. Adv. Exp. Med. Biol. 134, 1043-1044 
(1981). 
80. Prusiner, S. B. et al. Measurement of the scrapie agent using an incubation time interval 
assay. Ann Neurol. 11, 353–358 (1982). 
81. Prusiner, S. B., Groth, D. F., Cochran, S. P. & Masiarz, F. R. Molecular properties, 
partial purification, and assay by incubation period measurements of the hamster scrapie 
agent. Biochemistry 19, 4883-4891 (1980). 
82. Prusiner, S. B. et al. Further purification and characterization of scrapie prions. 
Biochemistry 21, 6942–6950 (1982). 
83. Hsiao, K. et al. Spontaneous neurodegeneration in transgenic mice with mutant prion 
protein. Science 250, 1587–1590 (1990). 
84. Kaneko, K. et al. A synthetic peptide initiates Gerstmann-Sträussler-Scheinker (GSS) 
disease in transgenic mice. J. Mol. Biol. 295, 997–1007 (2000). 
85. Legname, G. et al. Synthetic mammalian prions. Science 305, 673–676 (2004). 
86. Collinge, J. & Clarke, A. R. A General Model of Prion Strains and Their Pathogenicity. 
Science 318, 930–936 (2007). 
87. Nazor, K. E. et al. Immunodetection of disease-associated mutant PrP, which accelerates 
disease in GSS transgenic mice. EMBO J 24, 2472–2480 (2005). 
88. Colby, D. W. et al. Protease-Sensitive Synthetic Prions. PLoS Pathog. 6, e1000736 
(2010). 
89. Jackson, W. S. et al. Spontaneous Generation of Prion Infectivity in Fatal Familial 
Insomnia Knockin Mice. Neuron 63, 438–450 (2009). 
90. Colby, D. W. et al. Design and construction of diverse mammalian prion strains. Proc. 
Natl. Acad. Sci. U.S.A. 106, 20417–20422 (2009). 
91. Colby, D. W. & Prusiner, S. B. De novo generation of prion strains. Nat. Rev. Micro. 9, 
771–777 (2011). 
92. Supattapone, S. Biochemistry. What makes a prion infectious? Science 327, 1091–1092 
(2010). 
93. Saá, P., Castilla, J. & Soto, C. Ultra-efficient replication of infectious prions by 
automated protein misfolding cyclic amplification. J. Biol. Chem. 281, 35245–35252 
(2006). 
94. Saborio, G. P., Permanne, B. & Soto, C. Sensitive detection of pathological prion protein 
by cyclic amplification of protein misfolding. Nature 411, 810–813 (2001). 
95. Castilla, J., Saá, P., Hetz, C. & Soto, C. In Vitro Generation of Infectious Scrapie Prions. 
Cell 121, 195–206 (2005). 
	  43	  
96. Deleault, N. R., Harris, B. T., Rees, J. R. & Supattapone, S. From the Cover: Formation 
of native prions from minimal components in vitro. Proc. Natl. Acad. Sci. U.S.A. 104, 
9741–9746 (2007). 
97. Wang, F., Wang, X., Yuan, C. G. & Ma, J. Generating a Prion with Bacterially 
Expressed Recombinant Prion Protein. Science 327, 1132–1135 (2010). 
98. Büeler, H. et al. Normal development and behaviour of mice lacking the neuronal cell-
surface PrP protein. Nature 356, 577–582 (1992). 
99. Tiraboschi, P., Hansen, L. A., Thal, L. J. & Corey-Bloom, J. The importance of neuritic 
plaques and tangles to the development and evolution of AD. Neurology 62, 1984–1989 
(2004). 
100. Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839–840 (1997). 
101. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 
492–501 (2001). 
102. Hetz, C., Russelakis-Carneiro, M., Maundrell, K., Castilla, J. & Soto, C. Caspase-12 and 
endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO 
J. 22, 5435–5445 (2003). 
103. Forloni, G. et al. Neurotoxicity of a prion protein fragment. Nature 362, 543–546 
(1993). 
104. Collinge, J. et al. Transmission of fatal familial insomnia to laboratory animals. Lancet 
346, 569–570 (1995). 
105. Medori, R. et al. Fatal familial insomnia: a second kindred with mutation of prion 
protein gene at codon 178. Neurology 42, 669–670 (1992). 
106. Lasmézas, C. I. et al. Transmission of the BSE agent to mice in the absence of detectable 
abnormal prion protein. Science 275, 402–405 (1997). 
107. Brandner, S. et al. Normal host prion protein necessary for scrapie-induced 
neurotoxicity. Nature 379, 339–343 (1996). 
108. Mallucci, G. Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses 
Spongiosis. Science 302, 871–874 (2003). 
109. Mallucci, G. R. et al. Targeting Cellular Prion Protein Reverses Early Cognitive Deficits 
and Neurophysiological Dysfunction in Prion-Infected Mice. Neuron 53, 325–335 
(2007). 
110. Chesebro, B. et al. Anchorless prion protein results in infectious amyloid disease 
without clinical scrapie. Science 308, 1435–1439 (2005). 
111. Solforosi, L. et al. Cross-linking cellular prion protein triggers neuronal apoptosis in 
vivo. Science 303, 1514–1516 (2004). 
112. Klöhn, P. C. et al. PrP antibodies do not trigger mouse hippocampal neuron apoptosis. 
Science 335, 52 (2012). 
113. Rapoport, T. A., Jungnickel, B. & Kutay, U. Protein transport across the eukaryotic 
endoplasmic reticulum and bacterial inner membranes. Annu. Rev. Biochem. 65, 271–
303 (1996). 
114. Andrews, D. W. & Johnson, A. E. The translocon: more than a hole in the ER 
membrane? Trends Biochem. Sci. 21, 365–369 (1996). 
115. Hampton, R. Y. ER-associated degradation in protein quality control and cellular 
regulation. Curr. Opin. Cell Biol. 14, 476–482 (2002). 
	  44	  
116. Ma, J. & Lindquist, S. Wild-type PrP and a mutant associated with prion disease are 
subject to retrograde transport and proteasome degradation. Proc. Natl. Acad. Sci. U.S.A. 
98, 14955–14960 (2001). 
117. Rane, N. S., Kang, S. W., Chakrabarti, O., Feigenbaum, L. & Hegde, R. S. Reduced 
translocation of nascent prion protein during ER stress contributes to neurodegeneration. 
Dev. Cell. 15, 359–370 (2008). 
118. Kristiansen, M. et al. Disease-Associated Prion Protein Oligomers Inhibit the 26S 
Proteasome. Mol. Cell 26, 175–188 (2007). 
119. Aguzzi, A. & Calella, A. M. Prions: protein aggregation and infectious diseases. Physiol. 
Rev. 89, 1105–1152 (2009). 
120. Kim, S. J. & Hegde, R. S. Cotranslational partitioning of nascent prion protein into 
multiple populations at the translocation channel. Mol. Biol. Cell 13, 3775–3786 (2002). 
121. Kim, S. J., Mitra, D., Salerno, J. R. & Hegde, R. S. Signal sequences control gating of 
the protein translocation channel in a substrate-specific manner. Dev. Cell. 2, 207–217 
(2002). 
122. Kim, S. J., Rahbar, R. & Hegde, R. S. Combinatorial control of prion protein biogenesis 
by the signal sequence and transmembrane domain. J. Biol. Chem. 276, 26132–26140 
(2001). 
123. Hegde, R. S. et al. A transmembrane form of the prion protein in neurodegenerative 
disease. Science 279, 827–834 (1998). 
124. Hegde, R. S. et al. Transmissible and genetic prion diseases share a common pathway of 
neurodegeneration. Nature 402, 822–826 (1999). 
125. Silveira, J. R. et al. The most infectious prion protein particles. Nat. Cell Biol. 437, 257–
261 (2005). 
126. Hill, A. F. et al. Species-barrier-independent prion replication in apparently resistant 
species. Proc. Natl. Acad. Sci. U.S.A. 97, 10248–10253 (2000). 
127. Sandberg, M. K., Al-Doujaily, H., Sharps, B., Clarke, A. R. & Collinge, J. Prion 
propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470, 
540–542 (2011). 
128. Aguzzi, A. & Falsig, J. Prion propagation, toxicity and degradation. Nat Neurosci 15, 
936–939 (2012). 
129. Salman, M. D. Chronic wasting disease in deer and elk: scientific facts and findings. J. 
Vet. Med. Sci. 65, 761–768 (2003). 
130. Hamir, A. N. et al. Transmission of sheep scrapie to elk (Cervus elaphus nelsoni) by 
intracerebral inoculation: final outcome of the experiment. J. Vet. Diagn. Invest. 16, 
316–321 (2004). 
131. Green, K. M. et al. The elk PRNP codon 132 polymorphism controls cervid and scrapie 
prion propagation. J. Gen. Virol. 89, 598–608 (2008). 
132. Argue, C. K., Ribble, C., Lees, V. W., McLane, J. & Balachandran, A. Epidemiology of 
an outbreak of chronic wasting disease on elk farms in Saskatchewan. Can. Vet. J. 48, 
1241–1248 (2007). 
133. Kim, T. Y. et al. Additional cases of Chronic Wasting Disease in imported deer in 
Korea. J. Vet. Med. Sci. 67, 753–759 (2005). 
134. Williams, E. S. Chronic wasting disease. Vet. Pathol. 42, 530–549 (2005). 
135. Mathiason, C. K. et al. Infectious Prions in the Saliva and Blood of Deer with Chronic 
Wasting Disease. Science 314, 133–136 (2006). 
	  45	  
136. Safar, J. G. J. et al. Transmission and detection of prions in feces. J. Infect. Dis. 198, 81–
89 (2008). 
137. Tamgüney, G. et al. Asymptomatic deer excrete infectious prions in faeces. Nature 461, 
529–532 (2009). 
138. Haley, N. J., Seelig, D. M., Zabel, M. D., Telling, G. C. & Hoover, E. A. Detection of 
CWD prions in urine and saliva of deer by transgenic mouse bioassay. PLoS ONE 4, 
e4848 (2009). 
139. Johnson, C. J. et al. Prions Adhere to Soil Minerals and Remain Infectious. PLoS 
Pathog. 2, e32 (2006). 
140. Miller, M. W., Williams, E. S., Hobbs, N. T. & Wolfe, L. L. Environmental sources of 
prion transmission in mule deer. Emerg. Infect. Dis. 10, 1003–1006 (2004). 
141. Seidel, B. et al. Scrapie Agent (Strain 263K) Can Transmit Disease via the Oral Route 
after Persistence in Soil over Years. PLoS ONE 2, e435 (2007). 
142. Genovesi, S. et al. Direct detection of soil-bound prions. PLoS ONE 2, e1069 (2007). 
143. Rigou, P., Rezaei, H., Grosclaude, J., Staunton, S. & Quiquampoix, H. Fate of Prions in 
Soil:  Adsorption and Extraction by Electroelution of Recombinant Ovine Prion Protein 
from Montmorillonite and Natural Soils. Environ. Sci. Technol. 40, 1497–1503 (2006). 
144. Williams, E. S. & Miller, M. W. Chronic wasting disease in deer and elk in North 
America. Rev. Sci. Tech. 21, 305-316 (2002). 
145. Spraker, T. R. et al. Comparison of histological lesions and immunohistochemical 
staining of proteinase-resistant prion protein in a naturally occurring spongiform 
encephalopathy of free-ranging mule deer (Odocoileus hemionus) with those of chronic 
wasting disease of captive mule deer. Vet. Pathol. 39, 110–119 (2002). 
146. Williams, E. S. Scrapie and chronic wasting disease. Clin. Lab. Med. 23, 139–159 
(2003). 
147. Williams, E. S. & Young, S. Neuropathology of chronic wasting disease of mule deer 
(Odocoileus hemionus) and elk (Cervus elaphus nelsoni). Vet. Pathol. 30, 36–45 (1993). 
148. Liberski, P. P., Guiroy, D. C., Williams, E. S., Walis, A. & Budka, H. Deposition 
patterns of disease-associated prion protein in captive mule deer brains with chronic 
wasting disease. Acta. Neuropathol. 102, 496–500 (2001). 
149. Spraker, T. R. T. et al. Validation of monoclonal antibody F99/97.6.1 for 
immunohistochemical staining of brain and tonsil in mule deer (Odocoileus hemionus) 
with chronic wasting disease. J. Vet. Diagn. Invest. 14, 3–7 (2002). 
150. Anderson, R. M. et al. Transmission dynamics and epidemiology of BSE in British 
cattle. Nature 382, 779–788 (1996). 
151. Collinge, J. et al. Kuru in the 21st century - an acquired human prion disease with very 
long incubation periods. Lancet 367, 2068–2074 (2006). 
152. Marsh, R. F. & Hadlow, W. J. Transmissible mink encephalopathy. Rev. sci. tech. 11, 
539-550 (1992). 
153. Hilton, D. A. Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. J. 
Pathol. 208, 134–141 (2006). 
154. Llewelyn, C. A. et al. Possible transmission of variant Creutzfeldt-Jakob disease by 
blood transfusion. Lancet 363, 417–421 (2004). 
155. Kimberlin, R. H. & Walker, C. A. Pathogenesis of mouse scrapie: effect of route of 
inoculation on infectivity titres and dose-response curves. J. Comp. Path. 88, 39–47 
(1978). 
	  46	  
156. Scott, J. R., Foster, J. D. & Fraser, H. Conjunctival instillation of scrapie in mice can 
produce disease. Vet. Microbiol. 34, 305–309 (1993). 
157. Mabbott, N. A. & MacPherson, G. G. Prions and their lethal journey to the brain. Nat. 
Rev. Micro. 4, 201–211 (2006). 
158. Fraser, H. H. & Dickinson, A. G. A. Pathogenesis of scrapie in the mouse: the role of the 
spleen. Nature 226, 462–463 (1970). 
159. Pattison, I. H. & Millson, G. C. Further observations on the experimental production of 
scrapie in goats and sheep. J. Comp. Pathol. 70, 182–193 (1960). 
160. Pattison, I. H. & Millson, G. C. Distribution of the scrapie agent in the tissues of 
experimentally inoculated goats. J. Comp. Pathol. 72, 233-244 (1962). 
161. Klein, M. A. et al. A crucial role for B cells in neuroinvasive scrapie. Nature 390, 687–
690 (1997). 
162. Brown, K. L. et al. Scrapie replication in lymphoid tissues depends on prion protein-
expressing follicular dendritic cells. Nat. Med. 5, 1308–1312 (1999). 
163. Zabel, M. D. et al. Stromal complement receptor CD21/35 facilitates lymphoid prion 
colonization and pathogenesis. J. Immunol. 179, 6144–6152 (2007). 
164. Raymond, C. R., Aucouturier, P. & Mabbott, N. A. In vivo depletion of CD11c+ cells 
impairs scrapie agent neuroinvasion from the intestine. J. Immunol. 179, 7758–7766 
(2007). 
165. Spinner, D. S. et al. Accelerated Prion Disease Pathogenesis in Toll-Like Receptor 4 
Signaling-Mutant Mice. J. Virol. 82, 10701–10708 (2008). 
166. Sigurdson, C. J. et al. Oral transmission and early lymphoid tropism of chronic wasting 
disease PrPres in mule deer fawns (Odocoileus hemionus). J. Gen. Virol. 80, 2757–2764 
(1999). 
167. McBride, P. A. et al. Early spread of scrapie from the gastrointestinal tract to the central 
nervous system involves autonomic fibers of the splanchnic and vagus nerves. J. Virol. 
75, 9320–9327 (2001). 
168. Beekes, M. & McBride, P. A. Early accumulation of pathological PrP in the enteric 
nervous system and gut-associated lymphoid tissue of hamsters orally infected with 
scrapie. Neurosci. Lett. 278, 181–184 (2000). 
169. Glaysher, B. R. & Mabbott, N. A. Role of the GALT in scrapie agent neuroinvasion 
from the intestine. J. Immunol. 178, 3757–3766 (2007). 
170. Prinz, M. et al. Oral prion infection requires normal numbers of Peyer's patches but not 
of enteric lymphocytes. Am. J. Pathol. 162, 1103–1111 (2003). 
171. Murphy, K., Travers, P. & Walport, M. Janeway's Immunology. Garland science 
(2008). 
172. Corr, S. C., Gahan, C. C. G. M. & Hill, C. M-cells: origin, morphology and role in 
mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol. 52, 2–
12 (2008). 
173. Neutra, M. R., Pringault, E. & Kraehenbuhl, J. P. Antigen Sampling Across Epithelial 
Barriers and Induction of Mucosal Immune Responses. Annu. Rev. Immunol. 14, 275-
300 (1996). 
174. Phalipon, A. & Sansonetti, P. J. Microbial-host interactions at mucosal sites. host 
response to pathogenic bacteria at mucosal sites. Curr. Top. Microbiol. Immunol. 236, 
163–189 (1999). 
	  47	  
175. Sansonetti, P. J. & Phalipon, A. M cells as ports of entry for enteroinvasive pathogens: 
mechanisms of interaction, consequences for the disease process. Semin. Immunol. 11, 
193–203 (1999). 
176. Siebers, A. & Finlay, B. B. M cells and the pathogenesis of mucosal and systemic 
infections. Trends Microbiol. 4, 22–29 (1996). 
177. Heppner, F. L. et al. Transepithelial prion transport by M cells. Nat. Med. 7, 976–977 
(2001). 
178. Kujala, P. et al. Prion uptake in the gut: identification of the first uptake and replication 
sites. PLoS Pathog. 7, e1002449 (2011). 
179. Takakura, I. et al. Orally administered prion protein is incorporated by m cells and 
spreads into lymphoid tissues with macrophages in prion protein knockout mice. Am. J. 
Pathol. 179, 1301–1309 (2011). 
180. Donaldson, D. S. et al. M cell-depletion blocks oral prion disease pathogenesis. Mucosal 
Immunology 5, 216–225 (2012). 
181. Jeffrey, M. et al. Transportation of prion protein across the intestinal mucosa of scrapie-
susceptible and scrapie-resistant sheep. J. Pathol. 209, 4–14 (2006). 
182. Mishra, R. S. et al. Protease-resistant human prion protein and ferritin are cotransported 
across Caco-2 epithelial cells: implications for species barrier in prion uptake from the 
intestine. J. Neurosci. 24, 11280–11290 (2004). 
183. Theil, E. C. Ferritin: Structure, Gene Regulation, and Cellular Function in Animals, 
Plants, and Microorganisms. Annu. Rev. Biochem. 56, 289–315 (1987). 
184. Mowat, A. M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. 
Rev. Immunol. 3, 331–341 (2003). 
185. Kiyono, H. & Fukuyama, S. Nalt- versus peyer's-patch-mediated mucosal immunity. 
Nat. Rev. Immunol. 4, 699–710 (2004). 
186. Neutra, M., Frey, A. & Kraehenbuhl, J. Epithelial M Cells: Gateways for Mucosal 
Infection and Immunization. Cell 86, 345–348 (1996). 
187. Maignien, T. et al. Role of gut macrophages in mice orally contaminated with scrapie or 
BSE. Int. J. Pharm. 298, 293–304 (2005). 
188. Huang, F. P., Farquhar, C. F., Mabbott, N. A., Bruce, M. E. & MacPherson, G. G. 
Migrating intestinal dendritic cells transport PrPSc from the gut. J. Gen. Virol. 83, 267–
271 (2002). 
189. Carp, R. I. Transmission of scrapie by oral route: effect of gingival scarification. Lancet 
1, 170–171 (1982). 
190. Taylor, D. M., McConnell, I. & Fraser, H. Scrapie infection can be established readily 
through skin scarification in immunocompetent but not immunodeficient mice. J. Gen. 
Virol. 77, 1595–1599 (1996). 
191. Mohan, J., Hopkins, J. & Mabbott, N. A. Skin‐derived dendritic cells acquire and 
degrade the scrapie agent following in vitro exposure. Immunology (2005). 
192. Cordier-Dirikoc, S. & Chabry, J. Temporary Depletion of CD11c+ Dendritic Cells 
Delays Lymphoinvasion after Intraperitonal Scrapie Infection. J. Virol. 82, 8933–8936 
(2008). 
193. Aucouturier, P. Infected splenic dendritic cells are sufficient for prion transmission to 
the CNS in mouse scrapie. J. Clin. Invest. 108, 703–708 (2001). 
	  48	  
194. Bradford, B. M., Sester, D. P., Hume, D. A. & Mabbott, N. A. Defining the anatomical 
localisation of subsets of the murine mononuclear phagocyte system using integrin alpha 
X (Itgax, CD11c) and colony stimulating factor 1 receptor (Csf1r, CD115) expression 
fails to discriminate dendritic cells from macrophages. Immunobiology 216, 1228–1237 
(2011). 
195. Probst, H. C. et al. Histological analysis of CD11c-DTR/GFP mice after in vivo 
depletion of dendritic cells. Clin. Exp. Immunol. 141, 398–404 (2005). 
196. Carp, R. I. & Callahan, S. M. In vitro interaction of scrapie agent and mouse peritoneal 
macrophages. Intervirology 16, 8–13 (1981). 
197. Tagliavini, F et al. Amyloid protein of Gerstmann-Sträussler-Scheinker disease (Indiana 
kindred) is an 11 kd fragment of prion protein with an N-terminal glycine at codon 58. 
EMBO J. 10, 513–519 (1991). 
198. Chen, S. G. et al. Truncated forms of the human prion protein in normal brain and in 
prion diseases. J. Biol. Chem. 270, 19173–19180 (1995). 
199. De Gioia, L. et al. Conformational polymorphism of the amyloidogenic and neurotoxic 
peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem. 269, 7859–
7862 (1994). 
200. Forloni, G. et al. A neurotoxic prion protein fragment induces rat astroglial proliferation 
and hypertrophy. Eur. J. Neurosci. 6, 1415–1422 (1994). 
201. Selvaggini, C. et al. Molecular characteristics of a protease-resistant, amyloidogenic and 
neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem. 
Biophys. Res. Commun. 194, 1380–1386 (1993). 
202. Tagliavini, F. et al. Synthetic peptides homologous to prion protein residues 106-147 
form amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. U.S.A. 90, 9678–9682 (1993). 
203. Brown, A. R. et al. Inducible cytokine gene expression in the brain in the ME7/CV 
mouse model of scrapie is highly restricted, is at a strikingly low level relative to the 
degree of gliosis and occurs only late in disease. J. Gen. Virol. 84, 2605–2611 (2003). 
204. Campbell, I. L. I., Eddleston, M. M., Kemper, P. P., Oldstone, M. B. M. & Hobbs, M. V. 
M. Activation of cerebral cytokine gene expression and its correlation with onset of 
reactive astrocyte and acute-phase response gene expression in scrapie. J. Virol. 68, 
2383–2387 (1994). 
205. Walsh, D. T. D., Betmouni, S. S. & Perry, V. H. V. Absence of detectable IL-1beta 
production in murine prion disease: a model of chronic neurodegeneration. J. 
Neuropathol. Exp. Neurol. 60, 173–182 (2001). 
206. Williams, A., Van Dam, A. M., Ritchie, D., Eikelenboom, P. & Fraser, H. 
Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the 
CNS during the incubation period of murine scrapie correlates with progressive PrP 
accumulations. Brain Res. 754, 171–180 (1997). 
207. Williams, A. E., Lawson, L. J., Perry, V. H. & Fraser, H. Characterization of the 
microglial response in murine scrapie. Neuropathol. Appl. Neurobiol. 20, 47–55 (1994). 
208. Peyrin, J. M. et al. Microglial cells respond to amyloidogenic PrP peptide by the 
production of inflammatory cytokines. Neuroreport 10, 723–729 (1999). 
209. Bacot, S. M. Activation by prion peptide PrP106-126 induces a NF- B-driven 
proinflammatory response in human monocyte-derived dendritic cells. J. Leukoc. Biol. 
74, 118–125 (2003). 
 
	  49	  
210. Zhou, X. M., Xu, G. X. & Zhao, D. M. In vitro effect of prion peptide PrP 106-126 on 
mouse macrophages: Possible role of macrophages in transport and proliferation for 
prion protein. Microb. pathog. 44, 129-134 (2008). 
211. Kim, J. I. et al. Expression of cytokine genes and increased nuclear factor-kappa B 
activity in the brains of scrapie-infected mice. Brain Res. Mol. Brain Res. 73, 17–27 
(1999). 
212. Kordek, R. et al. Heightened expression of tumor necrosis factor alpha, interleukin 1 
alpha, and glial fibrillary acidic protein in experimental Creutzfeldt-Jakob disease in 
mice. Proc. Natl. Acad. Sci. U.S.A. 93, 9754–9758 (1996). 
213. Fabrizi, C., Silei, V., Menegazzi, M. & Salmona, M. The stimulation of inducible nitric-
oxide synthase by the prion protein fragment 106-126 in human microglia is tumor 
necrosis factor-alpha-dependent and involves p38 mitogen-activated protein kinase. J. 
Biol. Chem. 276, 25692-25696 (2001). 
214. Prinz, M. et al. Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO 
Rep. 4, 195–199 (2003). 
215. Clarke, M. C. & Haig, D. A. Multiplication of Scrapie Agent in Mouse Spleen. Res. Vet. 
Sci. 12, 195–& (1971). 
216. Hill, A. F. et al. Investigation of variant Creutzfeldt-Jakob disease and other human 
prion diseases with tonsil biopsy samples. Lancet 353, 183–189 (1999). 
217. Eklund, C. M., Kennedy, R. C. & Hadlow, W. J. Pathogenesis of scrapie virus infection 
in the mouse. J. Infect. Dis. 117, 15–22 (1967). 
218. Dickinson, A. G. A. & Fraser, H. H. Scrapie: effect of Dh gene on incubation period of 
extraneurally injected agent. Heredity (Edinb) 29, 91–93 (1972). 
219. Fraser, H. & Dickinson, A. G. Studies of the lymphoreticular system in the pathogenesis 
of scrapie: the role of spleen and thymus. J. Comp. Pathol. 88, 563–573 (1978). 
220. Kimberlin, R. H. & Walker, C. A. The role of the spleen in the neuroinvasion of scrapie 
in mice. Virus Res. 12, 201–211 (1989). 
221. Mohri, S., Handa, S. & Tateishi, J. Lack of effect of thymus and spleen on the 
incubation period of Creutzfeldt-Jakob disease in mice. J. Gen. Virol. 68, 1187–1189 
(1987). 
222. Kimberlin,	  R.	  H.	  &	  Walker,	  C.	  A.	  Pathogenesis	  of	  Scrapie	  (Strain	  263K)	  in	  Hamsters	  
Infected	   Intracerebrally,	   Intraperitoneally	   or	   Intraocularly.	   J.	   Gen.	   Virol.	  67,	   255–
263	  (1986).	  
223. Bradley, R. BSE transmission studies with particular reference to blood. Dev. Biol. 
Stand. 99, 35–40 (1999). 
224. Benestad, S. L. et al. Cases of scrapie with unusual features in Norway and designation 
of a new type, Nor98. Vet. Rec. 153, 202–208 (2003). 
225. Lavelle, G. C. G., Sturman, L. L. & Hadlow, W. J. W. Isolation from mouse spleen of 
cell populations with high specific infectivity for scrapie virus. Infect. Immune. 5, 319–
323 (1972). 
226. Clarke, M. C. & Kimberlin, R. H. Pathogenesis of mouse scrapie: Distribution of agent 
in the pulp and stroma of infected spleens. Vet. Microbiol. 9, 215–225 (1984). 
227. Fraser, H. & Farquhar, C. F. Ionising radiation has no influence on scrapie incubation 
period in mice. Vet. Microbiol. 13, 211–223 (1987). 
228. Klein, M. A. M. et al. PrP expression in B lymphocytes is not required for prion 
neuroinvasion. Nat. Med. 4, 1429–1433 (1998). 
	  50	  
229. Raeber, A. J. et al. PrP-dependent association of prions with splenic but not circulating 
lymphocytes of scrapie-infected mice. EMBO J. 18, 2702–2706 (1999). 
230. Montrasio, F. et al. B lymphocyte-restricted expression of prion protein does not enable 
prion replication in prion protein knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98, 4034–
4037 (2001). 
231. Kitamoto, T., Muramoto, T., Mohri, S., Doh-ura, K. & Tateishi, J. Abnormal isoform of 
prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob 
disease. J. Virol. 65, 6292–6295 (1991). 
232. Mabbott, N. A., Young, J., McConnell, I. & Bruce, M. E. Follicular dendritic cell 
dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically 
reduces scrapie susceptibility. J. Virol. 77, 6845–6854 (2003). 
233. Mohan, J., Bruce, M. E. & Mabbott, N. A. Follicular dendritic cell dedifferentiation 
reduces scrapie susceptibility following inoculation via the skin. Immunology 114, 225–
234 (2005). 
234. McCulloch, L. et al. Follicular Dendritic Cell-Specific Prion Protein (PrPc) Expression 
Alone Is Sufficient to Sustain Prion Infection in the Spleen. PLoS Pathog. 7, e1002402 
(2011). 
235. Manuelidis, L. et al. Follicular dendritic cells and dissemination of Creutzfeldt-Jakob 
disease. J. Virol. 74, 8614–8622 (2000). 
236. Montrasio, F. et al. Impaired prion replication in spleens of mice lacking functional 
follicular dendritic cells. Science 288, 1257–1259 (2000). 
237. Browning, J. L. Inhibition of the lymphotoxin pathway as a therapy for autoimmune 
disease. Immunol. Rev. 223, 202–220 (2008). 
238. Pasparakis, M. M., Alexopoulou, L. L., Episkopou, V. V. & Kollias, G. G. Immune and 
inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF 
alpha in the formation of primary B cell follicles, follicular dendritic cell networks and 
germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 
184, 1397–1411 (1996). 
239. Aguzzi, A. & Heikenwalder, M. Pathogenesis of prion diseases: current status and future 
outlook. Nat. Rev. Micro. 4, 765–775 (2006). 
240. Tew, J. G. et al. Follicular dendritic cells and presentation of antigen and costimulatory 
signals to B cells. Immunol. Rev. 156, 39–52 (1997). 
241. Heinen, E. E. et al. Retention of immune complexes by murine lymph node or spleen 
follicular dendritic cells. Role of antibody isotype. Scand. J. Immunol. 24, 327–334 
(1986). 
242. Mandels, T. E., Phippsi, R. P., Abbot, A. & Tew, J. G. The Follicular Dendritic Cell: 
Long Term Antigen Retention During Immunity. Immunol. Rev. 53, 29–59 (1980). 
243. Prinz, M. et al. Lymph nodal prion replication and neuroinvasion in mice devoid of 
follicular dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 99, 919–924 (2002). 
244. Heikenwalder, M. et al. Lymphotoxin-Dependent Prion Replication in Inflammatory 
Stromal Cells of Granulomas. Immunity 29, 998–1008 (2008). 
245. Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system 
for immune surveillance and homeostasis. Nat. Immunol. 11, 785–797 (2010). 
246. Sarma, J. V. & Ward, P. A. The complement system. Cell Tissue Res. 343, 227–235 
(2010). 
	  51	  
247. Janeway, C. A. J. & Medzhitov, R. Innate Immune Recognition. Annu. Rev Immunol. 20, 
197-216 (2002). 
248. Carroll, M. C. The complement system in regulation of adaptive immunity. Nat. 
Immunol. 5, 981–986 (2004). 
249. Dunkelberger, J. R. & Song, W. C. Complement and its role in innate and adaptive 
immune responses. Cell Res. 20, 34–50 (2009). 
250. Molina, H. et al. Markedly impaired humoral immune response in mice deficient in 
complement receptors 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 93, 3357–3361 (1996). 
251. Reynes, M. et al. Human follicular dendritic cells express CR1, CR2, and CR3 
complement receptor antigens. J. Immunol. 135, 2687–2694 (1985). 
252. Humphrey, J. H., Grennan, D. & Sundaram, V. The origin of follicular dendritic cells in 
the mouse and the mechanism of trapping of immune complexes on them. Eur. J. 
Immunol. 14, 859–864 (1984). 
253. Park, C. S. & Choi, Y. S. How do follicular dendritic cells interact intimately with B 
cells in the germinal centre? Immunology 114, 2–10 (2005). 
254. Lambris, J. D., Ricklin, D. & Geisbrecht, B. V. Complement evasion by human 
pathogens. Nat. Rev. Micro. 6, 132–142 (2008). 
255. Oliva, C., Turnbough, C. L. & Kearney, J. F. CD14-Mac-1 interactions in Bacillus 
anthracis spore internalization by macrophages. Proc. Natl. Acad. Sci. U.S.A. 106, 
13957–13962 (2009). 
256. Wang, M. et al. Fimbrial proteins of porphyromonas gingivalis mediate in vivo 
virulence and exploit TLR2 and complement receptor 3 to persist in macrophages. J. 
Immunol. 179, 2349–2358 (2007). 
257. Dumestre-Perard, C. et al. Activation of classical pathway of complement cascade by 
soluble oligomers of prion. Cell Microbiol. 9, 2870–2879 (2007). 
258. Sim, R. B., Kishore, U., Villiers, C. L., Marche, P. N. & Mitchell, D. A. C1q binding 
and complement activation by prions and amyloids. Immunobiology 212, 355–362 
(2007). 
259. Erlich, P. et al. Complement Protein C1q Forms a Complex with Cytotoxic Prion 
Protein Oligomers. J. Biol. Chem. 285, 19267–19276 (2010). 
260. Blanquet-Grossard, F., Thielens, N. M., Vendrely, C., Jamin, M. & Arlaud, G. J. 
Complement protein C1q recognizes a conformationally modified form of the prion 
protein. Biochemistry 44, 4349–4356 (2005). 
261. Ligios, C. et al. PrPSc in mammary glands of sheep affected by scrapie and mastitis. 
Nat. Med. 11, 1137–1138 (2005). 
262. Heikenwalder, M. et al. Chronic lymphocytic inflammation specifies the organ tropism 
of prions. Science 307, 1107–1110 (2005). 
263. Kovacs, G. G. et al. Creutzfeldt-Jakob disease and inclusion body myositis: Abundant 
disease-associated prion protein in muscle. Ann. Neurol. 55, 121–125 (2003). 
264. Seeger, H. et al. Coincident scrapie infection and nephritis lead to urinary prion 
excretion. Science 310, 324–326 (2005). 











While prions probably interact with the innate immune system immediately following 
infection, little is known about this initial confrontation.  Here we investigated incunabular 
events in lymphotropic and intranodal prion trafficking by following highly enriched, fluorescent 
prions from infection sites to draining lymph nodes.  We detected biphasic lymphotropic 
transport of prions from the initial entry site upon peripheral prion inoculation.    Prions arrived 
in draining lymph nodes cell autonomously within two hours of intraperitoneal administration.  
Monocytes and dendritic cells (DCs) required Complement for optimal prion delivery to lymph 
nodes hours later in a second wave of prion trafficking.  B cells constituted the majority of prion-
bearing cells in the mediastinal lymph node by six hours, indicating intranodal prion reception 
from resident DCs or subcapsulary sinus macrophages or directly from follicular conduits.  
These data reveal novel, cell autonomous prion lymphotropism, and a prominent role for B cells 
in intranodal prion movement. 
Introduction 
 
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are 
fatal neurodegenerative diseases that affect humans, cervids, bovids, and ovids.  According to the 
protein only hypothesis, the causative agent of prion diseases is a misfolded, abnormal isoform 
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of a normal, host-encoded protein1.  Termed PrPC, this 30-35 kDa glycoprotein is expressed most 
abundantly in the central nervous (CNS) and lymphoreticular systems, with lower expression in 
other tissues.  The absolute requirement of PrPC expression to generate prion diseases2 and the 
lack of instructional nucleic acid make prions unique among infectious agents. The pathologic, 
protease-resistant isoform (PrPSc) typically accumulates in the CNS and secondary lymphoid 
tissues of infected animals.  Upon neuroinvasion, prion diseases typically progress from 
transformation of PrPC to PrPSc to neuropathology including amyloid plaque formation, 
astrogliosis, and neuronal cell loss to inevitable death. 
 Before prions accumulate on follicular dendritic cells (FDCs) in secondary lymphoid 
organs (SLOs)3,4, they most likely interact with the innate immune system at the initial site of 
infection.  Complement proteins like C3 and C1q are important innate immune molecules shown 
to bind foreign bodies and altered-self-particles5, including protein amyloids6 and high density 
prion protein7. C1q, C3 and the Complement receptor CD21/35 have been shown to expedite 
peripherally-induced prion pathogenesis8-10. These data suggest that initial events in prion 
infection include Complement opsonization and inflammatory immune cell uptake and transport 
of prions from initial infection sites to draining lymph nodes, where peripheral prion replication 
occurs.  Complement may bind prions and enhance uptake by antigen presenting cells, as well as 
retention and replication of prions on FDCs in germinal centers. 
 Soluble complement proteins opsonize pathogens and facilitate their uptake by immune 
cells such as dendritic cells (DCs), macrophages (MΦs), and monocytes surveying nonlymphoid 
tissues.  These innate immune responses represent the first line of defense against invading 
pathogens.  Because these immune cells act as sentinels for microbial infections, investigators 
have implicated them as likely candidates for the uptake and spread of prions throughout the 
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 body.  Indeed, DCs, MΦs, and monocytes have been reported to both positively and negatively 
impact prion disease pathogenesis 8,9.  
Although substantial evidence links immune cells to prion disease, little data directly 
support a role for these cells in uptake and transport of prions hours after initial exposure.  
Because incunabular interactions between pathogens and immune cells often dictate the outcome 
of infection, insight into interactions of prions with the mononuclear phagocyte system at initial 
infection sites and within lymph nodes is vital to understanding incunabular events in prion 
infection.  In this study we analyzed the inflammatory response to prions that occurs within 
hours of infection, including lymphotropic and intranodal prion trafficking.  
Materials and Methods 
Mice 
PrP-/- (C57BL/6 X129sv), Tg(cerPrP)5037 and C1q-/- mice were generated as previously 
described33-35.  FVB, and C3-/- (C3tm1Crr/J) mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME). All mice were bred and maintained at Lab Animal Resources, accredited by 
the Association for Assessment and Accreditation of Lab Animal Care International, in 
accordance with protocols approved by the Institutional Animal Care and Use Committee at 
Colorado State University. 
Fluorescent Prions 
 Enrichment and fluorochrome labeling of prions were performed as previously described36-
38 with slight modifications. 10% Elk brain homogenate prepared in 0.32M sucrose, 150 uM 
NaCl, 4 uM EDTA diluted in PBS (PMCA buffer) were centrifuged at 3,000g for 10 minutes at 
4°.  The resulting supernatant were removed and saved and the pellet treated in PMCA buffer 
then centrifuged again at 3,000g for 10 minutes at 4°C.  Supernatants were then pooled and 
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centrifuged at 100,000g for 1 hr at 4°C and the resulting pellet treated with triton X-100 at 0°C at 
a final detergent concentration of 2% wt/vol, bringing the protein concentration to 5mg/ml in 
TBS measured by the Bradford assay.  The sample was then chilled on ice for 30 minutes and 
centrifuged at 100,000g for 30 minutes at 0°C.  The pellet was then washed twice at 0°C in 
10mM Tris HCL, 0.1 NaCl, 1mM EDTA, 5mM PMSF at a pH of 7.4 with and without 2% 
Triton X-100.  The supernatant was discarded and the pellet resuspended in PBS containing 1% 
(wt/vol) sarcosyl and protease inhibitors and stirred for 2 hours at 37°C before centrifuging 
through 0.32M sucrose in PBS at 100,000g for 60 minutes at 10°C.   The pellet was resuspended 
in a 2.3M NACl, 5% sarcosyl solution and sonicated 5 times at 40 second bursts.  The fractions 
were centrifuged at 13,000g for 15 minutes at 4°C, washed twice with TBS and stored at -70°C 
or conjugated to Dylight 649 using the Dylight Antibody Labeling Kit according to 
manufacturere’s protocol (Thermo Scientific Pierce).  
PK digestion and western blotting 
 Samples were digested with 50 µg/ml PK (Roche) for 30 min at 37°C. The reaction was 
stopped by adding lithium dodecyl sulfate sample loading buffer (Invitrogen) and incubating at 
95 °C for 5 min. Proteins were electrophoretically separated through 12% sodium dodecyl 
sulfate-polyacrylamide gels (Invitrogen), and transferred to polyvinylidene difluoride 
membranes (Millipore). Non-specific membrane binding was blocked by incubation in 5% milk 
blocking solution (Bio-Rad) for 1 h. Membranes were then incubated for 1 h at room temperature 
with horseradish peroxidase-conjugated Bar224 anti-PrP monoclonal antibody (SPI bio) diluted 
1:20,000 in Superblock (Pierce), washed 6 X10 min in PBS with 0.2% Tween 20, and incubated 
for 5 min with enhanced chemiluminescent substrate (Millipore).  Membranes were digitally  
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photographed using the FujiDoc gel documentation system equipped with a cooled charge-
coupled diode camera (Fuji). 
Prion Inoculations 
 Prion Inoculations were performed as previously described37,38.  Briefly, ice were 
inoculated IP with 100µl of PBS, or various concentrations of red fluorescent microspheres 
(Flourophex) or a suspension of prion aggregates described above.   
Live animal imaging  
 Mice were inoculated SC and PO with indicated amounts of fluorescent beads or prions, 
and visualized while anesthetized with 3 L/min Isofluorane in an IVIS 100 live animal imager 
(Caliper Life Sciences,Hopkinton, MA) at the indicated time points.  We analyzed images using 
Living Image 4.0 software (Caliper).   
Intraperitoneal wash 
 Immediately after euthanization of mice by C02 asphyxiation 10ml of PBS was injected 
into the peritoneal cavity of each mouse using a 12 ml syringe and 25 gauge x 1/2 in 
polypropylene hub hypodermic needle.  The Mice were set on a rocker or gently rocked 
manually for 2 minutes.  As much PBS as possible was recovered using the same 12ml syringe 
and a 16 gauge X 1½ in polypropylene hub hypodermic needle. 
The peritoneal wash fluid was collected in a 15 ml conical tube (falcon) and centrifuged at 
250 x g for five minutes.  The supernatant was discarded and the pellet re-suspended in 1 ml 





Isolation of cells from tissues 
 Following intraperitoneal wash the mediastinal lymph nodes (and where appropriate 
inguinal, spleen and mesenteric lymph nodes) were removed from the mice.  Lymph nodes were 
stored in 1 ml RMPI medium on ice for no longer than 30 min prior to separation of cells.  The 
lymph nodes were transferred to a 40 µm nylon cell strainer (Falcon ref 352340) with 1-3 ml 
PBS.  Lymph nodes were pressed through the screen with the plunger of a sterile 1 ml syringe.  
Lose cells were rinsed through the screen with an additional 1-2 ml PBS and the filtrate was 
transferred to a 15 ml conical tube. The plate was washed with 4-6 ml of PBS and transferred to 
the same 15 ml conical.  The 15 ml conical containing the single cell suspension from the lymph 
node was spun at 1000 rpm for 5 min.  The supernatant was discarded and the pellet re-
suspended in 1 ml FACS buffer and transferred to a 1.5 ml eppendorf tube for staining. 
Antibody staining of cells 
 106 cells were aliquoted from single cell suspensions were pelleted at 250 x g for 5 minutes 
on a bench top centrifuge.  Samples were washed twice in FACS buffer (0.1% BSA, 10mM 
EDTA in 1XPBS) by resuspending the cell pellet in 1 ml FACS followed by centrifugation at 
1000 rpm for 5 minutes.  Fc receptors were blocked using 2ng/ml solution of Purified rat anti-
mouse CD16/CD32 (BD Pharmingen) and incubated on ice for 20 min.  Fc block was removed 
by washing once with FACS buffer before staining solution was added to cell pellets. Cell pellets 
were stained using 50ul of a 1ng/mL solution of the antibodies listed in Table S1. Cells were 
washed twice following staining to remove unbound antibody and red blood cells were lysed by 
adding 1 ml of ACK buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) to the cell pellet 
and immediately centrifuging a250 x g  for 5 minutes.  The supernatant was removed and cell 
pellets were resuspended in 1X FACS for analysis. 
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Confocal Microscopy 
 Antibody-stained peritoneal cells were cytospun onto glass slides and mounted with 
ProLong Gold medium (Life Technologies, Grand Island, NY) and dried overnight at 4°C.  We 
acquired images with a LSM 510 Meta confocal microscope and software (Zeiss). 
Flow cytometric and statistical analyses 
 Flow cytometry data was acquired using a DakoCytomation CyAnADP flow cytometer 
and analyzed using FlowJo version 8 (Tree Star, Ashland, OR). Nonparametric statistical 
analyses were performed using GraphPad Prism 5 (La Jolla, CA). 
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Enrichment and fluorochrome conjugation of aggregated prion rods 
In order to monitor prion trafficking from inoculation sites to draining lymph nodes, we 
first enriched prion rods from a brain of an elk terminally sick with CWD from one liter of 10% 
crude brain homogenate, concentrating prion aggregate volume 104-fold to a final volume of 100 
µl using detergent solubilization and ultracentrifugation through a sucrose cushion (figure 2.1A).  
We enriched aggregated prion rods approximately 103-fold  (compare lanes 1 and 2 to 3 and 4).  
Like the crude brain homogenate, purified prion rods showed partial PK resistance (lanes 2 and 
4).  Normal brain homogenate contained no PK-resistant PrPC bands (lane 6).  Intracranial 
injection of 1 µg of enriched, sonicated prion aggregates resulted in terminal disease in 
susceptible mice 122 ± 5 (n=5) days post inoculation (DPI) compared to 157 ± 16 DPI for mice 
inoculated with 30 µg of 1% crude brain homogenate (n=8, p=.0003). We then conjugated 
enriched prions to Dylight 649 fluorochrome (figure 2.1B).  To evaluate the stability of the 
fluorochrome, we treated conjugated prions with PK (figure 2.1B, lanes 2 and 3) at physiological 
(lane 2) or supraphysiological temperatures  (lane 3). DyLight 649 still fluoresced even after 
SDS and PK treatment followed by incubation at 95OC.  In addition to demonstrating partial SDS 
and PK resistance (lanes 2 and 3), fluorescent prions could also aggregate into high molecular 
weight oligomers (lane 1). 
)$!
Figure 2.1 Purification and conjugation of prion rods from infected brain homogenate and 
real-time whole-mouse in vivo imaging.  A.  Western blot analysis depicting CWD infected elk 
brain homogenate used as starting material (5 %g in lane 1 and 100 %g in lane 2) from which we 
enriched prion rod aggregates (100 ng in lanes 3 and 4).  Lanes 5 and 6 show 100 %g of control 
elk normal brain homogenate. B.  SDS page gel depicting fluorochrome tagged prion rods.  
Prions treated at 37°C without Proteinase K (PK, lane 1) or with PK (lane 2), and at 95°C with 
PK (lane 3). Molecular weight markers are shown in kilodaltons to the left of the blots. C. In 
vivo detection of prion rods by epifluorescent whole-body optical imaging.  Representative 
images of tg5037 mice injected orally or subcutaneously with PBS or fluorescent prion rods or 1 
%m polystyrene microspheres (beads).  Images were acquired at indicated time points after 
injection. 
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Prion trafficking in live animals 
Resistance of fluorochrome conjugated prion rods to proteolytic and thermal degradation 
enabled us to visualize and track these fluorescent prions in vivo using whole mouse live imaging 
(Figure 2.1C).  Inoculation of 2 and 5 µg of sonicated, fluorescent prions via subcutaneous (SC) 
and per os (PO) routes, respectively, resulted in prion trafficking to areas consistent with the 
location of axillary lymph nodes within 2 hours post inoculation (HPI) PO and 4 HPI SC.  
Within 8 HPI SC, prions disseminate to areas consistent with the location of submandibular 
lymph nodes, spleen, and bladder. Prion trafficking from the oral cavity after PO inoculation was 
restricted primarily to areas consistent with the location of Peyer’s patches and axillary and 
mesenteric lymph nodes.  We observed little or no dissemination of 10 µg of 1 µm fluorescent 
polystyrene microspheres (beads) from their SC injection site, indicating specific trafficking of 
prion rods. 
Immune cells capture prions from the peritoneal cavity 2 HPI  
Particulate antigen can be transported to SLOs via cell dependent and independent 
mechanisms 10,11.  The presence of prions, but not beads, in various locations consistent with 
lymph nodes that drain the injection site suggested active uptake and trafficking by migratory 
immune cells.  To investigate this possibility, we first assessed whether immune cells associated 
with fluorescent prions hours after injection.  Isolation of adequate cell numbers from 
subcutaneous tissue and the oral cavity proved difficult for characterizing innate immune cells at 
these injection sites. We therefore chose the peritoneal cavity (PC) as an alternative inoculation 
route because it provides an optimal site for collecting immune cells. We inoculated mice 
intraperitoneally (IP) with 5 µg of fluorescent prions, collected cells by peritoneal lavage 2 HPI 
and analyzed them by flow cytometry (Figures 2.2 and 2.3). 
)&!
 
Figure 2.2.  Gating strategy for flow cytometry.  Side scatter parameter (SS or SSC) and all 
other axes are log scale except forward scatter (FS).  *CD23 gate not shown, but was set 
identically to the indicated gate.  **CD3 gate not shown, but was set identically to the indicated 
gate.  M$sF4/80 and DCsF4/80 cells were identified using F4/80 gating.  pr, prionophilic; M$s, 
macrophages; DCs, dendritic cells; LN, lymph node; SC, Subcapsulary. 
)'!
Figure 2.3.  Flow cytometric analysis of immune cells trafficking prions from the PC to MedLN 
2 HPI.   PBS (rows a-g, v-ab, ac-ai, and ax-bd), fluorescent beads (h-n, v-ab, aj-ap, and ax-bd) or 
prion rods (o-u, v-ab, aq-aw, ax-bd) were injected into the PC of mice and cells harvested from 
peritoneal lavage fluid (a-ab) or mediastinal lymph nodes (ac-bd) two hours later. Graphs in the 
first column show cells from mice treated with PBS (panels a, v ac, and ax), fluorescent beads (h, 
v,  aj, and ax) and prion rods (panels o, v, aq, and ax). Fluorescent cells (red or green dots) and 
total cells (grey dots) are plotted to show relative size (forward scatter, linear scale), granularity 
(side scatter, log scale) and proportion of total live cells that fluoresce. Cells were also stained 
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with antibodies against immune cell surface markers and gated for SSChiLy6G- Ly6C+CD11b+ 
monocytes (panels b, i, p, w, ad, ak, ar, and ay), SSChiLy6G+ Ly6C-CD11c- CD11b+  
neutrophils (c, j, q, x, ae, al, as, and az), SSChiLy6G- Ly6C-CD11b+CD11c+ DCs (d, k, r, y, af, 
am, at, ba), SSChiLy6G-Ly6C-CD11c-CD11b+ MΦs, (e, l, s, z,  ag, an, au, and b), 
SSCloB220+CD21+CD3- B cells (f, m, t, aa, ah, ao, av, and bc) and SSCloCD21-B220- CD3+ T 
cells (g, n, u, ab, ai, ap, aw, and bd). Cell counts in graphs are shown as log10 per 105 total cells.  
Horizontal bars below the PC and MedLN panels represent relative proportions of prion-bearing 
monocytes (red stripe), neutrophils (solid red), DCs (dotted), MΦs (checkered), B cells (white) 
and T cells (black). 
 
DCs and MΦs comprise the majority of prion-bearing immune cells (prionophils) in the PC   
We observed significant acquisition of prions and 10 µg of 1 µm fluorescent beads by 
immune cells present in the PC 2 HPI compared to PBS (Figures 2.3a, h and o).  Of the major 
antigen presenting cells analyzed from the PC, SSChiLy6G-Ly6C-CD11b+CD11c+ DCs (Figure 
2.2 and 2.3r) and SSChiLy6G-Ly6C-CD11c-CD11b+ MΦs (Figure 2.2 and 2.3s) were the 
predominant cell types capturing prions. Upregulation of CD11c on inflammatory MΦs can 
complicate their discrimination from DCs.  Although we observed no increase in CD11c+ cells 
in the PC, we performed an alternative gating strategy that gated for SSChiLy6C-Ly6G-
F4/80+CD11b+ MΦs and SSChiLy6C-Ly6G-F4/80-CD11b+CD11c+ DCs (Figure 2.2) to more 
clearly define these two cell populations.  Both strategies yielded very similar results, and are 
reported here as combined data.  We detected significant numbers of prionophilic DCs (prDCs, 
Figure 2.3y, median=3177; IQR=1280 to 33,968 per 100,000 cells, n=16 mice) and MΦs 
(prMΦs, Figure 2.3z, median=14,730, IQR=7598 to 29037, n=16) compared to DCs and MΦs 
from mice inoculated with PBS alone (pbsDCs, Figures 2.3d and y, e and z, median=8, IQR=1 to 
20 and pbsMΦs, median=4, IQR=1 to 7, respectively, n=13, p<0.001). prMΦs and prDCs 
accounted for 78.6% and 16.9%, respectively, of total prionophils.  
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DCs and B cells preferentially capture prions  
Comparing two particulate antigens, we detected three-fold more prDCs (median=3177) 
than bead-bound DCs (bDCs, median=1037, IQR=479 to 1654, n=5, p= 0.0262, Figure 2.3K and 
Y).  In a subset of mice whose cells acquired prions, we observed 40-fold more prDCs (6/16, 
median=41,905. IQR= 31,234 to 59,043, p=0.0022) than bDCs.  
We observed a small proportion (0.6% of total), yet significant number, of prionophilic 
SSCloB220+CD21+CD3- B cells (prB cells, Figures 2.2 and 2.3t and aa, median =117, IQR=84 
to 192 p<0.05) in the PC compared to PBS (Figures 2.3f, and aa, median=2; IQR=0 to 10) but 
little to no bead-bearing B cells (Figures 2.3m and AA, median=0, IQR=0 to 7, n=5). We 
detected no significant difference in numbers of peritoneal prMΦs or bead-bearing MΦs (Figure 
2.3z, median=10,700; IQR=9658 to 22,144, n=5).  
Relatively few Monocytes and Neutrophils capture prion rods from the PC 
SSChiLy6G-Ly6C+CD11b+ monocytes and SSChiLy6C-Ly6G+CD11c-CD11b+ 
neutrophils (Figure 2.2) also show a propensity to retain prions from the PC 2 HPI.  We collected 
significant numbers of prionophilic monocytes (prMonos, Figure 2.3p and w, median=638, 
IQR=276 to 967, n=16) and neutrophils (prNeuts, Figure 2.3q and x, median=77, IQR=38 to 
9874, n=10) compared to PBS inoculated controls (pbsMonos, Figures 2.3b and w, c and x, 
median=2; IQR 0 to 10, n=13 and pbsNeuts, median=0, IQR 0 to 2, n=10; p<0.001).  
Additionally, neutrophils exhibited the highest propensity for prion rod uptake, with up to 98% 
of neutrophils in PC capturing prions.  Still, prMonos and prNeuts comprised only 3.4% and 
0.4%, respectively, of total prionophils.  We also collected significant numbers of bead-
associated monocytes (bMonos, Figure 2.3i and w, j and x, median=401, IQR=171 to 4388; 
p<0.01) and neutrophils (bNeuts, IQR=66 to 839; n=5, p<0.01) compared to PBS, but observed 
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no difference in numbers of prMonos/Neuts versus bMonos/Neuts.  Finally, We detected no 
significant numbers of prionophilic or bead-associated SSCloB220-CD21-CD3+ T cells (Figure 
2.2, prT and bT cells, respectively) in the PC at 2 HPI (Figures 2.3g,n, u and ab).  We observed 
similar prionophil quantities and proportions from identical experiments using PrPC deficient 
mice (data not shown). 
Prionophils are present in the MedLN 2 HPI 
We then searched for prionophils in LNs to which these cells migrate.  We failed to 
identify significant numbers of prionophils in spleens or mesenteric lymph nodes in this assay, as 
expected for antigens injected IP.  However, we observed significant acquisition of fluorescent 
prions and beads by immune cells present in the mediastinal lymph nodes (MedLN) 2 HPI 
compared to PBS (Figures 2.3ac, aj and aq).  We also observed trafficking to inguinal lymph 
nodes, but at lower frequencies and cell counts compared to MedLNs (data not shown). Confocal 
microscopy revealed large prion aggregates in areas of MedLNs consistent with lymphoid 
follicles and capsules (Figure 2.4). Interestingly, we observed drastic changes in prionophil 
proportions in the MedLN compared to the PC.  
)+!
Figure 2.4. Confocal analysis of the mediastinal lymph node 2 hours post infection.  Prion 
rods (labeled red) were injected into the PC of mice and mediastinal lymph nodes harvested 2 
hours post infection.   Mediastianal lymph nodes were cut into 20 µm sections, labeled with 
antibodies against CD11c (green) and CD11b (blue), and analyzed by confocal microscopy.   
Areas marked in the merge are consistent with the capsule (C) and follicle (F).  Scale bar, 20 %m. 
M!s and B cells comprise the majority prionophils in the MedLN 
We observed more prM$s than any other immune cell type analyzed (Figure 2.3au and 
bb, median=34, IQR=11 to 70 n=16, compared to pbsM$s (Figures 2.3ag and bb, median=0, 
IQR=0 to 6 and n=13, p<0.001)), consistent with their predominance in the PC.  Surprisingly, 
though, prB cells represented the second highest number of prionophils in the MedLN (Figures 
2.3av and bc, median=23, IQR=17 to 32 p<0.01 compared to PBS inoculated controls). This 
represents a 44-fold increase in the proportion of prB cells in the MedLN (26.4%) compared to 
the PC (0.6%).  The proportion of prM$s decreased 2.1-fold from the MedLN (39.1%) 
	  69	  
compared to the PC (78.6%). We detected statistically insignificant numbers of bMΦs (Figure 
2.3an and bb, median=6; IQR=3 to 61, n=5) and bB cells (Figure 2.3AO and BC, median=10, 
IQR=4 to 26) in the MedLN.   
Increased proportion of monocytes in the MedLN  
We collected half as many prMonos (Figure 2.3ar and ay median=11; IQR 7 to 15; 
p<0.05) and prDCs (Figure 2.3at and ba, median=11; IQR=6 to 44 per 105 cells, n=16 mice) 
from the MedLN compared to prB cells. The proportion of prMonos increased 3.7-fold in the 
MedLN (12.6%) compared to the PC (3.4%), while prDC proportions decreased slightly. 
Interestingly, we detected four-fold more bMonos (Figure 2.3ak and ay median=45; IQR=14 to 
105; p<0.01) than prMonos. We observed no significant difference in the number of prDCs and 
bDCs (Figure 2.3 am and ba, median=7, IQR=3 to 83, n=5), and found no significant numbers of 
prNeuts (Figure 2.3as and az), bNeuts (al and az), prT (aw and bd) or bT (ap and bd) cells in the 
MedLN.  
Peritoneal prionophils both internalize and retain prion rods on their cell surfaces.   
We assessed subcellular location of captured prions by visulaizing peritoneal prionophils 
by confocal microscopy. While prMonos (Figure 2.5) and prMΦs (Figure 2.6) showed a 
tendency to internalize prion rods, these cells, as well as prDCs (Figure 2.7), and prNeuts 
(Figure 2.8) demonstrated the ability to retain prion rods on both the cell surface and intracellular 
compartments.  Internalized fluorescent prions generally appeared more diffuse, while cell 
surface prions appeared as bright, punctate fluorescent aggregates ranging in size from 1 -3 µm3 




Figure 2.5.  Analysis of monocytes capturing prion rods in the PC by confocal microscopy.  PBS 
and prion rods (labeled red) were injected into the PC of mice and CD11b+Ly6C+ (labeled blue 
and green, respectively) monocytes were analyzed for prion retention.  Z stack images were 
collected at 0.28 µm intervals and range from 0.64 to 7.31 µm. Image shown in row three, 
column six indicates isotype and PBS controls.  Bottom row starting from the left show single 
stains of the nucleus (white), Ly6C, CD11b, and prion rods.  The Last 2 panels in the bottom row 
represent a merged z stack image and an orthogonal image. 
*$!
 
Figure 2.6.  Analysis of M!s capturing prion rods in the PC by confocal microscopy. PBS 
and prion rods (labeled red) were injected into the PC of mice and cells harvested from 
peritoneal lavage fluid and labeled with antibodies against cell surface markers, CD11b (blue) 
and CD11c (green). Cells were cytospun onto glass slides and Z-stack images were collected at 
0.32 µm intervals and range from 0.64 to 5.40µm.  Image shown in row one, column two 
indicates isotype and PBS controls.  Bottom row starting from the left shows single stains of 
nuclei (white), CD11b, CD11c, and prion rods.  Last two panels in bottom row represent a 
merged z stack and orthogonal image. 
*%!
 
Figure 2.7.  Analysis of DCs capturing prion rods in the PC by confocal microscopy.  PBS 
and prion rods (labeled red) were injected into the PC of mice and cells harvested from 
peritoneal lavage fluid and labeled with antibodies against cell surface markers, CD11b (blue) 
and CD11c (green). Cells were cytospun onto glass slides and Z-stack images were collected at 
0.32 µm intervals and range from 0.64 to 7.31µm.  Image shown in row one, column two 
indicates isotype and PBS controls.  Bottom row starting from the left shows single stains of 
nuclei (white), CD11c, CD11b, and prion rods.  Last two panels in bottom row represent a 
merged z stack and orthogonal image. 
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Figure 2.8.  Analysis of neutrophils capturing prion rods in the PC by confocal microscopy. 
PBS and prion rods (labeled red) were injected into the PC of mice and cells harvested from 
peritoneal lavage fluid and labeled with  antibodies against cell surface markers, CD11b (blue) 
and CD11c (green). Cells were cytospun onto glass slides and Z-stack images were collected at 
0.32 µm intervals and range from 0.64 to 5.40µm.  Image shown in row one, column two 
indicates isotype and PBS controls.  Bottom row starting from the left shows single stains of 
nuclei (white), CD11b, CD11c, and prion rods.  Last two panels in bottom row represent a 
merged z stack and orthogonal image. 
Dynamics of prion trafficking kinetics over time 
Most prionophil proportions in the PC remained relatively constant from 2 to 36 hours 
(Figure 2.9), except for a 26-fold increase in prNeuts from 2 (0.4%) to 6 HPI (10.3%).  
Consistent with data collected 2 HPI, at 6 HPI prB cells increased their proportion 201-fold from 
the PC (Figures 2.9 and 2.10, 0.3%) to the MedLN (60.3%), becoming the predominant 
prionophil, while the prM$ proportion decrease 6.4-fold from the PC (70.9%) to the MedLN 
(11.1%).  By 16 HPI, we observed a relatively even distribution of all prionophils analyzed, save 
prNeuts (Figures 2.9 and 2.11).  The share of prDCs increased 4.4-fold from the PC to MedLN 
*'!
at 16 HPI, then plateaued to 36 HPI (Figures 2.9, 2.11 and 2.12). Proportions of prMonos from 
PC to MedLN increased steadily over every time point, reaching its maximum share of total 
prionophils in the MedLN at 36 HPI (41.8%).  The distribution of the other prionophils analyzed 
remained relatively constant from 16 to 36 HPI, except for prMonos, whose percentage 
increased two-fold over that time. We failed to detect any fluorescent prions or beads one week 
after inoculation (data not shown). 
 
Figure 2.9.  Dynamics of prion trafficking kinetics over time. 
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Figure 2.10. Flow cytometric analysis of immune cells trafficking prions from the PC to 
mediastinal lymph nodes 6 HPI. PBS (rows A-G, O-U, V-AB, and AJ-AP), or Prion rods (H-
N, O-U, AC-AI, and AJ-AP) were injected into the PC of mice and cells harvested from 
peritoneal lavage fluid (A-U) or mediastinal lymph nodes (V-AP) six hours later. Graphs in the 
first column show cells from mice treated with PBS (panels A, O, V, and AJ), and prion rods 
(panels H, O, AC, and AJ). Total cells (grey dots) are plotted to show relative size (forward 
scatter), granularity (side scatter) and proportion of total live cells that fluoresce. Cells were also 
stained with antibodies against immune cell surface markers and gated as outlined in Figure 2.2
for monocytes (panels B, I, P, W, AD, and AK), neutrophils (C, J, Q, X, AE, and AL), DCs (D, 
K, R, Y, AF, and AM), M$s, (E, L, S, Z, AG, and AN), B cells (F, M, T, AA, AH, and AO ) and 
T cells (G, N, V, AB, AI, and AP). Graphs depict total number of monocytes in the PC and 
mediastinal lymph node (panels W and AY), neutrophils (X and AZ), DCs (Y and BA), M$s (Z 
and BB), B cells (AA and BC), and T cells (AB and BD). 
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Figure 2.11.  Flow cytometric analysis of immune cells trafficking prions from the PC to 
mediastinal lymph nodes 16 HPI.  Figure panels are arranged identically as in figure 2. Graphs 
depict total number of monocytes in the PC and MedLN (panels W and AY), neutrophils (X and 
AZ), DCs (Y and BA), M$s (Z and BB), B cells (AA and BC), and T cells (AB and BD). 
**!
 
Figure 2.12.  Flow cytometric analysis of immune cells trafficking prions from the PC to 
mediastinal lymph nodes 36 hours after inoculation. Figure panels are arranged identically as 
in figure 3. Graphs depict total number of monocytes in the PC and mediastinal lymph node 
(panels W and AY), neutrophils (X and AZ), DCs (Y and BA), M$s (Z and BB), B cells (AA 
and BC), and T cells (AB and BD). 
Passive and active transport of prions to MedLNs 
Previous studies indicate that DC trafficking antigen to draining lymph nodes occurs 12 -
16 HPI 10-12.  Given the early detection of prionophils in the MedLN in as little as 2 HPI, we 
postulated passive prion delivery might occur at early time points whereas active transport by 
prionophils may occur later in infection.   To test this hypothesis we injected prions IP into the 
PC of donor mice and harvested cells from the PC and MedLN two hours later. Peritoneal cells 
from donor mice were washed to remove unbound prions and 106 cells transferred into the PC of 
each recipient mouse. MedLN from donor and recipient mice were analyzed for resident and 
migratory prionophils, respectively. 
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 SSChiCD11b+CD169+ subcapsulary sinus MΦs (SCS MΦs, Figure 2.13A) isolated from 
donor mice show a high propensity for prion uptake 2 HPI (Figure 2.13B (red cloud) and 13D 
(red dots), median=94; IQR=27 to 148 per 100,000 cells, n=17 mice, p<0.01) compared to mice 
inoculated with PBS (Figure 2.13B (blue cloud) and 13D (blue squares, median=6; IQR 2 to 7, 
n=3 mice).  SSChiCD11c+CD8α+ resident DCs also show a significant ability to take up prions 
(Figure 2.13C and 2.13E (red cloud and dots) median=8; IQR 4 to 11, n=17, p<0.05) compared 
to PBS controls (blue cloud and dots, median=2; IQR 1 to 5, n=3).  
We assessed active prion transport by isolating cells from the MedLN of recipient mice 
inoculated with prion-loaded donor cells. We detected a small number of prMonos in MedLNs at 
two HPI (Figure 2.13F, H, and J, median=6 IQR=4 to 24) and 16 HPI (Figure 2.13G, I, and K, 
median=4 IQR=1 to 9). While these median numbers are low, we did detect 13 and 181 prMonos 
in two mice, and 15 prMΦs in one mouse at 16 HPI. 
We also performed adoptive transfer experiments at 6 HPI to analyze MedLN cells for 
prB cells to assess the drastic increase in their proportions at this time point.   In donor MedLNs 
we detected significant numbers of prionophilic SSCloCD5-CD11b-B220+CD23+CD21+ 
follicular B2 cells (prB2, Figure 1.14B and D, median=24; IQR=3 to 40, n=5, p=0.008).  
Surprisingly, we also detected significant numbers of prionophilic SSCloB220-CD21-CD23-
CD11b+CD5+ B1 cells (prB1, Figure 1.14C and E, median=7; IQR 4 to 21, n=7, p=0.005) there.  
MedLNs from recipient mice contained prB2 (Figure 1.14G and H, red peak and dots, 
median=108 per 104 B cells, IQR=41 to 179, p=0.045), but not prB1 (green, median=1, IQR=1 
to 29) cells 6 HPI.  
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Figure 2.13.  Flow cytometric analysis of passive and active transport of prion rods.  Prion 
rods were injected IP into donor mice and two hours later immune cells harvested from the PC 
and mediastinal lymph nodes. Peritoneal cells were washed to remove unbould prion rods and 
transferred into the PC of recipient mice. MedLN from donor mice 2 HPI (panels a-e), and 
recipient mice 2 and 16 HPI (panels f-k), were analyzed for prion-bearing resident and migratory 
immune cells, respectively. Total cells from the MedLN (grey dots in panels a, f and g) are 
plotted to show relative size (forward scatter, linear scale), granularity (side scatter, log scale) 
and proportion of total live cells that bear prions (red dots). Resident MedLN cells were analyzed 
for  SSChiCD11b+CD169+ SCS M$s (b and d) and SSChiCD11c+CD8"+ DCs (c and e) bearing 
prion rods.  Prion-loaded cells from donor mice were injected into the PC of recipient mice and 
lymph nodes harvested 2 and 16 hours later.  Migratory immune cells were also analyzed for 
monocytes (depicted as red peaks (h and i) and dots (Jjand k)), DCs (green) and M$s (purple) 
using the same phenotypic markers used in Figure 3.  These cell subsets were compared to cells 
in MedLN from PBS inoculated control mice (blue).   Cell counts in graphs d, e, j and k are 
shown as log10 per 105 total cells. 
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Figure 2.14. Flow cytometric analysis of B cell subsets in transport of prion rods.  Adoptive 
transfer experiment was performed similarly as experiments in Figure  2.13.  Prion rods were 
injected IP into donor mice and six hours later immune cells harvested from the PC were washed 
and transferred into the PC of recipient mice. MedLN from donor (panels a-e) and recipient mice 
(panels f-h) were analyzed 6 HPI for prion-bearing B1 and B2 cells. Donor MedLN cells were 
analyzed for  SSCloCD21+B220+CD5-CD11b-CD23+ follicular B2 cells  (b and d) and 
SSCloB220- CD21-CD23-CD11b+CD5+ B-1 cells (c and e) bearing prion rods. Recipient MedLNs 
were also analyzed for prion uptake by B2 cells (red peak (g) and dots (h)) and B1 cells (green).  
B cell subsets were compared to cells in MedLN from PBS inoculated control mice (blue).   Cell 
counts in graphs are shown as log10 per 105 total cells (d and e) or per 104 B cells (h). 
The role of Complement in prionophil uptake and trafficking of prions 2 HPI 
Complement facilitates prion pathogenesis, replication and uptake by FDCs and conventional 
DCs 13-15. To examine the interplay of complement with prions in early inflammatory events 
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involving the MPS, we inoculated mice deficient in complement components C1q or C3 with 
prions IP and analyzed immune cells from the PC and MedLN for prion retention 2 HPI.    
Impaired ability of DCs from Complement deficient mice to capture prions from the PC   
While C1q-/- and C3-/- mice possessed similar numbers of total prionophils in the PC, they 
exhibited altered prionophil proportions compared to controls (figure 2.15, panels f, k, p, and u).  
We detected fewer prDCs from C1q-/- (panels n and x, median=390; IQR=184 to 1077 n=11, 
p=0.01) or C3-/- mice (panel s and x, median=913; IQR=165 to 1492 n=7, p=0.01) than from wt 
mice (panels i and x, median= 3089; IQR=982 to 33614 n=17, p=0.001). Concomitantly, we 
observed increases in prNeuts from C1q-/- (panels m and w, median 4006; IQR=296 to 8508 
n=11, p=0.01) and C3-/- (panels r and w, median 2420; IQR=1383 to 10098 n=7, p=0.05) mice 
compared to wt mice (panels h and w, median 93; IQR=42 to 6669 n=11, p=0.001).   
Consequently, the proportion of prDCs in the PC decreased 8.4-fold in C1q-/- (figure 2.15, pie 
chart right of panel O, dotted purple wedge) and two-fold in C3-/- mice (dotted green wedge from 
panel T pie chart) compared to wt (dotted red wedge from Panel J pie chart), while prNeut 
proportions increased 40.6 and 21-fold for C1q-/- and C3-/- mice, respectively (compare black 
wedges in the three pie charts right of j, o and t).  We also detected a two-fold decrease in 
prMonos from C3-/- (striped green) but not C1q-/- (striped purple) mice compared to wt (striped 
red).  We detected no significant proportional changes in prMΦs (solid colored wedges), which 
remained the predominant prion scavenger in the PC of wt (j and y), C1q-/- (o and y) and C3-/- (t 
and y) mice. 
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Figure 2.15. Flow cytometric analysis of immune cells trafficking prions in complement 
deficient mice. Figure panels are arranged similarly as in Figure 4. Pie charts to the right of the 
flow cytographs of prionophils from wt (f-j), C1q-/-- (k-o) and C3-/- (p-t) mice represent relative 
frequencies of  prionophils. Pie chart wedges depict M$s from wt (red), C1q-/- (purple), and C3-/-
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(green) mice, DCs from wt (dotted red), C1q-/- (dotted purple), and C3-/- (dotted green) mice, 
monocytes from wt (striped red), C1q-/- (striped purple), and C3-/- (striped green) mice, and 
neutrophils (black) from wt, C1q-/-, and C3-/- mice. 
 
Impaired ability of DCs from Complement deficient mice to capture prions in the MedLN 
Surprisingly, we detected more prionophils in MedLNs from both C1q-/- (figure 2.15 
panels aj and at) and C3-/- (ao and at) mice compared to wt mice (panels ae and at).  However, 
consistent with data derived from the PC, we observed an approximately four-fold reduction in 
the proportion of prDCs in both C1q-/- (dotted purple wedge from pie chart right of an) and C3-/- 
(dotted green wedge in chart right of as) MedLNs compared to wt (dotted red wedge, chart right 
of AI).     
Also consistent with PC data, prMΦs from wt (ai and ax, median=36; IQR=11 to 90 
n=17, p=0.01), C1q-/- (an and ax, median=161; IQR=123 to 333 n=11, p=0.001) and C3-/- mice 
(as and ax, median=137; IQR=37 to 419 n=7, p=0.001) constitute the majority of immune cells 
involved in prion uptake.  We observed increases in both raw numbers (ax) and proportions of 
prMΦs from C1q-/- and C3-/- mice compared to wt (compare solid colored wedges from the pie 
charts to the right of panels ai, an and as).  Relative proportions of prMonos (striped purple, 
green and red wedges), prNeuts (black wedges) and prB cells (data not shown) remained similar 
in C1q-/-, C3-/- and wt MedLNs. 
Discussion 
 
In order to gain insight into incunabular immunological events in prion infection, when 
the innate immune system initially confronts prions, we used highly enriched, fluorochrome 
conjugated prions to document prion trafficking and immune cell confrontation hours after initial 
exposure.    We attempted to model prion trafficking as closely to a natural infection as possible 
using nonsaturating amounts of highly enriched, heterogeneously-sized, bona fide infectious 
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prions.   Fluorochrome conjugation of enriched prions eliminated detection using anti-prion 
protein antibodies, which cross-react with endogenous PrPC and complicate data interpretation.  
Many studies suggest a role for MΦs and CD11c+ DCs in the capture, degradation and/or 
transport of prions 8,9,16-23.  Consistent with these previous data, prMΦs and prDCs comprised 
the vast majority of prionophils detected in the PC 2 HPI, while prMonos, prB cells and prNeuts 
comprised the remaining small fraction.  Only DCs and B cells preferentially captured prions 
over beads, evincing receptor mediated capture by these cells, perhaps by innate immune 
receptors as previously suggested7,13,15,24.  
Based on current paradigms of cell-mediated trafficking of antigens10,25-27, including 
prions22,24, from infection sites to draining lymph nodes, we expected to find few prionophils in 
the MedLN before 16 HPI.  Instead, we found considerable numbers of prMΦs, prMonos, 
prDCs and, strikingly, huge increases in prB cell proportions well before then.  These data raise 
the strong possibility that a considerable portion of prions that we injected IP passively traveled 
through lymphatics draining the PC, arriving in MedLNs via afferent lymphatics and captured by 
resident immune cells, as has been observed for other free antigens10,26,28.  We substantiated this 
possibility for prions by identifying significant numbers of prionophilic resident DCs, SCS MΦs, 
innate B1 and follicular B2 cells in MedLNs 2 to 6 HPI.  Adoptive transfer experiments revealed 
a small number of monocytes and B2 cells, but not migratory DCs, MΦs and B1 cells, pre-
loaded with prions from donor mice, present in MedLNs of recipient mice at these times.  We 
assert that the very small number of monocytes are not likely to transport the large amount of 
prions to MedLNs and transfer them to very large numbers of SC MΦs there.  These data 
compellingly support a mechanism of cell autonomous movement of smaller prion aggregates 
from the infection site to draining lymph nodes.   
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 Data supporting a cell autonomous route of lymphotropic prion trafficking also lends 
insight into intranodal prion movement. The incredible proportion of prB cells in MedLNs at 
early time points indicates that B cells are most likely receiving prions from other immune cells, 
probably SCS MΦs and resident DCs within the lymph nodes, consistent with current models of 
intranodal antigen trafficking26,29.  B cells are likely not the only cells receiving prions from 
other cells in the LN.   FDCs, which trap and replicate prions in germinal centers, originate from 
stromal cells and are sessile, permanent residents in LNs30,31.  Thus, they must receive prions 
intranodally from another source, perhaps prB cells or by directly capturing small prion 
aggregates arriving in the LN through follicular conduits.  We also reproducibly observed a 
considerable proportion of prT cells in MedLNs but not in the PC, at all time points, further 
supporting intranodal, intercellular prion transfer.  Future experiments documenting intranodal 
prion trafficking in real time using multiphoton intravital microscopy will confirm this 
hypothesis. 
Numerous studies corroborate the facilitative role of Complement in peripheral prion 
pathogenesis.  In this study we found that fewer DCs captured prions without C1q or C3 and 
fewer monocytes captured prions without C3, while neutrophil capture dramatically increased in 
the PC.  MΦs predominantly and efficiently captured prions seemingly independent of C1q and 
C3.  We interpret these data to reveal that DCs and monocytes require C1q and/or C3 for optimal 
prion retention, perhaps through Complement receptors like Mac-1, SIGN-R1 or Calreticulin 7,28.  
The neurotoxic prion peptide PrP106-126  has been shown to bind the G protein-coupled receptor, 
formyl peptide receptor-like 1 (FPRL-1) on, and enhance proinflammatory cytokine production 
from monocytes32.  Prions binding FPRL-1 on monocytes could explain this prionophil’s 
apparently reduced dependence on Complement for prion capture. 
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Based on the data described here, we propose an updated, more detailed model of 
lymphotropic and intranodal prion trafficking by immune cells (Figure 2.16).  Biphasic 
lymphotropic transport of prions occurs from the initial entry site upon peripheral prion 
infection.  A first wave of smaller prion aggregates passively percolate through interstitia, and 
collect into and quickly travel through the lymphatic system to draining lymph nodes.  A small 
number of monocytes also rapidly and actively transport larger prion aggregates.  SCS MΦs 
capture free prions as they emerge from afferent lymphatic vessels, while resident DCs extend 
processes into follicular conduits and extract free prions.  MΦs at the site of infection capture 
large and small aggregates with or without Complement, perhaps by scavenger or other 
phagocytic receptors, or even macropinocytosis.  These peripheral MΦs more likely degrade 
and/or sequester the majority of prions, whereas DCs and monocytes preferentially retain 
Complement-opsonized prions on their cell surfaces via Complement receptors.   These prDCs 
and prMonos deliver the second wave of prions to draining LNs at least 12 hours later.    
Inside LNs, SCS MΦs capture free prions or receive them from incoming prDCs and 
prMonos. prDCs or SCS prMΦs (which are more prone to present antigen than phagocytic 
peripheral prMΦs) transfer prions to follicular B2 cells (and perhaps a few T cells), most likely 
but not necessarily aided by Complement.  prB2 cells then shuttle prions from the SCS or 
follicular conduits to FDCs, which express copious amounts of PrPC that is converted into PrPSc 
in this optimized prion bioreactor.  Cell autonomous prions not captured by SCS MΦs or resident 
DCs may encounter follicular B2 cells at follicular conduit termini or travel deep into the follicle 
where FDCs directly bind them.  While prion replication certainly requires PrPC, incunabular 
prion capture and trafficking does not. 
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Figure 2.16.  Prion Trafficking Model.  Immune cells encounter prions in the PC and MedLN.  
M', DCs, monocytes, neutrophils, B and T cells have all been shown to associate with prions in 
the PC and MedLN early after infection.  Small prion particles traffic passively through the 
lymphatic system and enter the lymph node through afferent lymphatic vessels where they 
encounter B cells through follicular conduits.  DCs may also access prions through protrusion of 
their dendrites through tight junctions into follicular condiuts. SCS M's trap larger prion or 
prion-complement immune complexes through scavenger or complement receptor 3 and may 
present them to underlying follicular B cells. Inflammatory monocytes actively transport prions 
to SCS M's, B cells, or DCs in the draining lymph node.  B cells facilitate intrafollicular prion 
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CHAPTER 3: 
GENETIC DEPLETION OF COMPLEMENT RECEPTOR CD21/35 PREVENTS 






The Complement System has been shown to facilitate peripheral prion pathogenesis.  
Mice lacking Complement receptors CD21/35 partially resist terminal prion disease when 
infected intraperitoneally with mouse-adapted scrapie prions.  Chronic wasting disease (CWD) is 
an emerging prion disease of captive and free-ranging cervid populations that, like scrapie, has 
been shown to involve the immune system, which probably contributes to their relatively facile 
horizontal and environmental transmission.  Here we show that mice overexpressing the cervid 
prion protein and susceptible to CWD (Tg(cerPrP)5037 mice) but lack CD21/35 expression 
completely resist clinical CWD upon peripheral infection.  CD21/35 deficient Tg5037 mice 
exhibit greatly impaired splenic prion accumulation and replication throughout disease, similar to 
CD21/35 deficient murine PrP mice infected with mouse scrapie.  TgA5037;CD21/35-/- mice 
exhibited little or no neuropathology and deposition of misfolded, protease-resistant PrP 
associated with CWD.  CD21/35 translocates to lipid rafts and mediates a strong germinal center 
response to prion infection that we propose provides the optimal environment for prion 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	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   published	   as:	   Michel, B. et al. Genetic Depletion of Complement Receptors 
CD21/35 Prevents Terminal Prion Disease in a Mouse Model of Chronic Wasting Disease. J 
Immunol. (2012). http://www.jimmunol.org/content/early/2012/09/21/jimmunol.1201579.full.pdf	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accumulation and replication. We further propose a potential role for CD21/35 in selecting prion 
quasi-species present in prion strains that may exhibit differential zoonotic potential compared to 
the parental strains. 
Introduction 
 
 Chronic Wasting Disease (CWD) is the only recognized naturally occurring transmissible 
spongiform encephalopathy (TSE), affecting captive and free-ranging cervids 1 in North America 
and captive cervids in South Korea.  Similar to other TSEs, CWD is caused by prions, unusual 
infectious agents devoid of instructional nucleic acid 2 and characterized by the accumulation of 
PrPRES, a proteinase K (PK) resistant form of the normal cellular prion protein, PrPc.  CWD 
and the sheep TSE Scrapie can be transmitted relatively efficiently compared to other TSEs, 
probably contributing to their higher prevalences 3,4.  Prions have been detected in nervous and 
lymphoid tissue, muscle, blood, saliva, urine and feces 5-13.  Of particular interest are lymphoid 
tissues because they contain prions often before the central nervous system, implicating the 
lymphoid system as an initial site of extracerebral prion accumulation and replication.  
Lymphoid follicles or inflammatory foci accumulate and replicate prions primarily on follicular 
dendritic cells (FDCs) that express relatively large amounts of PrPC 14-18.  FDCs originate from 
perivascular precursor cells 19 and trap immune complexes on their elaborate projections and 
present them to B cells, which can be positively selected, activated, undergo immunoglobulin 
affinity maturation and become plasma cells. FDCs may retain Ag on their cell surfaces for 
prolonged periods, maximizing presentation to B cells and consequently affecting the humoral 
immune response.  
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 FDC depletion significantly impairs prion replication and FDC specific PrPc expression 
has been shown to be essential for optimal peripheral prion infection 14,17,18,20.  B cells, while 
replicating little prion, also play an essential role in peripheral prion pathogenesis 21,22.  This 
requirement presumably relates to B cells’ ability to supply FDCs with critical cytokines 
important in FDC maturation and maintenance, but may also be involved in lymphotropic and/or 
intranodal prion trafficking.   
 Substantial evidence supports a significant role for the Complement system in expediting 
peripheral prion disease by mediating prion interaction with FDCs and B cells.  Complement 
activation leads to asymmetrical cleavage of both C3 and C4 bound to pathogens.   Complement 
receptors CD21/35 expressed on B cells and FDCs trap opsonized pathogens by binding cleaved 
C3 and C4 opsonins.  Mice express CD21 and CD35 only on B cells and FDCs from 
alternatively spliced transcripts generated from a single gene, while humans express them on 
more cell types from separate genes 23,24.  While Complement mediated antigen trapping 
enhances both innate and adaptive immune responses to microbial pathogens, it actually 
exacerbates prion pathogenesis.  Elimination of complement receptors CD21/35 reduced prion 
trapping, replication and disease 17.  Interestingly, depletion of CD21/35 has a greater impact on 
disease progression than deleting their ligand sources, C3 and C4, alluding to a role for CD21/35 
in peripheral prion pathogenesis independent of their endogenous ligands.  Genetic depletion of 
C1q also delays prion disease at high doses and prevents disease at low doses after 
intraperitoneal (I.P.) infection 25,26, and C1q has been shown to bind prions in vitro 27,28. 
 In this study, we show that complete elimination of the complement receptor CD21/35 in 
transgenic mice susceptible to CWD significantly delays splenic prion accumulation and blocks 
progression to terminal disease upon inoculation with CWD prions.  To assess the kinetics of 
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prion accumulation in the spleen we developed a semiquantitative prion amplification scoring 
system based on protein misfolding cyclic amplification (PMCA), which allowed us to evaluate 
prion replication and/or accumulation at 15, 30, 70, and 140 days post inoculation (DPI).  Mice 
deficient in CD21/35 show a significant impairment in prion retention and replication compared 
to CD21/35 sufficient mice. We also observed significant germinal center formation during 
scrapie prion infection that was dependent on CD21/35 and PrPc expression on FDCs.  Lipid raft 
flotation experiments show movement of CD21/35 into lipid rafts on B cells upon prion 
infection.  Overall, these data demonstrate that CD21/35 mediated prion trapping on FDCs and 
possibly B cells marks an important event in lymphoid prion pathogenesis that promotes terminal 
prion disease in these mouse models. 
Material and Methods 
 
Mice 
 Prnpo/oCD21/35-/-, C3/C4-/-, Tg5037 and TgA20 mice were made as previously 
described 17,29,30.  Prnpo/oCD21/35-/- were crossed with TgA20 or Tg5037 mice to produce 
TgA20;Prnpo/oCD21/35-/- (TgA20;CD21/35-/-) and Tg5037;Prnpo/oCD21/35-/- 
(Tg5037;CD21/35-/-) mice. All mice were bred and maintained at Lab Animal Resources, 
accredited by the Association for Assessment and Accreditation of Lab Animal Care 
International, in accordance with protocols approved by the Institutional Animal Care and Use 
Committee at Colorado State University.  Bone marrow chimeric mice were produced as 
previously described 17. 
Preparation of inoculum 
 10% brain homogenates were prepared in PMCA buffer (4mM EDTA, 150 mM NaCl in 
PBS) from E2 homogenates derived from a terminally diseased elk brain.  RML5 prions were 
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prepared as previously described 17.  10% homogenates were diluted 1:10 (E2 and RML5) or 
1:1000 (RML5) in 320 mM sucrose supplemented with 100 units/mL Penicillin and 100 µg/mL 
Streptomycin (Gibco) in PBS immediately prior to inoculation. 
Inoculations, Clinical scoring and Dissections 
 Mice were inoculated intraperitoneallly with 100 µl of inoculum using a 28G Insulin 
syringe. Mice were monitored for clinical symptoms of prion disease, including tail rigidity, 
impaired 95extensor reflex, akinesia, tremors, ataxia and weight loss.  Mice with any four of 
these symptoms or paralysis were scored terminally sick and euthanized. 
 Mice were inoculated with inocula described above and euthanized at indicated time 
points by CO2 inhalation. Brains and spleens were collected and divided sagittally. One brain 
hemisphere and half a spleen was fixed in 4% paraformaldehyde in PBS for histology and one 
was homogenized and used for NaPTA precipitation, PMCA or PK digestion. 
Sodium phosphotungstic (NaPTA) Precipitation of PrPRES 
 NaPTA precipitation was performed exactly as described previously 17. Briefly, Gross 
cellular debris was removed by centrifugation at 80 x g and 500 µl of supernatant mixed 1:1 with 
4% sarkosyl in PBS. Samples were incubated for 15 min at 37°C with constant agitation, then 
incubated with 50 U/ml benzonase and 12.75 mM MgCl2 for 30 min at 37°C with constant 
agitation. Prewarmed NaPTA stock solution (pH 7.4) was added to a final concentration of 0.3% 
and the sample was incubated at 37°C for 30 min with constant agitation and centrifuged at 37°C 
for 30 min at maximum speed in an Eppendorf microcentrifuge. The pellet was resuspended in 
30 µl of 0.1% sarkosyl in PBS and digested with 20 µg/ml PK for 30 min at 37°C.  
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Protein misfolding cyclic amplification (PMCA),  PK digestion and Western blotting (WB) 
 PMCA was performed and quantified as previously described 13 with slight 
modifications.  Samples were sonicated at 70–85% maximum power for 40 s in a microplate 
horn sonicator (Qsonic, Framingham), followed by a 30-minute incubation at 37 °C repeated for 
24 hours per round for up to five rounds total.  PK digestion and WB was performed as 
previously described 31, except that spleen homogenates were digested with 10 µg/mL PK. PrP 
was detected using HRP-conjugated Bar244 antibody (Bertin Pharma, Paris).  
Histochemistry and Immunohistochemistry 
 Slides were prepared and stained as previously described 31.  Briefly, 10 µm sections 
were cut from paraffin-embedded spleen tissue and mounted onto glass slides.  Splenic follicles 
were stained with rat anti-mouse IgM (02031D, Pharmingen) followed by goat anti-rat IgG 
(H+L) followed by AP-conjugated donkey anti-goat IgG (705-055-147, Jackson) and visualized 
with Fast Blue (Polysciences, Warrington, PA).  Germinal centers were stained with Biotin-
conjugated peanut agglutinin (PNA) ABComplex/horseradish peroxidase (ABC/HRP, Dako) and 
visualized with 3-Amino-9-Ethylcarbazole (AEC, A5754, Sigma).  
Splenocyte isolation and flotation assays  
 Individual whole spleens from at least five mice per group were ground through a nylon 
mesh to release lymphocytes into single cell suspensions, which were then centrifuged 5 min at 
200g and washed twice with ice cold PBS. The remaining splenic tissue was digested for 20 min 
at 37oC in 1 mg/mL Collagenase, 0.5 mg/mL Dispase and 40µg/mL DNase I (Roche, 
Mannheim, Germany) with agitation. Supernatants were collected and the remaining tissue 
digested for another twenty minutes. The samples were pooled and centrifuged 5 min at 200 x g. 
Cell pellets were washed twice with ice cold PBS, combined with corresponding lymphocyte 
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pellets and incubated 30 min on ice in 400µl 1% Triton X-100 in TNE buffer (25mM Tris-HCl 
ph7.4, 150mM NaCl, 5mM EDTA 5mM dithiotheitol (DTT)) containing protease inhibitors 
(Complete Mini tablet, Roche). Samples were centrifuged 10 min at 1000 x g at 4°C to pellet 
debris and supernatants transferred to new tubes. 133 µl of lysates were mixed with 267 µl 60% 
(w/v) Optiprep solution (Axis-Shield, Oslo, Norway) and pipetted to the bottom of 13 x 51 mm 
UltraClear centrifuge tubes (Beckman-Coulter, Palo Alto, CA, USA). 200 µl aliquots of 35%, 
30%, 25%, and 20% Optiprep were gently layered on top of the lysates. Tubes were centrifuged 
12 h at 4°C in a S55S Sorvall M150SE rotor at 120,000 x g. Two hundred microliter fractions 
were collected from the top of the tube. SDS-PAGE loading buffer was added to aliquots of each 
fraction with or without PK digestion (20µg/mL for 30 min) and subjected to 4-12% gradient 
PAGE.   
Germinal Center counting, statistical and phylogenetic analyses. 
 Follicles were counted in three non-consecutive sections from five distinct areas from at 
least five spleens as IgM+ B cells forming characteristic follicular foci.  Germinal centers were 
counted as PNA+ B cells (brown stain) within follicles (IgM+ blue stain).  We derived 
percentages of follicles containing GCs (%GCs) by dividing the number of GCs by the number 
of follicles and multiplying by 100.  Statistical analyses were performed using Excel (Microsoft) 
and Prism software (GraphPad).  CD21 sequence alignment and phylogenetic anyalysis was 
performed using Geneious (BioMatters, Auckland, New Zealand). 
Results 
 
Absence of CD21/35 protects mice from CWD 
To create a mouse deficient in complement receptors CD21/35 and susceptible to CWD 
prions, mice deficient in both CD21/35 (CD21/35-/-) and mouse PrPC (Prnpo/o) were crossed to 
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Tg (cerPrP) 5037 mice that express high levels of elk, but no mouse, PrPC.  Offspring were then 
screened and resulting Tg5037;CD21/35-/- and Tg5037 littermates inoculated with 100 µg brain 
homogenate from an elk terminally infected with CWD prions (E2).   Tg5037;CD21/35-/- mice 
showed complete resistance to CWD prions, with no mice showing any clinic signs at the end of 
the study, while infected Tg5037 mice died from CWD at a median time of 301 DPI (Figure 
3.1A).  We next examined terminally sick Tg5037 and DPI matched Tg5037;CD21/35-/- mice 
for characteristic signs of CWD neuropathology (Figure 3.1B-G).  Minimal astrogliosis and 
vacuolization with no PrP
RES
 deposition was observed in nonclinical Tg5037;CD21/35-/- mice at 
285 DPI (Figure 3.1B, D and F).  However, significant vacuolization, astrogliosis, and PrP
RES
 
deposition were observed in terminally sick Tg5037 mice at 285 DPI (Figure 3.1C, E and G).   
Western blot and densitometric analyses revealed PrP
RES 
in only 3 of 11 brains from 
Tg5037;CD21/35-/- mice, significantly less than in brains from terminally sick Tg5037 mouse, 
all of which contained PrP
RES  and, when compiled together, contained 3.5-fold more PrPRES 
(Figure 3.1H and I).  
,,!
 
Figure 3.1. Mice deficient in CD21/35 show resistance to CWD prion infection. (A) Tg5037 
(blue line, n=8) and Tg5037;CD21/35-/- (red line, n=11) mice were inoculated with 100 %g of 
brain homogenate from an elk terminally infected with CWD and monitored for terminal disease.  
Tg5037 mice show a median survival time of 301 dpi, compared to Tg5037;CD21/35-/- mice, all 
of which remained nonclinical to the end of the study (>500 DPI). (B) IHC of brain sections 
from nonclinical Tg5037;CD21/35-/- mice 285 dpi (B, D and F) exhibited minimal vacuolization, 
prion deposition and astogliosis compared to DPI-matched Tg5037 mice (C,E and G).  (H) 
Western blot (WB) analysis of PrPRES content from Tg5037 and Tg5037;CD21/35-/- mice.  All 
samples contain 100 %g of protease digested brain homogenate except lanes 1,3 and 8, which 
contain 20 %g of undigested brain homogenate (Tg5037 mice (lanes 3 and 8) express five-fold 
more PrP than cervids (E2, lane 1)).  (I) Densitometric analyses of protease resistant bands in the 
western blot confirm that the brains from terminal Tg5037 mice contain significantly higher 
PrPRES content compared to Tg5037;CD21/35-/- mice. 
Absence of CD21/35 delays prion propagation in the spleen 
We next used a semiquantitative prion amplification assay to estimate prion loads in 
spleens of CWD infected Tg5037 and Tg5037;CD21/35-/- mice.  PMCA, a technique used to 
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amplify prions in vitro, takes advantage of a prion’s ability to self propagate, using seeded 
protein fibrilization (Figure 3.2A).  We employed PMCA to amplify and quantify minute 
amounts of PrP
RES
 from spleen homogenates from mice at various intervals after infection.  
Tg5037 mice at 15 DPI show a significant difference in the amount of splenic PrP
RES
 (Figure 
3.2B and C, 75.49 ± 4.43 rpu) compared to Tg5037;CD21/35-/- mice (25.56 ± 4.24 rpu).  Using 
our standard curve for this assay generated previously, we estimate that splenic PrP
RES load in 
Tg5037 mice approximates 20,000 pg/g of spleen tissue (Figure 3.2C).  The PMCA score for 
Tg5037;CD21/35-/- mice falls just out of the dynamic range of our assay (29 rpu), so we can 
only estimate the load to be < 100 pg/g.  We detected much less PrP
RES in spleens from Tg5037 
mice at 30 DPI (17.17 ± 0.16 rpu) while Tg5037;CD21/35-/- spleens showed only a slight 
decrease in PrP
RES 
load (21.88 ± 0.15 rpu).  Both scores fall just below the range of the PMCA 
score standard curve.  Accumulation of PrP
RES
 differed drastically between the two groups after 
30 DPI.  PrP
RES
 load increased significantly more in Tg5037 mice  from 70 (37.50 ± 0.15 rpu, 
250 pg/g) to 140 DPI (55.56 ± 0.11 rpu, 2000 pg/g) to terminal disease (71.00 ± 0.2 rpu, 10,000 
pg/g).  We detected significantly less PrP
RES in spleens from nonclinical Tg5037;CD21/35-/- at 
70 (20.00 ± 0.14 rpu, <100 pg/g) and 140 DPI (41 ± 0.16 rpu, 500 pg/g) and at DPIs matched to 
sick Tg5037 mice (47.00 ± 0.50rpu, 900 pg/g).  
$-$!
 
FIGURE 3.2.  Tg5037;CD21/35-/- mice show delayed prion accumulation in the spleen.  (A) 
Schematic representation of PMCA.  Alternating cycles of incubation and sonication of cellular 
PrP seeded with PrPRES with substrate followed by Proteinase K (PK) digestion and western 
blotting (WB) amplify and detect minute quanttites of prions. (B) Representative WB showing 
PMCA results from round four and five of spleen samples from both Tg5037 and 
Tg5037;CD21/35-/- mice (n ) 5).    All samples contain 100 %g of protease digested PMCA 
sample except lane 1, which contains 20 %g of undigested sample. We detected PrPRES in Tg5037 
spleen samples in round 4 and in Tg5037; CD21/35-/- spleen samples in round 5, indicating a 
higher CWD prion concentration in mice that express CD21/35. (C) Tg5037  mice accumulate 
significantly more CWD prions in the spleen at 15, 70, 140 DPI and terminal disease compared 
to Tg5037;CD21/35-/-  mice.  Left axis shows PMCA score in relative PMCA units (rpu).  Right 
axis shows PrPRES load in pg/g of infected spleen homogenate.  At least five replicates of each 
sample was assayed (n ) 8, *p<0.01). 
CD21/35 mediates a strong germinal center response during prion infection 
Increased PrPRES retention could be mediated via formation of germinal centers (GCs). 
Antigen trapping by Fc* receptors and CD21/35 on FDCs, and concomitant B cell signaling 
through the B cell receptor (BCR) and the CD21/CD19/CD81 coreceptor stimulates lymphoid 
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follicles to generate GCs 32-35 containing arborized FDCs.   Prolonged antigen presentation by 
FDCs and additional signals (CD40-CD40L) activates B cells to become plasma or memory B 
cells 36,37.   CD21/35-/- and C3-/- mice have reduced size and numbers of germinal centers before 
antigenic stimulation 38,39 but high doses of antigen increase GCs to near wt levels. We observed  
a similar phenomenon in spleens of mice overexpressing PrPc (TgA20, Tg5037, 
TgA20;CD21/35-/- and Tg5037;CD21/35-/- mice), which exhibited significant GC formation 
during prion infection independent of CD21/35 expression (data not shown).  This most likely 
occurred because increased PrPC expression increases prion replication and concomitant 
antigenic stimulation of GC formation, just as high doses of microbial antigens can.   
In mouse models expressing normal physiological levels of PrPC and CD21/35, scrapie 
prion infection causes abnormal GC reactions characterized by hypertrophic FDC dendrites,  
PrPRES accumulation, and increased maturation and numbers of B cells 40. We therefore 
investigated the role of CD21/35 in this process by analyzing GC formation in mice expressing 
normal wild type mouse PrPC levels, with or without CD21/35 expression, after infecting them 
with RML5 mouse adapted scrapie prions.  We discovered that intraperitoneal inoculation of 
high and low doses of prions, but not uninfected (mock) brain homogenate, stimulated 
significant GC formation in spleens of wt, but not CD21/35-/- mice (Figures 3.3A-D and Table 
3.1, n ≥ 5). Interestingly, prion infection, but not 108 colony forming units (cfu) of heat-killed E. 
coli or DNP-KLH (data not shown), induced GC formation in C3/4-/- mice, suggesting that 
CD21/35 can mediate prion-induced GC reactions independent of its endogenous ligands.  
Moreover, we detected significant amounts of CD21/35 in PrPRES preparations enriched by  
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NaPTA precipitation from spleen homogenates of infected mice 60 DPI, but very little CD21/35 
from NaPTA precipitates from mock infected spleens (Figure 3.3E).  We recovered far less 
PrPRES from CD21/35-/- spleens, consistent with our PMCA data from Tg5037;CD21/35-/- 
spleens. 
$-'!
Figure 3.3.  Prion infection stimulates germinal center (GC) formation and increases CD21/35 
presence in prion-enriched spleen preparations.  (A-E) Mice (n ) 10) were inoculated i.p. with 
0.1%, prion-infected brain homogenate, sacrificed 60 DPI and frozen spleen sections stained 
with IgM (blue stain) and PNA  (brown) that reveal GCs in splenic follicles from uninfected wt 
(A) mice that increased in size and number upon prion infection (B), Spleens from CD21/35-/-
mice contain relatively few, small GCs (C) that were only nominally increased and less than wt 
spleens upon prion infection (D). (E)  CD21/35 is greatly enriched in NaPTA precipitated PrPRES
preparations from spleens of terminally sick mice compared to PrP-/- and mock-infected wt mice.  
PrPRES was precipitated from 500 %g of total spleen homogenate and equal volumes loaded into 
each lane.  
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Table 3.1.  Germinal Center Formation in Peripheral Prion Disease 
 
  %GC+a 
Inoculum DPIb WT CD21/35–/– C3/4–/– 
1% NBHc 120 34 ± 5 14 ± 3d 15 ± 4d 
0.1% IBHe 30 33 ± 8 25 ± 3 20 ± 3 
 60 44 ± 14 17 ± 5d 37 ± 7 
 90 55 ± 6 21 ± 4d 51 ± 5 
 termf 67 ± 4 23 ± 3d 62 ± 6 
1% IBH termf 96 ± 16 27 ± 5d 72 ± 14 
108 E. coli 7 83 ± 8 19 ± 6 17 ± 4 
anumber of germinal centers/number of follicles 
bDPI, days post inoculation 
cNBH, normal brain homogenate 
d p<0.01 
eIBH, infected brain homogenate 
fDPI ranged from 280-385 days  
 
CD21/35 translocates to lipid rafts on B cells upon prion infection  
GC formation by the traditional primary immune response requires CD21/35 expression 
on B cells but not FDCs 35. Closer examination of GC formation in BM chimeric mice infected 
with prions divulged a pattern of GC formation predominantly dependent on both CD21/35 and 
PrPC expression on FDCs (Table 3.2, n ≥ 5), suggesting that CD21/35 antigen presentation is 
more important than CD21/35 signaling to mediate this reaction. To resolve this discrepancy in 
GC formation we assessed whether prion infection alters localization of CD21/35 on the plasma 
membrane. In a typical primary immune response, C3d or C4d-opsonized antigen binds to 
specific short consensus repeats (SCRs) of CD21/35, inducing CD19-mediated palmitoylation of 
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the tetraspanin CD81 41,42 that moves the entire complex into lipid rafts, cholesterol- and 
sphingolipid-rich microdomains of the plasma membrane 43. This offers an attractive model of 
prion replication because PrPC resides in lipid rafts via its glycerophosphatidylinositol (GPI) 
anchor, and translocation of CD21/35 to the same rafts upon prion infection could effectively 
bring PrPRES to PrPC. We therefore monitored CD21/35 translocation to lipid rafts on splenocytes 
from infected mice by lysing them in cold Triton X-100 and subjecting the cleared lysate to 
density gradient centrifugation. CD21/35 resides predominantly outside lipid rafts on splenocytes 
from mock-infected wild type mice, as indicated by its presence in detergent soluble fractions 
(Figure 3.4A). In contrast, PrP was detected in detergent insoluble fractions containing lipid rafts 
that float to the top of the density gradient and colocalize with the raft marker flotillin. Upon 
prion infection, a significant amount of CD21/35 moved into detergent insoluble fractions 
(Figure 3.4B). CD21/35 was present in the same fractions as flotillin and PK-resistant PrPRES, 
but not the immunoglobulin heavy chain (IgH), indicating that CD21/35 translocation occurred 
independent of the BCR. Furthermore, while a T cell-dependent antigen failed to stimulate 
CD21/35 translocation to lipid rafts in C3/4-/- mice (Figure 3.4C), prion infection induced a 
significant amount of CD21/35 translocation (figure 3.4D). These data strongly suggest that 
CD21/35 can interact with prions independent of its endogenous ligands, which could explain 
why CD21/35-/- mice exhibit a more significant delay in disease progression than C3/4-/- mice. 
While the lack of CD21/35 expression does not completely prevent PrPRES accumulation in lipid 
rafts, it significantly decreases PrPRES load (Figure 3.4E).  Flotation assays on spleens from BM 
chimeric mice revealed that FDCs appear to express only the short form of the Complement 
receptor, CD21, and that prion infection fails to translocate CD21 to lipid rafts on FDCs (Figure  
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3.4F). Thus, prion infection provokes CD21/35 translocation on B cells, which express all 




Figure 3.4. Prion infection stimulates CD21/35 translocation to lipid rafts on B cells in 
CD21/35-expressing mice.  2 x 107 splenocytes were lysed in ice-cold Triton X-100 and cleared 
lysates were centrifuged at the bottom of a density gradient (see Methods). (A) CD21/35 and the 
B cell receptor (BCR) immunoglobulin heavy chain (IgH) reside outside lipid rafts on mock-
infected wt splenocytes. (B) CD21/35, but not IgH, translocates to lipid rafts and colocalizes 
with PrPRES and the raft marker flotillin on prion-infected wt splenocytes. (C) CD21/35 resides 
outside lipid rafts on C3/4-/- splenocytes from mice inoculated i.p with 108 cfu of heat killed E. 
coli. (D) Upon prion infection, CD21/35 moves into lipid rafts independent of its endogenous 
ligands in C3/4-/- mice. (E) Infected CD21/35-/- splenocytes retain less PrPRES than infected wt 
splenocytes (compare to B). (F) Irradiated wt mice reconstituted with CD21/35-/- bone marrow 
express CD21 only on FDCs. Upon prion infection, CD21 remains outside lipid rafts, indicating 
that prion-stimulated CD21/35 translocation occurs only on B cells.  Data are representative of at 
least five independent experiments. 
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Table 3.2. Germinal Center Formation in Bone Marrow Chimeric Mice Infected with 
Prions 
 




wt wt both both 72 ± 12 
wt CD21/35-/- B cells both 22 ± 4e 
CD21/35-/- wt FDCs both 78 ± 13 
CD21/35-/- CD21/35-/- neither both 23 ± 3e 
wt PrP-/- both B cells 15 ± 11e 
CD21/35-/- PrP-/- FDCs B cells 11 ± 7e 
PrP-/- wt both FDCs 73 ± 9 
PrP-/- CD21/35-/- B cells FDCs 21 ± 2e 
PrP-/- PrP-/- both neither 14 ± 4e 
PrP-/- CD21/35-/- wt FDCs FDCs 75 ± 9 
PrP-/- CD21/35-/- CD21/35-/- neither FDCs 19 ± 2e 
PrP-/- CD21/35-/- PrP-/- FDCs neither 14 ± 5e 
wt PrP-/- CD21/35-/- B cells B cells 13 ± 6e 
PrP-/- PrP-/- CD21/35-/- B cells neither 10 ± 4e 
CD21/35-/- PrP-/- CD21/35-/- neither B cells 12 ± 2e 
PrP-/- CD21/35-/- PrP-/- CD21/35-/- neither neither 13 ± 4e 
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Table 3.2. Germinal Center Formation in Bone Marrow Chimeric Mice Infected with 
Prions 
 
aBM was isolated from mice of the indicated genotype. 
b Hemopoietic systems of sublethally irradiated mice of the indicated genotypes were 
reconstituted with donor BM. 
c CD21/35/35 or PrP expression was restricted to the indicated cell types for each 
reconstitution group. 






We investigated the role of the complement receptor CD21/35 in CWD prion 
accumulation, replication, and disease progression.  We observed a complete rescue from 
terminal CWD of Tg5037 mice lacking CD21/35.  Just 3/11 nonclinical Tg5037;CD21/35-/- 
mice displayed detectable, yet reduced, prion neuropathology and PrPRES deposition in their 
brains.  These results reveal a more dramatic outcome than earlier studies showing only a partial 
rescue of CD21/35 deficient mice from scrapie infection, despite those mice expressing only 
wild type (i.e., five-fold less) PrPC levels.  This could reflect differences between mouse and 
cervid CD21 expression, as are apparent between mouse and human CD21.  However, little is 
known about cervid CD21.  The gene has yet to be cloned, so comparative analyses with murine 
CD21/35 are impossible to date.  We can, however, compare CD21 sequence homology and 
phylogeny among other species that are susceptible to TSEs.  For example, sheep, which are 
susceptible to scrapie, a TSE that closely resembles CWD in transmission efficiency and 
lymphotropism, express a CD21 molecule that shares 65% sequence identity with murine 
CD21/35, including their ligand binding domains (figure 3.5A).  This may explain the similar 
lymphotropic characteristics of murine and ovine scrapie.  Ovine CD21 also shares 65% identity 
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with human CD21/35.  Overall, CD21/35 from these three species share 52% identity and 64% 
similarity.  In contrast, bovine CD21, which is 40% larger than the other three CD21/35 
molecules (~1400 aa compared to ~1000 aa, respectively), shares less than 20% similarity to the 
other three CD21/35 molecules.  Phylogenetic analysis reveals a clustering of murine, ovine and 
human CD21/35 proteins, with bovine CD21 much more distantly related (figure 3.5B).  
Interestingly, BSE has been shown to have little or no lymphotropic characteristics 44-47, perhaps 
due to the vastly different CD21 molecule that bovines express. 
$$%!
 
Figure 3.5.  Sequence and phylogenetic analyses of CD21/35.  A.  Sequence alignment of 
ligand binding domains of bovine, human, mouse and sheep CD21.  B.  Phylogenetic tree 
showing relative relatedness of bovine, human, mouse and sheep CD21. 
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These results indicate a significant role in prion pathogenesis for CD21/35, the 
importance of which may vary by prion strain.  Complement components C1q and C3 have 
recently been shown to exhibit similar strain preferences in vitro and in vivo 48. We are currently 
investigating other prion strains to determine the contribution of CD21/35 to prion pathogenesis 
in those infection models.  Interestingly, cross-species prion transmission was recently shown to 
result in a higher infection rate of the lymphoreticular system than the central nervous system in 
the xenohost 49.  This cross-species infection resulted in distinct lymphotropic and neurotropic 
strains with differential host ranges.  These strains may result from tissue-specific strain selection 
or mutation.  The higher efficiency of prion infection in the spleen (which harbor CD21/35 
expressing FDCs and B cells) compared to the brain (which lacks them) alludes to a critical role 
for CD21/35 in prion retention, replication, and possibly strain selection in trans-species prion 
infection.  The lack of CD21/35 that delays peripheral prion accumulation might further limit the 
lymphoid replication of neurotropic prion strains, resulting in delayed or abrogated disease 
progression. If so, this would have profound implications for prion xenotransmission and 
possible therapeutic approaches aimed at CD21/35.  For example, targeting CD21/35 to slow the 
spread of neurotropic prions could be an attractive alternative to most prion disease therapeutics 
developed to date that target the central nervous system, which can complicate drug delivery.  
Interfering with CD21/35 mediated prion strain selection could also mitigate emergence of new 
prion strains with expanded host ranges and prevent a breach of the species barrier like the one 
that likely caused the BSE and subsequent new-variant CJD outbreak fifteen years ago in the 
United Kingdom. 
To study the kinetics of extraneural CWD prion accumulation, we amplified PrPRES from 
spleens of CWD prion infected Tg5037 and Tg5037;CD21/35-/- mice at various time points 
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throughout infection.  At 15, 70, 140 DPI and terminal disease prion accumulation was 
significantly lower in CD21/35 deficient mice.  The extremely high prion load detected at 15 DPI 
most likely reflects increased retention of prion inocula early after infection.  This delay in 
extraneural prion accumulation strongly correlates with abrogation of prion neuropathology and 
terminal disease.  These results coincide with our previous data from scrapie mouse models (17), 
further strengthening evidence that CD21/35 plays an integral part in prion accumulation in 
peripheral lymphoid organs that ultimately facilitates neuroinvasion.   
Furthermore, we show that CD21/35 is present in prion preparations enriched from 
spleen homogenates by NaPTA precipitation.  We also demonstrate germinal center formation in 
spleens during prion infection primarily dependent on CD21/35 and PrPC expression on FDCs.  
It may seem surprising that CD21/35 expression on FDCs, rather than B cells, correlates with 
prion-induced GC formation, since CD21/CD19/CD81 B cell coreceptor (BCCR) ligation helps 
activate B cells to form GCs.  However, maximal B cell activation and GC formation requires 
signaling from both the BCR and BCCR 32,33.  Here we show that although prion infection 
stimulates CD21/35 translocation to lipid rafts on B cells, signaling appears to be suboptimal for 
GC formation in the absence of concomitant BCR translocation.  We observed a strong 
dependence on both PrP and CD21/35 expression on FDCs for a strong GC response. 
Paradoxically, CD21/35 translocation did not occur on FDCs, which are the major prion trappers 
and replicators, but lack other BCCR components required for CD21/35 movement. One could 
therefore argue that GC formation represents an artifact, rather than a driver of splenic prion 
replication.  Elimination of GCs had no effect on peripheral prion replication and disease 
progression in mice infected i.p. with RML5 50, supporting this interpretation.  However, GC-
deficient mice infected intracranially with 139A mouse adapted scrapie prions exhibited a 
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significant delay to terminal disease 51.  Thus, distinct prion strains may differentially influence 
GC formation and subsequent prion pathogenesis.  Additionally, this discrepancy further 
highlights potential preferences of distinct tissues for different prion strains. CD21/35 expressing 
cells within GCs may facilitate this selection process in the lymphoid system.  Increased 
retention of prions on FDCs could induce a persistent state of prion presentation to adjacent B 
cells sufficient to cause an atypical germinal center response 40.  FDCs may coax B cells to linger 
there, providing increased Lymphotoxin signaling to FDCs that may promote formation of 
hypertrophic dendrites that efficiently retain and replicate prions. Consistent with their role as 
long-lived, long-term antigen presenting cells, FDCs may also present prions to neighboring 
PrPC-expressing B cells that could induce CD21/35 translocation and move prions proximal to 
PrpC in lipid rafts and promote further prion replication and GC formation. 
Taken together, these data support a principal role of CD21/35 in peripheral prion 
pathogenesis  by trapping PrPRES on both B cells and FDCs.  CD21/35 expression on FDCs 
remains of paramount importance in this process, with B cells playing a lesser, but still important 
role.  We have recently shown that few prion-bearing B cells transport prions from infection sites 
to draining lymph nodes, but their presence increased dramatically within lymph nodes, 
indicating a prominent role for B cells in intranodal prion trafficking 52.  We propose that 
CD21/35 mediates this and other crucial processes in lymph node prion trapping and replication 
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CHAPTER 4:  
COMPLEMENT PROTEIN C3 EXACERBATES DISEASE IN A MOUSE MODEL OF 




Accumulating evidence shows a critical role of the complement system in facilitating 
attachment of prions to both B cells and FDCs and assisting in prion replication. Complement 
activation intensifies disease in prion-infected animals, and elimination of complement 
components inhibits prion accumulation, replication, and pathogenesis.  Chronic wasting disease 
is a highly infectious prion disease of captive and fee-ranging cervid populations that has utilized 
the complement system for efficient peripheral prion replication and most likely efficient 
horizontal transmission.  Here we show that complete genetic or transient pharmacological 
depletion of C3 prolongs incubation times and significantly delays splenic accumulation in a 
CWD transgenic mouse model.  Using a semiquantitative prion amplification scoring system we 
show that C3 impacts disease progression in the early stages of disease by slowing the kinetic 
rate of accumulation and/or replication of PrPRES. The delayed kinetics in PrPRES replication 
correlates with delayed disease kinetics in mice deficient in C3.  Taken together, these data 
support a critical role of C3 in peripheral CWD prion pathogenesis.  
Introduction 
 
 Chronic Wasting Disease (CWD) is a highly contagious prion disease of unknown origin 
affecting both wild and farmed raised deer, moose and elk 1,2. First described as a disease entity 
by E.S. Williams and colleagues in the 1970s 1, CWD has become the most contagious and 
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puzzling prion disease to date.  Similar to other prion diseases, CWD is characterized by the 
accumulation PrPRES, a proteinase K (PK) resistant form of the cellular prion protein, PrPC 3.  
According to the Prion hypothesis, PrPRES is the non-genomic pathogen that causes prion 
diseases. CWD seems to be unique among prion diseases in its prevalence in both wild (≤ 45% 4) 
and captive (≤ 90% 5) animal populations.  
 Prions have been found in lymphoid and nervous tissue, muscle, blood, feces, urine and 
saliva 6-11.  Much research has focused on lymphoid tissues, as peripheral prion accumulation and 
replication has been documented there.  Prion accumulation and replication occur on follicular 
dendritic cells (FDCs) within lymphoid follicles of secondary lymphoid organs (SLOs) 12,13.  
FDCs differentiate from perivascular precursors and display antigenic immune complexes on 
their dendritic processes to B cells to promote survival, Immunoglobulin affinity maturation and 
activation to plasma cells 14.    
 FDCs and B cells are both important for optimal peripheral prion pathogenesis 15-18.   
Accumulating evidence shows a critical role of the complement system in facilitating attachment 
of prions to both B cells and FDCs and assisting in prion replication 19,20.  The complement 
system plays a vital role in immune-mediated defense against pathogens.  Multiple pathways 
activate the complement system, all converging at C3 activation 21.  C3 is the most abundant 
complement protein, present in the blood at mean physiological concentrations of 1.2 mg/ml 22.  
C3 convertases asymmetrically cleave C3, revealing a thioester bond on the large fragment, C3b, 
that reacts with carbohydrates on microbial surfaces. Covalently bound C3b molecules opsonize 
microbial pathogens and mark them for phagocytosis by innate immune cells or lysis by the 
membrane attack complex. Murine Complement receptors CR2(CD21)/ CR1 (CD35) expressed 
on B cells and FDCs trap pathogens coated with C3 cleavage products and mediate appropriate 
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immune responses.  Opsonization is critical for eliminating invading pathogens. However, many 
pathogens manipulate complement regulatory components to avoid being eliminated 23 or 
promote their attachment to or infection of the host 24,25.  Complement activation exacerbates 
disease in prion-infected animals, and elimination of CD21/35 inhibits prion accumulation, 
replication, and pathogenesis 35, 36. 
In this study, we show that complete genetic or transient pharmacological depletion of C3 
prolongs incubation times and significantly delays splenic accumulation in a CWD transgenic 
mouse model.  Using a semiquantitative prion amplification scoring system we show that C3 
impacts disease progression in the early stages of disease by slowing the kinetic rate of 
accumulation and/or replication of PrPRES. The dilatory kinetics in PrPRES replication correlates 
with dilatory disease kinetics in mice deficient in C3.       
Materials and Methods 
Mice 
C3-/- were purchased from Charles River (Wilmington, MA), Prnpo/o and Tg5037 mice were 
made as previously described 26,27. Prnpo/o and C3-/-mice were bred to produce Prnpo/oC3-/- mice, 
which were crossed with Tg5037 mice to produce Tg5037;Prnpo/oC3-/- (Tg5037;C3-/-) mice. All 
mice were bred and maintained at Lab Animal Resources, accredited by the Association for 
Assessment and Accreditation of Lab Animal Care International, in accordance with protocols 
approved by the Institutional Animal Care and Use Committee at Colorado State University.  
Preparation and inoculation of cobra venom factor 
Cobra venom factor (CVF) is a C3b homologue that forms a C3 convertase with Factor 
Bb, but is resistant to inactivation by Complement regulatory proteins CR1 and Factor I, 
resulting in rapid and near complete temporarily depletion of C3.  At least one intraperitoneal 
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injection of 100 µl of 900 µg/ml of CVF (Sigma) in PBS or PBS alone as a control, was given 24 
h before inoculation with CWD. Following CWD infection, additional injections of CVF at 5, 
10, and 15 dpi were given. C3 concentration was assayed by enzyme-linked immunosorbent 
assay (ELISA).  
ELISA 
Double antibody sandwich ELISAs were performed as outlined by the manufacturer 
(Immunology Consultant Laboratory, Inc).  Briefly, serum collected from mice were diluted 
1/50000 and 100 µl of this serum transferred into an anti-C3 ELISA microtiter plate and 
incubated for 20 minutes.  Following incubation the contents were aspirated and wells washed 
four times with diluted wash solution.  Next, 100 µl of enzyme antibody conjugate was added 
and the samples incubated in the dark for 20 minutes. The solution was aspirated and wells 
washed four times.  100 µl of TMB substrate was added into each well and allowed to incubate 
in the dark for 20 minutes.  After incubation 100 ul of stop solution was added to each well. 
Fully-developed plates were read at 405 nm by an Opsys MR plate reader.  
Preparation of inoculum 
10% elk and deer brain homogenates infected with CWD prions were prepared in PMCA 
buffer (4mM EDTA, 150 mM NaCl in PBS).  These 10% homogenates were diluted 1:10 in 320 
mM sucrose supplemented with 100 units/mL Penicillin and 100 µg/mL Streptomycin (Gibco) in 
PBS immediately prior to inoculation. 
Inoculations, Clinical scoring and Dissections 
Mice were inoculated intraperitoneallly with 100 µl of CWD infected brain homogenate 
using a 28G Insulin syringe.  Mice were observed throughout the study for clinical signs of prion 
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disease, including tail rigidity, impaired extensor reflex, akinesia, tremors, ataxia and weight 
loss.  Mice displaying any four of these signs or paralysis were scored terminally ill and 
sacrificed.    
Inoculated mice were sacrificed at distinct time points by CO2 inhalation. Spleens and 
brains collected from these mice were divided sagittally. One brain hemisphere and half a spleen 
were fixed in 4% paraformaldehyde in PBS for 5 days before histology.  The other brain 
hemisphere and half spleen was homogenized and used for PK digestion, western blot analysis, 
and PMCA. 
Histology and Immunocytochemistry 
 Slides were prepared and stained as previously described 28.   
PMCA, PK digest and WB 
 PMCA on spleen samples was performed and semiquantified as previously described 29.  
Briefly, spleen samples were sonicated at 70–85% maximum power for 40 s in a microplate horn 
sonicator (Qsonic, Framingham, MA), followed by a 30-minute incubation at 37 °C repeated for 
24 hours per round for up to five rounds total. PK digestion and WB was performed as 
previously described 28, except that spleen homogenates were digested with 10 µg/mL PK. 
 We weighted sample scores according to the PMCA round at which they first appeared 
positive by WB and set a detection threshold distinguishing positive from negative PMCA 
samples based on the 99.9% confidence interval for designating NBH samples as negative, 
calculated from the mean PMCA score of 73 NBH control samples using the Student’s t-table.  
We estimated cervid PrPRES (PrPCWD) loads in spleens by first generating a standard curve by 
plotting serial dilutions of known concentration of PrPCWD titrated into uninfected spleen 
homogenates versus their PMCA scores generated after prion amplification.  We then quantified 
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PrPCWD loads (y) by substituting PMCA scores (x) into the nonlinear equation y= -
0.6626x0.3771+17.87x0.1845  (r2=0.88). 
Results 
Genetic or pharmacological depletion of C3 results in significant delays in CWD 
pathogenesis.  
We tested whether Complement protein C3 is important early in or throughout peripheral 
prion infection, or both.  To create mice deficient in C3 and susceptible to CWD prions, mice 
deficient in both C3 (C3-/-) and mouse PrPC (Prnpo/o) were crossed to Tg5037 mice that express 
high levels of elk, but no mouse, PrP.  Offspring from breeding pairs were then screened for 
Tg5037;C3-/- mice.  To temporarily deplete C3, Tg5037 were inoculated with either 100 µl of 
900 µg/ml of the C3 convertase-activating CVF (Sigma) or PBS at least 24 hours prior to and 5, 
10, and 15 days post inoculation (dpi) of 100 µg brain homogenate from an elk terminally 
infected with CWD prions (Figure 4.1A).  At all time points tested there was a significant 
decrease in C3 concentration in the serum of CVF treatedTg5037 mice compared to PBS treated 
Tg5037 mice.  Although serum C3 concentrations were significantly different at 15 DPI, C3 
concentrations of CVF treated mice rose above normal physiological levels (~1mg/ml) indicating 
a probable antibody response against CVF that limited its effectiveness after the third 
administration.  We estimate that C3 levels remained at or below 50% of PBS-treated mice for 7-
10 DPI. 
Both Tg5037;C3-/- and CVF treated Tg5037 mice showed a median survival time of 513 
and 441 dpi, respectively.  These median survival times were significantly longer than 
Tg5037control mice, which showed a median survival time of 312 dpi  (Figure 4.1B).  
Terminally ill Tg5037;C3-/- mice, CVF treated Tg5037 mice, and control PBS treated Tg5037 
$%(!
mice exhibited vacuolization, PrPSc deposition, and severe astrogloisis (D-I). Western blot and 
densitometric analyses revealed PrPRES in all brains from terminally ill Tg5037;C3-/-, CVF and 
PBS treated Tg5037 mice.  
FIGURE 4.1.  Mice genetically and pharmacologically deficient in C3 show delays in CWD 
prion infection.  Tg5037 mice were inoculated with either CVF (n=8) or PBS (n=5) at least 24 
hours prior to i.p. inoculation (0 hpi) of 100 %g of CWD infected brain homogenate.  After 
infection with CWD prions, additional CVF inoculations at 5, 10, and 15 days post infection 
were administered to maintain transient C3 depletion (A).  At 0 hpi, 8, and 16 dpi there was a 
significant depletion of C3 in mice treated with CVF.  (B) CVF treated Tg5037 (red) and 
Tg5037;C3-/-mice (blue) show a median survival time of 441 and 513 dpi respectively compared 
to PBS and non PBS treated Tg5037 mice (black), which show a median survival time of 312 dpi
(p value=0.0064).  (C) IHC of brain sections from PBS (C-D), CVF (E-F), and C3-/- (G-H) mice.  
(J) Western blot (WB) analysis of PrPSc content from PBS, Tg5037;C3-/-, and CVF mice.  
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 Absence of C3 delays prion propagation in the spleen.   
 We next used PMCA to evaluate the prion loads in the spleens of CWD infected Tg5037, 
Tg5037;C3-/-, and CVF mice.  These semiquantitative prion amplification assay takes advantages 
of a prion’s ability to self propagate, using seeded protein fibrilization.  This diagnostic 
technique is employed to amplify diminutive amounts of infectious protease-resistant forms of 
PrP (PrPRES) to detectable levels by stimulating its conversion from PrPC 30.  We utilized PMCA 
to amplify and semi-quantify small amounts of PrPRES from spleen homogenates from mice at 
distinct intervals after CWD prion infection.  Tg5037 mice at 15 dpi showed a significant 
difference in the amount of splenic PrPRES (Figure 4.2, 63.49 ± 8.160 rpu) compared to 
Tg5037;C3-/- mice (11.36 ± 9.15 rpu).  Using our previously generated standard curve for this 
assay 29, we show that splenic PrPRES load in bothTg5037 to be approximately 5,500 pg/g of 
spleen tissue (figure 4.2).  The PMCA score for tg5037;C3-/- mice fall out of the dynamic range 
of our assay, so we can only estimate the load to be <100pg/g.  Tg5037 mice at 30 DPI showed 
no significant difference in prion load (22.920 ± 6.540 rpu, <100pg/g) compared to Tg5037;C3-/- 
mice (20.00 ± 9.72 rpu, <100 pg/g).  PrPRES increased significantly at 70 DPI (38.930 ± 6.9, 350 
pg/g) and 140DPI (42.8 ± 6.33, 500 pg/g) in Tg5037 mice.  We detected significantly less PrPRES 
in the spleens of TG5037;C3-/- mice at 70 DPI (0± 0, <100 pg/g) and 140 DPI (22.50 ± 10.17, 
<100 pg/g ).   
In addition to genetically depleting C3, we temporarily depleted C3 with CVF and 
checked for PrPRES accumulation in the spleen of Tg5037 mice.  One dose of CVF was 
administered one and five dpi.  Although not significantly different, CVF treated mice at 45 
(0±0, <100 pg/g), 70 (23.33±9.55 rpu, <100 pg/g), and 151 (20.00 ± 11.95, <100 pg/g) dpi 
exhibited consistently lower mean prion loads compared to TG g5037 mice.  
$%*!
FIGURE 4.2. C3-deficient mice showed delayed prion accumulation in the spleen at early time 
points. Tg5037 mice (n=83) accumulated significantly more CWD prions in the spleen at 15, 70 
and 140 dpi compared to Tg5037;C3-/- mice (15, 70, and 140 dpi p<0.05 n=41).  There was no 
significant difference in prion accumulation between PBS treated (n=24) Tg5037 mice and CVF 
treated Tg5037 mice (n=18) at 45, 70 and 151 dpi. 
Discussion 
We investigated the role of complement protein C3 in CWD prion accumulation, 
replication, and disease progression.  CWD development in mice with genetic or 
pharmacological depletion of C3 showed significant delays in disease development.  In
Tg5037;C3-/- mice the median survival time was longer than that seen in CVF treated mice.  This 
difference may be attributed to both transient depletion and incomplete knockdown of C3.  The 
delays in disease development in CWD infected Tg5037;C3-/- mice were more drastic than 
previous studies of C3 deficient mice infected with scrapie 19, 37 , even though these mice 
expressed five-fold less PrPC.  Complement components C1q and C3 have recently been shown 
to display similar strain preferences in vitro and in vivo 31.  These results point to a vital role in 
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prion pathogenesis for C3, the importance of which may differ by prion strain. Interestingly, in 
CWD and scrapie prion infections, depleting CD21/35 impacts disease progression significantly 
more than depleting its endogenous ligands, C3 and C4.  Furthermore, CD21/35 was greatly 
enriched in NaPTA precipitated PrPRES preparations from spleens of terminally sick mice 19.  
These Data strongly suggests a role of C21/35 in peripheral prion pathogenesis independent of its 
endogenous ligands.  Recently, prion transmission barriers were shown to be more readily 
breached in the lymphoreticular system than in the nervous system 32.  These cross-species 
infections resulted in distinct lymphotropic and neurotropic strains with differential host ranges.  
We hypothesized that this phenomenon may be due to the peripheral expression of CD21/35 by 
FDCs and B lymphocytes.  This expression of CD21/35 may play an important role in 
propagation, replication and strain selection in the spleen.  In light of our current findings, we 
extend our recent hypothesis to include C3.  As with CD21/35, lack of C3 may inhibit the 
efficiency of selection, propagation, and replication of neurotropic prion strains. If true, this 
would have serious implications for cross-species transmission, subclinical infections, and 
possible therapeutic approaches aimed at both complement proteins and their respective 
receptors.   
 To study the kinetics of splenic CWD prion accumulation, we amplified PrPRES from 
spleens of CWD prion infected Tg5037, Tg503;C3-/-, and CVF treated mice at various time 
points throughout infection.  At 15, 70, 140 dpi, Tg5037;C3-/- mice showed significantly less 
PrPRES than Tg5037 mice, whereas, no significant difference in splenic PrPRES could be detected 
in CVF-treated mice at any of the time points tested.  We hypothesize that the incomplete 
transient knockdown of C3 in CVF treated mice may contribute to higher concentrations PrPRES 
compared to Tg5037;C3-/- mice.  Although PrPRES was not significantly different between 
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Tg5037 and CVF treated mice at the time points tested, CVF treated mice showed a significant 
delay in disease development compared toTg5037 mice.  This indicates that similar to 
Tg5037;C3-/- mice, CVF treated mice most likely showed a significant decrease in PrPRES 
accumulation before 45 dpi.  This points to a more pronounced role of C3 in the earlier stages of 
disease.  This delay in splenic prion replication and/or accumulation strongly corresponds with a 
delay in terminal disease.    
 While C3 exerts most of its effect early in prion disease; complete, sustained C3 depletion 
results in less severe prion pathogenesis and longer delays in incubation times than incomplete, 
transient depletion.  This result is most likely due to insufficient depletion of C3 with CVF, 
resulting in not only residual endogenous ligands for CD21/35 early during infection, but also 
normal levels of C3 throughout most of the infection.  Consequently, this transient, incomplete 
depletion of C3 may lead to higher kinetic rates of accumulation and/or replication in the spleen 
later in infection.  C3 may help to recapture newly synthesized prions from FDCs in SLOs, as 
well as prions emanating from the CNS in centrifugal movement back to SLOs.  This may 
increase the rate of prionogenesis, resulting in higher prion titers and shorter incubation times in 
mice replete with C3 at later stages of disease. This result could also be attributed to C3 
expression in the central nervous system (CNS) 33,34.  Unlike Tg5037;C3-/- mice, CVF treated 
mice likely express C3 in the CNS after transient depletion with CVF, which may exacerbate 
disease in the later stages of CWD.  
 Taken together, these data support a critical role of C3 in peripheral CWD pathogenesis.  
C3 opsonization of PrPCWD may facilitate trapping by B lymphocytes and FDCs optimizing 
intranodal trafficking or peripheral prion replication.  Recently, we have shown that B 
lymphocytes within lymph nodes trap large amounts of prions hours after infection, indicating a 
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important role for this lymphocyte in intranodal trafficking.  We have also shown that depleting 
C3 in these mice affects prion capture by APCs.  We suspect that, similar to DCs and monocytes, 
C3 depletion may also affect prion uptake by CD21/35 positive follicular B cells.  This may in 
turn delay transport of prions to FDCs, consequently leading to delays in prion accumulation, 
replication, and perpheral prion pathogenesis. We are currently investigating the potential role of 
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CWD is an emerging and highly infectious prion disease of captive and free-ranging 
cervid populations that, similar to scrapie, has been shown to involve the immune system, 
perhaps contributing to their relatively facile horizontal and environmental transmission.  While 
prions most likely engage the innate immune system immediately following infection, little is 
known about this initial confrontation. In the first part of this thesis I investigated incunabular 
events in lymphotropic and intranodal CWD prion trafficking by following highly enriched, 
fluorescent prions from infection sites to draining lymph nodes.  I detected biphasic 
lymphotropic transport of prions from the initial entry site upon peripheral prion inoculation. 
Prions arrived in draining lymph nodes cell autonomously within two hours of intraperitoneal 
administration, and this process was independent of complement components C1q and C3.  A 
second wave of cells, dominated by monocytes, infiltrated the lymph nodes hours later in a 
second wave of prion trafficking.  Although their role in early prion passive transport was 
inconsequential, complement was required for optimal prion uptake by DCs.  This finding lends 
support to a receptor-mediated mechanism for prion uptake by DCs.  The drastic increase in 
proportion of prion-bearing B cells in MedLNs at early time points indicates that B cells most 
likely received prions from resident lymph node immune cells, probably SCS macrophages and 
paracortical DCs. These data reveal novel, cell autonomous prion lymphotropism, and a 
prominent role for B cells in intranodal prion movement. 
The complement system has been shown to facilitate scrapie peripheral prion 
accumulation and/or replication and neuroinvasion. In the second part of my thesis, we 
demonstrate that complete removal of the complement receptor CD21/35 in transgenic mice 
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susceptible to CWD greatly delays splenic prion accumulation and blocks progression to 
terminal disease upon inoculation with CWD prions. We also observed significant germinal 
center formation during scrapie prion infection that was dependent on CD21/35 and PrPC 
expression on FDCs. Lipid raft flotation experiments show movement of CD21/35 into lipid rafts 
on B cells upon prion infection, and this translocation occurred independent of endogenous 
ligand C3.  Taken together, these data suggest that CD21/35 mediated prion trapping on FDCs, 
and possibly B cells, marks an important event in lymphoid prion pathogenesis that contributes 
to terminal prion disease in these mouse models. 
C3 is the most abundant complement protein, being found in the blood at physiological 
concentrations of 1.2 mg/ml. C3 cleavage may occur through any one of the multiple 
complement pathways and leads to the opsonization of the outer surface of microbial pathogens.  
CD21/CD35 expressed on B cells and FDCs trap pathogens coated with C3 cleavage products 
and mediate appropriate immune responses.  Here we show that complete genetic or transient 
pharmacological depletion of C3 increases incubation times and significantly delays splenic 
accumulation in a CWD transgenic mouse model. Using PMCA we show that C3 affects disease 
progression in the early stages of disease by slowing the rate of accumulation and/or replication 
of PrPRES.  The delayed kinetics in PrPRES replication corresponds with delayed disease kinetics 
in mice deficient in C3. Taken together, these data support a critical role of C3 in peripheral 




Although intraperitoneal inoculation of prion-infected brain homogenate is very efficient 
in causing disease, this route of infection does not correspond to what is normally seen in nature.  
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Many TSEs, including Kuru, variant Creutzfeldt–Jakob disease (vCJD), BSE, scrapie, and CWD, 
are acquired through an oral route of infection 1-5.  Acquisition of disease through this route 
involves transcytosis of prions through the intestinal epithelium, replication on FDCs, and 
infection of the enteric nervous system 6-10.   Despite the fact that considerable data links immune 
cells to prion diseases post oral exposure, little evidence directly show a role for these cells in the 
capture and transport of prions hours after initial infection 11-13. Because pathogen-immune cell 
interactions often occur within hours of exposure and dictate the outcome of infection, 
understanding the interactions of prions with the oral mucosa is vital to comprehending 
incunabular events in a natural prion infection. With this in mind, we will orally inoculate 
animals to characterize the immune cell types involved in uptake and trafficking of CWD prions.  
B cells have been shown to play a critical role in prion neuroinvasion 14.  Although their 
role in this process relies less on replication and more on the enrichment of FDCs with critical 
cytokines, B cells and their intimate association with FDCs remains poorly described15.  We 
describe in chapter one a model in which B cells receive prions from SCS Mɸ, migrate into 
lymphoid follicles and deliver prions to FDCs.  However, this possible mechanism remains to be 
proven experimentally.  Recently, intravital microscopy (IVM) has resolved the kinetics of 
intranodal antigen trafficking and physiological processes associated with germinal center 
formation 16-22.  This powerful technique allows scientists to image biological processes in living 
animals at microscopic resolution. IVM makes it possible to visualize cellular reactions over 
time and space, and allows scientists to carry out experiments under conditions that closely 
resemble those seen in a natural setting 23. IVM could provide insight into the cellular 
interactions that exist between SCS macrophages, B cells, and FDCs during a prion infection. 
 
	  136	  
We are pursuing a potential collaboration in an effort to provide quantitative and dynamic 
insights into prion immunology. 
Over the past several years the study of protein dynamics and interactions often 
employed optical methods.  One method, surface plasmon resonance (SPR), has been used to 
describe a wide variety of biomolecular interactions in real time 24,25.  This method is able to 
detect binding between two unlabeled biomolecules by tracking changes in light refraction off 
the interface between an aqueous solution of possible binding ligands and a biosensor surface 
coupled to bait proteins (potential receptors) 26,27.  We will be using SPR to study the role of 
CD21/35 as a potential prion receptor, which could further give insight into peripheral prion 
replication, xenotransmission, strain selection, and possible therapeutic approaches targeted to 
CD21/35.  Targeting CD21/35 to inhibit the spread of neurotropic prions could be an attractive 
alternative to most prion disease therapeutics developed to date that target the central nervous 
system, which is a challenging site for drug delivery. Preventing CD21/35 mediated prion strain 
selection could also diminish emergence of new prion strains with enlarged host ranges and 
prevent a breach of the species barrier like the one that most likely caused the BSE and 
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